Pick a protocol, then a treatment inside it, for the actives, the mechanism, the evidence and where that evidence stops.
Browse the science by protocol
Read the last column of every evidence table. It is the part that matters most: it says whether the study was the same active, the same route, the same dose and the same kind of patient. Where it was not, the finding is being read across rather than measured directly, and that is a weaker claim.
The Shed Protocol Weight Loss
SHED is built around the incretin pathway. Semaglutide is a GLP-1 receptor agonist; tirzepatide activates both the GIP and the GLP-1 receptor. Both are prescribed here as compounded preparations, which are not FDA-approved products, and two of the four are in oral-mucosal forms that the pivotal trials never studied. The evidence below is strongest for the weekly injections and thinnest for the oral forms, and each panel says which is which.
Why do the ODT and the chewable have no trial data of their own? ▾
Because every published weight-management trial of semaglutide and tirzepatide used a once-weekly subcutaneous injection of an FDA-approved branded product. No published study has measured how much of a dose reaches the bloodstream from a compounded orally disintegrating tablet or a compounded chewable, and none has tested either form for effect on body weight. The approved oral semaglutide tablet is not a counterexample: it is swallowed and absorbed in the stomach with a dedicated absorption enhancer, which a compounded ODT does not contain. These forms exist because some people will not use an injection, and that is an adherence trade-off rather than an equivalent.
Does the price change as my dose goes up? ▾
No. The injection plans are billed per month rather than per milligram, so a dose increase does not change what you pay, and doses, supplies and cold shipping are included. Your physician decides whether and when to change your dose on clinical grounds, never on cost.
Why is the dose increased slowly instead of starting at the top? ▾
Titration is how tolerability is managed with this class. Gastrointestinal effects, most commonly nausea, tend to cluster around each dose increase, so stepping up gradually over months gives the body time to adjust. The pivotal trials titrated the same way. Your prescriber sets the pace and may hold or step back a dose.
What is the thyroid boxed warning about? ▾
In rodent studies, semaglutide and tirzepatide both caused thyroid C-cell tumours at clinically relevant exposures. The FDA labels state it is unknown whether this applies to humans, because the human relevance of the rodent finding has not been determined. Because of it, both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. Tell your provider if either is in your family history.
Semaglutide Injection
A once-weekly subcutaneous injection of semaglutide, a GLP-1 receptor agonist, prescribed alongside reduced calorie intake and increased activity.
Tirzepatide Injection
A once-weekly subcutaneous injection of tirzepatide, which activates two incretin receptors rather than one.
Semaglutide ODT
A compounded orally disintegrating tablet containing semaglutide, taken daily, for people who will not or cannot use an injection.
Tirzepatide Chewable
A compounded chewable form of tirzepatide, for people who want the dual-receptor active without an injection.
How it is understood to work
GLP-1 is a hormone your gut releases after eating. It is part of how your body decides it has had enough. Semaglutide is built to look like that hormone and to last far longer than the natural one does, so the appetite signal stays switched on across the whole week rather than fading within minutes. Most people describe it as food taking up less room in their thinking.
The pharmacology underneath
The FDA label describes semaglutide as a GLP-1 receptor agonist that selectively binds and activates the GLP-1 receptor, and notes that the GLP-1 receptor is present in several brain areas involved in appetite regulation. Animal studies cited in the label show distribution to and activation of neurons in those regions. Structural modification, including a fatty-acid chain that promotes albumin binding, extends the half-life to roughly one week and is what makes weekly rather than daily dosing possible. Gastric emptying is also slowed, particularly early in therapy, which contributes to both the satiety effect and the gastrointestinal side effects. The label states plainly that the exact mechanism of cardiovascular risk reduction has not been established.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
STEP 1, a phase 3 trial in 1961 adults, reported mean body weight change of about 14.9 percent with semaglutide 2.4 mg once weekly versus about 2.4 percent with placebo at 68 weeks, alongside lifestyle intervention.2Adults with overweight or obesity without diabetes.Same active and same subcutaneous weekly route as this offering, but the trial used the FDA-approved branded product, not a compounded preparation. Compounded product is not part of that evidence base.
STEP 4, a randomised withdrawal trial, reported that participants who continued semaglutide kept losing weight while those switched to placebo regained a substantial share of what they had lost.3Adults with overweight or obesity who had already completed a run-in on semaglutide.Directly relevant to route and active, but it is a statement about what happens when therapy stops, not a promise about any individual. Again the branded product.
STEP 8, a head-to-head trial in 338 adults, reported greater mean weight reduction with weekly semaglutide 2.4 mg than with daily liraglutide 3.0 mg at 68 weeks.4Adults with overweight or obesity without diabetes.Comparative rather than absolute. It positions semaglutide within its class; it does not establish anything about compounded semaglutide specifically.
The FDA label reports a boxed warning derived from rodent carcinogenicity studies: in mice and rats semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumours at clinically relevant exposures.1Rodents. The label states it is unknown whether the finding applies to humans.Animal data, extrapolated. The label is explicit that human relevance has not been determined, which is precisely why the contraindication is written as a precaution rather than a demonstrated human risk.
Where the evidence stops
The pivotal trials studied the FDA-approved branded subcutaneous product at defined doses under trial conditions. What is dispensed here is the same molecule by the same route from a 503A compounding pharmacy, which is a closer read-across than any other offering in this protocol, but it is still a read-across: compounded semaglutide has not itself been through a randomised efficacy trial, and potency, excipients and stability are the compounding pharmacy's responsibility rather than a manufacturer's approved specification.
What is inside
Semaglutide
The sole active. A GLP-1 analogue with 94 percent sequence homology to human GLP-1, which binds and activates the GLP-1 receptor.
Form and route
Subcutaneous injection, once weekly.
Semaglutide is a peptide. Swallowed on its own it would be broken down by stomach acid and digestive enzymes before it could reach the bloodstream in any useful amount, which is why the injectable route exists at all. The weekly interval is a consequence of the albumin-binding modification that stretches the half-life to about seven days.
What to expect, and when
Dosing is titrated upward in steps over a period of months rather than started at a full dose, specifically to limit nausea. Gastrointestinal effects, most commonly nausea, are typically front-loaded around each dose increase. Weight change in the trials accumulated gradually across many months rather than in the first few weeks, and individual response varied widely around those trial averages. Your prescriber decides the pace, and nothing here predicts what will happen for you.
Regulatory status
The semaglutide dispensed here is compounded by a 503A pharmacy and is not an FDA-approved product; the reference brand injections are approved, and this is not interchangeable with them. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2. This is an absolute contraindication on the label and carries a boxed warning.
Anyone who has had a serious hypersensitivity reaction to semaglutide or to any excipient in the product. Anaphylaxis and angioedema have been reported.
People with a history of pancreatitis need a careful conversation first. Acute pancreatitis occurred in clinical trials, and the label instructs prompt discontinuation if it is suspected.
People taking insulin or an insulin secretagogue, without a dose review. The label warns that concurrent use raises the risk of hypoglycaemia, including severe hypoglycaemia.
People with a history of diabetic retinopathy, who the label says should be monitored, and anyone with severe gastrointestinal disease, given the reported gallbladder and kidney-injury signals.
Anyone already taking another GLP-1 receptor agonist or another semaglutide-containing product. The label does not recommend coadministration.
Source: FDA label, WEGOVY (semaglutide), SPL v6, effective 2024-04-23. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
Your gut releases more than one hormone after a meal. Tirzepatide is designed to speak to two of those hormone receptors instead of one. The practical difference people describe is a stronger and steadier reduction in appetite than they have had on a single-receptor medication, though that is a description of the class, not a promise about you.
The pharmacology underneath
The FDA label describes tirzepatide as a GIP receptor and GLP-1 receptor agonist that selectively binds and activates both receptors. It contains a C20 fatty diacid that enables albumin binding and prolongs half-life, which is what permits weekly dosing. GLP-1 is described in the label as a physiological regulator of appetite and caloric intake; the label notes that nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake, wording that is deliberately tentative about how much of the effect the GIP arm actually contributes in humans. Both receptor types are found in brain regions involved in appetite regulation.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
SURMOUNT-1, a 72-week phase 3 trial randomising 2539 participants, reported mean weight reduction across the 5 mg, 10 mg and 15 mg weekly doses that reached roughly 15 to 21 percent depending on dose and analysis, against a much smaller change on placebo.2Adults with obesity, or with overweight plus at least one weight-related comorbidity, without type 2 diabetes.Same active and same subcutaneous weekly route, but the trial used the FDA-approved branded product. Compounded tirzepatide was not studied.
The FDA label carries an approved indication not only for weight reduction but also for moderate to severe obstructive sleep apnoea in adults with obesity.1Adults with obesity and moderate to severe obstructive sleep apnoea.That indication belongs to the approved branded product. It is not what is being prescribed here, and sleep apnoea is a diagnosis and a management decision for a physician, not something this protocol addresses.
The label reports a boxed warning: in rats, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumours at clinically relevant exposures.1Rats. The label states human relevance has not been determined.Animal data extrapolated to a human precaution, exactly as with semaglutide.
The label adds warnings that distinguish tirzepatide in day-to-day practice, including severe gastrointestinal reactions, a recommendation against use in severe gastroparesis, and reports of pulmonary aspiration during general anaesthesia or deep sedation in patients on GLP-1 receptor agonists.1Patients in the clinical trial and postmarketing populations for the approved product.Safety signals read across more readily than efficacy does, because they attach to the molecule and the exposure rather than to the trial protocol. The anaesthesia warning matters for anyone with surgery planned.
Where the evidence stops
As with semaglutide, the efficacy evidence is for the branded subcutaneous product. Compounded tirzepatide has not been through a randomised trial of its own. Beyond that, tirzepatide's dual-receptor design means the head-to-head literature against single-agonist GLP-1 medications is still developing, so comparative statements about which molecule suits which person are clinical judgement rather than settled evidence.
What is inside
Tirzepatide
The sole active. A dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor.
Form and route
Subcutaneous injection, once weekly.
Tirzepatide is a peptide and would be degraded in the gastrointestinal tract if swallowed. The fatty-diacid albumin-binding modification named in the label is what stretches its half-life far enough to make a weekly injection viable rather than a daily one.
What to expect, and when
Dosing is titrated upward over months. Nausea, and gastrointestinal effects generally, tend to cluster around dose increases. In the trials, weight change accumulated over the full 72 weeks rather than in an early burst, and individual results varied considerably around the reported means. Your prescriber sets the titration and decides whether to hold or step back.
Regulatory status
The tirzepatide dispensed here is compounded by a 503A pharmacy and is not an FDA-approved product. The reference brand injection is approved and is not interchangeable with this. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2. Absolute contraindication, carrying a boxed warning.
Anyone with known serious hypersensitivity to tirzepatide or any excipient. Anaphylaxis and angioedema have been reported.
People with severe gastroparesis, in whom the label does not recommend use, and anyone with a history of pancreatitis without a careful prescriber conversation.
People taking insulin or an insulin secretagogue without a dose review, because of the raised hypoglycaemia risk noted in the label.
Anyone with elective surgery or a procedure under general anaesthesia or deep sedation coming up should tell their care team they are on this class, because of reported pulmonary aspiration.
Anyone already taking another GLP-1 receptor agonist or tirzepatide-containing product. Coadministration is not recommended.
Source: FDA label, ZEPBOUND (tirzepatide), SPL v38, effective 2026-04-22. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
The molecule is the same one used in the injection, and what it is designed to do in the body is the same: act on the GLP-1 receptor to support the feeling of having eaten enough. What is different, and what matters here, is how much of it actually gets into your bloodstream from a tablet that dissolves in your mouth. That question does not have a published answer for this product.
The pharmacology underneath
The receptor pharmacology is the semaglutide pharmacology described on the injection panel: selective GLP-1 receptor agonism, activity at appetite-regulating brain regions, a long half-life driven by albumin binding. The uncertainty is entirely at the absorption step. Semaglutide is a 31-amino-acid peptide and a large, polar molecule; oral mucosa has limited permeability to molecules of that size and character. The FDA-approved oral semaglutide product solves this a completely different way, by co-formulating with the absorption enhancer SNAC, which promotes transport across the gastric epithelium, and even then reported absolute bioavailability is on the order of about 1 percent. A compounded orally disintegrating tablet contains no such enhancer system and has no published pharmacokinetic characterisation of its own.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
All of the efficacy evidence for semaglutide in weight management, including STEP 1, comes from the once-weekly subcutaneous route.2Adults with overweight or obesity in the STEP programme.Different route entirely. There is no published trial of a compounded orally disintegrating semaglutide tablet at any dose, so the injection results cannot be read across to this form.
The FDA-approved oral semaglutide tablet achieves systemic exposure only with the SNAC absorption enhancer, and published assessments put absolute oral bioavailability at roughly 1 percent, with absorption occurring predominantly in the stomach.3Pharmacokinetic and regulatory assessment of the approved oral product.This tells you how hard oral delivery of this peptide is, not that a compounded ODT achieves it. The approved product is swallowed and gastric-absorbed with an enhancer; an ODT is neither.
Reviews of oral peptide delivery describe consistent obstacles: degradation in the gastrointestinal tract and limited mucosal permeability to large polar molecules.4Pharmaceutical literature on peptide delivery generally.General pharmacology rather than a finding about this product. It is the reason the disclosure above is worded as strongly as it is.
The label safety profile, including the boxed warning on thyroid C-cell tumours and the contraindications, attaches to semaglutide as a molecule.1Rodent carcinogenicity data plus the approved-product clinical and postmarketing populations.Safety read-across is more defensible than efficacy read-across, because the contraindications follow the active. They therefore apply here in full even though the efficacy evidence does not.
Where the evidence stops
This is the most important disclosure in the SHED protocol. There are no published efficacy trials of compounded oral-mucosal semaglutide, and no published bioavailability data establishing how much of a dose from an orally disintegrating tablet reaches the bloodstream. The trial results that make semaglutide well known were all generated with weekly subcutaneous injection of an approved product. Nothing on this page should be read as evidence that this form performs comparably. It exists as an option for people for whom an injection is not workable, and that trade-off is a decision to make with a prescriber who has told you what is and is not known.
What is inside
Semaglutide
The sole active. The same GLP-1 receptor agonist as the injection, in a tablet designed to disintegrate in the mouth rather than be swallowed whole.
Form and route
Orally disintegrating tablet, dissolved in the mouth, taken daily.
The honest reason this form exists is adherence, not pharmacology. Some people will not start or will not continue an injectable, and a daily tablet removes that barrier. It also removes needles, sharps disposal and the cold chain. What it does not do is replicate a characterised dose, and daily dosing is used because there is no basis for assuming the weekly kinetics of the injection carry over.
What to expect, and when
Set expectations lower and hold them loosely. Because absorption from this form has not been characterised, response is less predictable than with the injection, and a lack of response may reflect absorption rather than the molecule. Report back to your provider rather than escalating on your own. Gastrointestinal effects remain the most commonly reported issue with the active.
Regulatory status
This is a compounded orally disintegrating tablet. It is not an FDA-approved product, the oral-mucosal route has not been through an approval process for semaglutide, and it is not the same thing as the approved swallowed oral semaglutide tablet. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2. The contraindication follows the active regardless of the form.
Anyone who has had a serious hypersensitivity reaction to semaglutide or to a formulation excipient.
People with a history of pancreatitis, without a careful conversation with the prescriber first.
People taking insulin or an insulin secretagogue without a dose review, because of hypoglycaemia risk.
Anyone already taking another GLP-1 receptor agonist or another semaglutide-containing product.
Anyone who needs a predictable, characterised dose. If reliable systemic exposure is clinically important for you, this is not the right form and your prescriber should say so.
Source: FDA label, WEGOVY (semaglutide), SPL v6, effective 2024-04-23, applied to the active. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
The molecule is the same dual-receptor active used in the injection. What differs is delivery. A chewable has to get a large peptide across the lining of the mouth or the gut, and for tirzepatide there is no published data showing how much of it makes that journey.
The pharmacology underneath
Receptor pharmacology is as described on the injection panel: dual agonism at the GIP and GLP-1 receptors, with the label noting that the GIP contribution to food-intake regulation is suggested by nonclinical studies. The C20 fatty diacid that produces albumin binding and the long half-life was designed around subcutaneous administration. Tirzepatide is a 39-amino-acid peptide, larger than semaglutide, and the same barriers apply with more force: gastrointestinal enzymatic degradation, and limited permeability of oral mucosa to large polar molecules. Unlike the approved oral semaglutide product, there is no absorption-enhancer system here and no published pharmacokinetic characterisation of a compounded chewable.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
SURMOUNT-1 and the rest of the tirzepatide obesity programme studied once-weekly subcutaneous injection of the approved branded product.2Adults with obesity or with overweight plus a weight-related comorbidity.Different route. No published trial has studied chewable or oral-mucosal tirzepatide, so none of those results transfer to this form.
No approved oral tirzepatide product exists, and no absorption-enhancer formulation for oral tirzepatide has reached approval, unlike the semaglutide case where SNAC made an approved oral tablet possible at roughly 1 percent bioavailability.3Regulatory record for the molecule.The comparison is instructive rather than reassuring. Even the one peptide in this class that has an approved oral form needed a dedicated enhancer system to get there.
The FDA label safety profile, including the boxed warning on thyroid C-cell tumours in rats and the contraindications, attaches to tirzepatide as a molecule.1Rat carcinogenicity data plus the approved-product clinical and postmarketing populations.Safety carries across the change of form because it follows the active. Efficacy does not.
Pharmaceutical reviews of oral peptide delivery consistently describe degradation in the gastrointestinal tract and limited mucosal permeability as the central obstacles for molecules of this size.4Peptide delivery literature generally.General principle, not a measurement of this product. It is why no efficacy expectation is offered here.
Where the evidence stops
There is no published efficacy or bioavailability evidence for chewable tirzepatide. Everything known about tirzepatide's effect on body weight was generated by weekly subcutaneous injection of an approved product. This is a wider gap than the semaglutide ODT faces, because tirzepatide is a larger peptide and, unlike semaglutide, has no approved oral counterpart to reason from at all. Anyone choosing this form should understand they are choosing convenience against an uncharacterised dose, and should make that choice with a prescriber who has said so out loud.
What is inside
Tirzepatide
The sole active. The same dual GIP and GLP-1 receptor agonist as the injection, in a chewable rather than injectable form.
Form and route
Chewable, taken by mouth.
This form exists to remove the needle, the sharps handling and the refrigeration requirement. That is a real adherence benefit for some people and it is the honest rationale. It is not a pharmacokinetic rationale, and there is no published basis for treating a chewable dose as interchangeable with an injected one.
What to expect, and when
Response is less predictable than with the injection and may reflect how much is absorbed rather than how the molecule behaves. Report back rather than self-escalating. Gastrointestinal effects remain the most commonly reported issue with this active in any form.
Regulatory status
This is a compounded chewable preparation. It is not an FDA-approved product, and no chewable or oral-mucosal tirzepatide product has been approved by the FDA in any country we are aware of. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2. The contraindication follows the active.
Anyone with known serious hypersensitivity to tirzepatide or to a formulation excipient.
People with severe gastroparesis or a history of pancreatitis, without a careful prescriber conversation.
People taking insulin or an insulin secretagogue without a dose review.
Anyone already taking another GLP-1 receptor agonist or tirzepatide-containing product.
Anyone for whom a predictable, characterised systemic dose is clinically important.
Source: FDA label, ZEPBOUND (tirzepatide), SPL v38, effective 2026-04-22, applied to the active. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
The Apex Protocol Men's Hormones
APEX is built on enclomiphene, a selective estrogen receptor modulator that acts at the hypothalamus and pituitary to raise the body's own luteinising hormone and therefore its own testosterone production. Enclomiphene is not an FDA-approved drug in the United States and every use of it is off-label and compounded. Both offerings here are enclomiphene-based, and the published evidence for them rests on hormone measurements rather than on symptom outcomes.
How is enclomiphene different from testosterone replacement? ▾
Enclomiphene does not add any hormone to your body. It blocks estrogen receptors at the hypothalamus and pituitary, which removes part of the brain's negative feedback and raises the luteinising hormone signal telling the testes to produce more of your own testosterone. Exogenous androgen works the opposite way, by supplying hormone from outside and suppressing that signal. Nuvari does not offer testosterone replacement therapy; the contrast is here to explain the mechanism, not to describe an alternative we sell.
Will enclomiphene affect my fertility? ▾
This is the main reason the mechanism is chosen. In a randomised phase 2 trial, enclomiphene raised serum testosterone while sperm concentration was preserved, in contrast to a topical testosterone comparator arm. Those are laboratory measurements rather than pregnancy outcomes, so it is evidence about a marker and not a fertility guarantee. If you are trying to conceive now or may want to later, say so at intake, because it changes what your prescriber will consider.
Is enclomiphene FDA-approved? ▾
No. Enclomiphene citrate has never been approved in the United States. It reached phase 3 as Androxal and received Complete Response Letters, and development stopped. At the Pharmacy Compounding Advisory Committee meeting of 8 June 2022 the FDA proposed that enclomiphene citrate not be added to the 503A Bulks List, and the committee voted against inclusion. It is dispensed as a compounded preparation on an individual prescription, and every use is off-label.
What does Man Power add over enclomiphene on its own? ▾
It adds DHEA, boron and pregnenolone to the same enclomiphene base, on a precursor and cofactor rationale. Be clear-eyed about the evidence: no trial has studied this four-ingredient combination, and the individual evidence for those three is null, small or inconsistent. Enclomiphene is the component with randomised data in men. DHEA is also listed as a prohibited anabolic agent under the World Anti-Doping Agency prohibited list, so anyone subject to drug testing should check before taking it.
Enclomiphene
A daily oral capsule of enclomiphene citrate, prescribed off-label to support the body's own testosterone production through the hypothalamic-pituitary-gonadal axis.
Man Power
A compounded four-ingredient capsule pairing enclomiphene with DHEA, boron and pregnenolone.
How it is understood to work
Your body decides how much testosterone to make using a feedback loop. The brain reads the estrogen circulating in your blood and, if it sees enough, it dials down the signal telling the testes to produce. Enclomiphene blocks the brain from reading that estrogen signal properly. The brain concludes more is needed, sends a stronger signal, and the testes respond by producing more of your own testosterone. Nothing external is being added.
The pharmacology underneath
Clomiphene citrate is a mixture of two isomers: zuclomiphene and enclomiphene. Enclomiphene is the trans-isomer and carries most of the estrogen-antagonist activity, while zuclomiphene has a much longer half-life and more estrogenic character, which is the pharmacological rationale for isolating the trans-isomer. Antagonism at hypothalamic and pituitary estrogen receptors removes negative feedback on gonadotropin-releasing hormone, raising pituitary output of luteinising hormone and follicle-stimulating hormone. Raised LH stimulates testicular Leydig cells to increase endogenous testosterone; raised FSH acts on Sertoli cells and is the reason spermatogenesis is generally preserved rather than suppressed. That mechanism only works if the testes can respond, which is why it is described in the literature for secondary rather than primary hypogonadism.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
A randomised phase 2 trial reported that enclomiphene citrate raised serum testosterone while preserving sperm concentration, in contrast to a topical testosterone comparator arm.2Men with secondary hypogonadism enrolled in the Repros phase 2 programme.The endpoints are serum testosterone and sperm concentration, which are surrogate markers. The trial did not establish symptom outcomes such as energy, mood or sexual function, and it studied the investigational product rather than a compounded capsule.
Review of SERM pharmacology in male hypogonadism describes the hypothalamic-pituitary mechanism and the fertility-preservation rationale for clomiphene and enclomiphene relative to exogenous androgen.3Narrative and mechanistic review of hypogonadal men.Review rather than trial evidence, and it summarises a literature built largely on hormone measurements rather than patient-reported outcomes.
Enclomiphene never obtained FDA approval, and its compounding status has itself been contested: at the Pharmacy Compounding Advisory Committee meeting of 8 June 2022, the FDA proposed that enclomiphene citrate NOT be included on the 503A Bulks List, and the committee voted against inclusion.4Regulatory record.A regulatory fact rather than an efficacy finding, and a more pointed one than the sermorelin situation. Sermorelin has a discontinued approved product that FDA found was not withdrawn for safety reasons; enclomiphene has an FDA recommendation against adding it to the 503A Bulks List. Those two positions are not equivalent and should not be read as such.
Professional guidelines on the evaluation and management of testosterone deficiency discuss SERMs among the options for men who wish to preserve fertility, while emphasising that diagnosis rests on repeated morning testosterone measurement plus symptoms.5Guideline populations of men with confirmed testosterone deficiency.Guidelines address a diagnosed clinical population evaluated in person with laboratory confirmation. They do not endorse compounded enclomiphene as a product, and they are cited here for mechanism and context rather than as approval of this offering.
Where the evidence stops
The single biggest limitation is that the evidence is about numbers, not about how men feel. The enclomiphene trials measured serum testosterone and sperm concentration; they were not powered or designed to demonstrate improvement in the symptoms that bring men to this protocol. On top of that, the trials tested an investigational product that was never approved, whereas what is dispensed is a compounded capsule with no trial of its own. Enclomiphene also only makes sense where the pituitary-testis axis can respond, so it is not an option for primary testicular failure, and distinguishing the two requires laboratory evaluation by a clinician.
What is inside
Enclomiphene citrate
The sole active. The trans-isomer of clomiphene citrate, acting as a selective estrogen receptor modulator that antagonises estrogen receptors at the hypothalamus and pituitary.
Form and route
Oral capsule, taken daily.
Enclomiphene is a small orally bioavailable molecule, so a capsule is the straightforward route with no formulation problem to solve. Daily dosing reflects the isomer's shorter half-life relative to zuclomiphene, and the whole point of isolating the trans-isomer was to avoid accumulating the longer-lived, more estrogenic isomer that comes with using clomiphene.
What to expect, and when
Hormonal changes measured in the trials appeared over weeks rather than days, and how that maps onto how you feel is exactly the part the evidence does not establish. Your prescriber may want baseline and follow-up laboratory work; treatment and monitoring decisions are theirs. If you are trying to conceive, or may want to later, tell your prescriber, because that is a large part of why this mechanism is chosen over alternatives.
Regulatory status
Enclomiphene citrate is not an FDA-approved drug in the United States. It reached phase 3 as Androxal but was never approved, and it is available only as a compounded preparation through a 503A pharmacy on an individual prescription. Every use of it is off-label. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Men with primary hypogonadism, meaning testicular failure. The mechanism depends on the testes being able to respond to a stronger pituitary signal, and where they cannot, it has no pathway to work through.
Anyone with a history of venous thromboembolism, or a thrombophilia. SERMs as a class carry thrombotic concerns and the approved clomiphene labelling reflects them.
Anyone with liver disease or abnormal liver function, which is a stated precaution in the clomiphene citrate labelling from which enclomiphene's safety expectations are largely inferred.
Anyone with an undiagnosed abnormality that could account for the symptoms. Low testosterone can be a sign of a pituitary lesion, thyroid disease, sleep apnoea or other issues, and this is not a work-up.
Women, and anyone who is or may become pregnant. This is prescribed here for men only.
Anyone who experiences visual disturbance on it should stop and contact their prescriber. Visual symptoms are a recognised class effect of clomiphene-type SERMs.
Source: Derived from FDA labelling for clomiphene citrate, the approved parent compound, since enclomiphene itself has no FDA label; plus the professional guidelines cited below. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
The idea behind the blend is to combine the one ingredient with real trial data in men, enclomiphene, with three upstream precursors and cofactors that sit near the same hormonal machinery. The honest position is that enclomiphene is doing the work the evidence describes, and the other three are added on a rationale rather than on demonstrated benefit in this combination.
The pharmacology underneath
Enclomiphene's pharmacology is the hypothalamic-pituitary SERM mechanism described on the single-ingredient panel. DHEA is converted peripherally to androstenedione and onward to testosterone and estradiol, and dose-response analyses show oral DHEA can raise measured testosterone, but the clinical translation of that in men has been poor in randomised work. Pregnenolone sits above DHEA in the steroidogenic pathway as the product of cholesterol side-chain cleavage, so the rationale is precursor supply; whether oral pregnenolone meaningfully shifts downstream steroid production in men is not established. Boron has been reported in small studies to influence steroid hormone concentrations and to affect the metabolism of minerals and sex hormones, with mixed and non-replicated results. Crucially, none of this has been studied as a four-ingredient combination, so any interaction between the components, favourable or otherwise, is unknown.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
The enclomiphene component carries the randomised phase 2 evidence described on the single-ingredient panel, reporting raised serum testosterone with preserved sperm concentration.1Men with secondary hypogonadism.That trial studied enclomiphene alone. It says nothing about what happens when three further ingredients are added, and it used surrogate hormone endpoints rather than symptom outcomes.
A randomised trial of DHEA in elderly men and women reported no meaningful benefit on body composition, physical performance or quality of life, and broader reviews conclude DHEA has not been shown to improve cognitive function, bone strength, muscle strength or physical performance in older adults.2Older adults, men and women.Different population from the men this blend targets, and studied as a single agent. Still the best available controlled evidence, and it points away from benefit rather than towards it.
A controlled study of boron supplementation in 19 male bodybuilders reported no significant effect on lean body mass, plasma testosterone or strength, while other small studies have reported changes in plasma steroid hormones.3Small groups of male athletes, and separately postmenopausal women.Small, inconsistent and not replicated at scale, in populations unlike most men taking this. This is why the ingredient role above says the contribution is not established.
Clinical investigation of pregnenolone in humans is sparse. One of the few controlled studies in healthy volunteers examined chronic pregnenolone and reported attenuation of benzodiazepine-induced sedation.4Healthy adult volunteers.A pharmacodynamic interaction endpoint in healthy volunteers, entirely unrelated to anything this blend is taken for. It is cited to show how thin and how off-target the human pregnenolone record is, not as support. No study exists of pregnenolone in a combination like this one.
DHEA appears on the World Anti-Doping Agency prohibited list as an anabolic agent.5Regulated athletes.Not an efficacy finding at all, but a practical one. Anyone subject to anti-doping testing should not take this blend without checking, and that is a disclosure rather than an inference.
Where the evidence stops
There is no trial of this four-ingredient combination. Everything above is single-ingredient evidence assembled after the fact, and for three of the four ingredients that evidence is small, inconsistent or null. The defensible statement is that enclomiphene is the component with randomised data in men and that the other three are included on a precursor-and-cofactor rationale that has not been demonstrated in combination. Adding ingredients also adds unknowns: interactions between them have not been characterised, and a compounded multi-ingredient capsule is harder to attribute effects or side effects to than a single active.
What is inside
Enclomiphene citrate
The primary active and the only ingredient in the blend with randomised trial data in men. A selective estrogen receptor modulator that raises pituitary LH and FSH and therefore endogenous testosterone.
DHEA (dehydroepiandrosterone)
An adrenal steroid precursor upstream of both androgens and estrogens. Randomised work in older adults has generally not shown benefit for muscle strength, physical performance or cognition, so its contribution within this blend is not established. DHEA is listed as a prohibited anabolic agent under the World Anti-Doping Agency prohibited list, which matters for anyone subject to drug testing.
Boron
A trace mineral. Small studies have reported effects on plasma steroid hormones and mineral metabolism, but results are inconsistent and one controlled study in male bodybuilders found no significant effect on testosterone, lean mass or strength. Included in the compounded blend; the evidence for its contribution in this combination is limited.
Pregnenolone
A neurosteroid and the upstream precursor from which other steroid hormones are synthesised. Human research is sparse; early clinical work in healthy volunteers did not show mood improvement. Included in the compounded blend; the evidence for its contribution in this combination is limited.
Form and route
Oral capsule, taken daily.
All four ingredients are orally bioavailable small molecules or steroids, so a single capsule is simply the practical way to combine them. The reason a combination exists at all is adherence and simplicity rather than pharmacokinetics, and that is worth being straightforward about.
What to expect, and when
Treat expectations here as no higher than for enclomiphene alone, because that is where the evidence is. Hormonal change in the trials of the enclomiphene component developed over weeks. Your prescriber decides on laboratory monitoring. If you are choosing between this and the single-ingredient option, the trade-off is simplicity against attributability, and that is a fair conversation to have with your provider.
Regulatory status
This is a compounded four-ingredient blend. Enclomiphene is not FDA-approved; DHEA, boron and pregnenolone are sold in the United States as dietary supplement ingredients rather than approved drugs. No FDA-approved product contains this combination and no clinical trial has studied it. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Men with primary hypogonadism, for the same reason as single-ingredient enclomiphene: the mechanism needs a testis that can respond.
Anyone with a history of venous thromboembolism or thrombophilia, or with liver disease, following the precautions on the approved clomiphene labelling.
Anyone with a hormone-sensitive cancer, or a personal or strong family history of one. DHEA and pregnenolone are precursors to both androgens and estrogens and that exposure has not been characterised in this context.
Athletes subject to anti-doping testing, unless they have checked. DHEA is a prohibited anabolic agent under the WADA prohibited list.
Women, and anyone who is or may become pregnant.
Anyone who wants to know which ingredient is responsible for an effect or a side effect. With four actives in one capsule that question often cannot be answered, and a single-ingredient option exists for exactly that reason.
Source: Derived from FDA labelling for clomiphene citrate, the approved parent compound of enclomiphene, plus the WADA prohibited list and the component literature; no FDA label exists for this combination. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
The Rewind Protocol Longevity
REWIND covers two very different things. Sermorelin is a growth-hormone-releasing hormone analogue whose approved product was discontinued years ago and whose adult longevity use is entirely off-label. Rapamycin is an approved immunosuppressant being used off-label on the strength of animal lifespan data. Both panels below are candid that the human outcome evidence people hope for does not yet exist, and rapamycin in particular carries real risk that has to be weighed by a physician.
The body's largest natural growth hormone pulse occurs in early sleep. Dosing at night is intended to work with that rhythm rather than against it. Sermorelin prompts the pituitary to release its own growth hormone rather than supplying growth hormone from outside, so the body's own feedback control stays in the loop and the effect is limited by what the pituitary can produce.
Is the troche as good as the injection? ▾
We cannot tell you that it is, because no published human study has measured sermorelin blood levels after a troche and no bioequivalence against the injection has been established. Sermorelin is a 29-amino-acid peptide, and the lining of the mouth is a difficult route for a molecule that size. A troche does avoid stomach acid and first-pass liver metabolism, which is why it is the sensible non-injectable format, but that is a reason to prefer it over a swallowed tablet rather than evidence it matches an injection.
What is rapamycin's evidence base, really? ▾
The strongest evidence is in animals: the NIA Interventions Testing Program reported median lifespan extension in genetically heterogeneous mice, replicated across three independent laboratories. The human evidence is small and short. The PEARL trial gave weekly rapamycin to healthy adults aged 50 to 85 for 48 weeks and reported no serious drug-related adverse events, but it was a safety and tolerability study, not a trial powered for clinical outcomes. No human study has shown that rapamycin extends lifespan or healthspan. Sirolimus is approved only as an immunosuppressant and its label carries a boxed warning covering infection risk and malignancy, so this is an experimental choice that belongs with a physician who knows your full history.
Is sermorelin FDA-approved? ▾
Not currently. The branded product GEREF was discontinued in 2008, and the FDA formally determined it was not withdrawn for reasons of safety or effectiveness, which is the legal basis on which a 503A pharmacy may compound it. GEREF's approvals covered diagnostic use and growth hormone deficiency in children, never adult anti-aging, so all adult use is off-label and compounded medications are not FDA-approved.
Sermorelin Injection
A nightly subcutaneous injection of sermorelin acetate, a growth-hormone-releasing hormone analogue prescribed off-label to support the body's own growth hormone release.
Sermorelin Troche
A compounded troche that dissolves in the mouth, containing sermorelin acetate, for people who will not use a nightly injection.
Rapamycin (Sirolimus)
An approved immunosuppressant prescribed here off-label on an intermittent schedule, on the basis of animal lifespan research rather than human outcome data.
How it is understood to work
Rather than putting growth hormone into you, sermorelin asks your pituitary to release its own. It copies the natural signal the hypothalamus sends. The practical consequence is that your body's own control systems stay in the loop: if the pituitary has released enough, the normal feedback still applies. It also means the effect is limited by what your pituitary can actually produce.
The pharmacology underneath
Sermorelin binds the pituitary-specific GHRH receptor, a G-protein coupled receptor cloned and characterised in the early 1990s, stimulating somatotrophs to release stored growth hormone in a pulsatile fashion. Downstream, growth hormone drives hepatic IGF-1 production, which is the marker usually measured. Because release depends on pituitary stores and remains subject to somatostatin and IGF-1 negative feedback, the mechanism is self-limiting in a way that administering recombinant growth hormone is not. Human infusion studies showed that GHRH stimulates pulsatile release with a magnitude limited by the available pituitary pool, and separate work showed 14 days of continuous GHRH administration did not desensitise or deplete somatotrophs. Nightly dosing is chosen to align with the body's largest natural growth-hormone pulse, which occurs in early sleep.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
A multicentre trial in 110 prepubertal growth-hormone-deficient children reported that daily subcutaneous sermorelin at 30 mcg/kg at bedtime increased mean height velocity from 4.1 to 8.0 cm per year at six months, with good tolerability.3Prepubertal children with growth hormone deficiency.A completely different population and a completely different endpoint from adult wellness use. Children with a deficiency growing taller says nothing about body composition or wellbeing in a healthy adult, and this is the largest single piece of clinical evidence sermorelin has.
Human GHRH infusion studies established that GHRH stimulates pulsatile growth hormone release from the pituitary, with magnitude limited by available pituitary stores.5Normal adult men.Adults, which helps, but the endpoint is a hormone measurement over hours, not a clinical outcome over months. This is mechanism confirmation, not efficacy.
Continuous GHRH administration over 14 days did not produce somatotroph desensitisation or depletion, supporting the feasibility of ongoing GHRH-based dosing.6Normal men and one growth-hormone-deficient boy.Fourteen days is very short relative to how long people take this. It addresses tachyphylaxis, not long-term safety or benefit.
The FDA determined that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness; it was discontinued in 2008 for business reasons.1Regulatory record.This is a regulatory fact, not evidence of benefit. It explains why compounding is lawful, and nothing more. GEREF's approvals were for diagnostic use and for growth hormone deficiency in children, never for adult anti-aging.
Review literature describes sermorelin's pharmacology and safety profile, with transient facial flushing and injection-site pain as the most commonly reported adverse events.4Largely paediatric clinical experience.The safety picture is drawn from a paediatric diagnostic and treatment context at defined doses, not from long-term adult wellness use.
Where the evidence stops
The honest summary is that sermorelin has good mechanistic evidence, reasonable short-term safety evidence, and essentially no long-term outcome evidence in the population that takes it. The substantial clinical trial base is paediatric growth hormone deficiency. Adult studies measure IGF-1 and growth hormone pulse amplitude, which are surrogate endpoints, and no randomised trial of longer than a year has established body-composition, functional or longevity outcomes in healthy adults using compounded sermorelin. The protocol page states this too, and it should stay stated.
What is inside
Sermorelin acetate
The sole active. A synthetic 29-amino-acid peptide corresponding to the biologically active fragment of human growth-hormone-releasing hormone, GHRH(1-29).
Form and route
Subcutaneous injection, typically at night.
Sermorelin is a 29-amino-acid peptide. Swallowed, it would be degraded by gastric acid and proteases before reaching the circulation, which is why the injectable route exists. Night-time dosing is deliberate: the largest physiological growth-hormone pulse occurs in early sleep, so dosing then works with the body's own rhythm rather than against it.
What to expect, and when
Anything that happens here happens slowly. The measurable changes described in the literature are hormonal, and they develop over weeks to months. Injection-site reactions and transient flushing are the most commonly reported effects. Your prescriber decides on monitoring, and if anything changes about your health, particularly anything oncological, tell them promptly.
Regulatory status
Sermorelin is not currently FDA-approved for any indication. The branded product GEREF was discontinued in 2008, and the FDA has formally determined it was not withdrawn for reasons of safety or effectiveness, which is the legal basis on which 503A pharmacies may compound it. All adult use is off-label. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Anyone with an active malignancy. Growth hormone and IGF-1 are growth-promoting signals, and this is the most important exclusion in the protocol.
Anyone with untreated obstructive sleep apnoea, which is a stated exclusion for this protocol.
Anyone with known hypersensitivity to sermorelin or to a formulation excipient.
Anyone who is pregnant or breastfeeding. There is no characterisation of compounded sermorelin in pregnancy.
Anyone expecting this to substitute for evaluation of a suspected pituitary or endocrine problem. Adult growth hormone deficiency is a specific diagnosis made by an endocrinologist with dynamic testing, and this is not that.
Anyone who wants a therapy with long-term randomised safety data behind it. Beyond one year in healthy adults, that data does not exist for this.
Source: No current FDA label exists for sermorelin; drawn from the historical GEREF product record, the published review literature and the protocol's own medical notice. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
The molecule and the intended pituitary mechanism are the same as the injection. The difference is delivery, and it is a real one: this is a 29-amino-acid peptide being asked to cross the lining of the mouth, which is not a route peptides of that size cross easily. How much actually reaches the bloodstream from a troche has not been measured and published.
The pharmacology underneath
Receptor pharmacology is identical to the injection: GHRH receptor agonism at pituitary somatotrophs, pulsatile growth hormone release, downstream IGF-1, with feedback intact. The uncertainty is at absorption. Oral mucosa has limited permeability to large polar molecules, and sermorelin is both large and hydrophilic. Buccal and sublingual routes do avoid gastric acid and first-pass hepatic metabolism, which is the pharmacological argument for a troche over a swallowed tablet, and that argument is sound as far as it goes. What it does not do is establish a delivered dose. No published human pharmacokinetic study reports sermorelin plasma concentrations after troche administration, and there is no bioequivalence data against the subcutaneous route.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
All of the clinical evidence for sermorelin, including the paediatric growth-velocity trial, used subcutaneous injection.3Prepubertal growth-hormone-deficient children, and adult GHRH infusion studies.Different route. None of that evidence has been shown to transfer to an oral-mucosal preparation, and it was already a different population and endpoint from adult wellness use.
No published human study demonstrates that any oral or oral-mucosal form of sermorelin achieves plasma concentrations comparable to injection, and no bioequivalence has been established.7Absence of evidence rather than a study population.This is the central disclosure for this offering. A troche is not a characterised dose, and it should not be assumed to be equivalent to the injection at any strength.
Pharmaceutical literature on buccal and sublingual delivery describes limited mucosal permeability to large polar molecules as the governing constraint for peptides.4Formulation science literature generally.A general principle rather than a measurement of this product, but it is the reason to be cautious rather than optimistic here.
The FDA determined GEREF was not withdrawn for reasons of safety or effectiveness, which is the basis on which sermorelin may be compounded at all.1Regulatory record.Regulatory rather than clinical, and it says nothing about which route or formulation is appropriate.
Where the evidence stops
The troche has no pharmacokinetic evidence of its own. Everything known about sermorelin's effects came from injection, and everything known about peptide delivery says the oral mucosa is a difficult route for a molecule this size. This offering exists because some people will not inject nightly, and an unmeasured dose taken consistently may be a better real-world choice for them than an injection they abandon. That is a legitimate clinical trade-off, but it is a trade-off, not an equivalent, and no one should be told otherwise.
What is inside
Sermorelin acetate
The sole active. The same GHRH(1-29) peptide as the injection, formulated in a troche intended to dissolve against the cheek or under the tongue.
Form and route
Troche, dissolved against the cheek or under the tongue, typically at night.
A troche is chosen over a swallowed tablet for a genuine pharmacological reason: dissolving in the mouth avoids gastric acid and the proteases that would destroy the peptide, and bypasses first-pass hepatic metabolism. That is why the troche is the sensible non-injectable format rather than a capsule. What it does not resolve is how much crosses the mucosa, which remains unmeasured.
What to expect, and when
Expect less predictability than the injection, and understand that a lack of effect may reflect absorption rather than the molecule. Local irritation or an unfamiliar taste are possible with any troche. Let the troche dissolve rather than swallowing it, since swallowing defeats the reason the format was chosen. Report back to your provider rather than escalating on your own.
Regulatory status
This is a compounded troche. Sermorelin has no current FDA approval in any form, and no oral, buccal or sublingual sermorelin product has ever been approved or characterised in a published human pharmacokinetic study. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Anyone with an active malignancy, for the same reason as the injection.
Anyone with untreated obstructive sleep apnoea.
Anyone with known hypersensitivity to sermorelin or to a troche excipient, including flavouring and base components that the injection does not contain.
Anyone who is pregnant or breastfeeding.
Anyone for whom a characterised, reliable dose matters clinically. If that is you, this is not the right format and the injection is the one with the evidence.
Anyone with significant oral mucosal disease or ulceration, where absorption would be even less predictable and irritation more likely.
Source: No current FDA label exists for sermorelin in any form; drawn from the historical GEREF record, the review literature and the protocol's own medical notice. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
mTOR is the switch cells use to decide between growing and building, or slowing down and cleaning house. Rapamycin pushes that switch towards the second setting. In laboratory animals, doing that has extended lifespan more reproducibly than almost any other intervention tested. Whether it does anything comparable in humans is not known, and the same switch is what makes the drug an immunosuppressant.
The pharmacology underneath
Sirolimus binds the immunophilin FKBP-12, and that complex inhibits mTORC1. Downstream, inhibition of mTORC1 suppresses ribosomal protein S6 kinase and 4E-BP1 signalling, reducing cap-dependent translation and cell-cycle progression from G1 to S phase, and de-represses autophagy. In lymphocytes this blocks interleukin-2-driven proliferation, which is the basis of its approved immunosuppressant use. The longevity hypothesis rests on the same pathway: reduced anabolic signalling and increased autophagy are the mechanisms invoked by the animal lifespan work. The intermittent dosing used in longevity practice is an attempt to bias towards mTORC1 inhibition while limiting the sustained mTORC2 effects associated with metabolic side effects, but that separation is a rationale rather than a demonstrated property in humans.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
The NIA Interventions Testing Program reported median lifespan extension in genetically heterogeneous mice, replicated across three independent laboratories, with effects varying by dose and sex.2Genetically heterogeneous mice.Animals. This is the strongest evidence rapamycin has, and it is not human evidence. Mouse lifespan findings have repeatedly failed to translate to human outcomes for other interventions, and no human lifespan trial exists or is likely to.
The PEARL trial administered 5 or 10 mg rapamycin weekly for 48 weeks in healthy adults aged 50 to 85 and reported no serious drug-related adverse events, with some sex-specific changes in healthspan metrics.3Healthy older adults, small sample.A safety and tolerability study, not a registration trial and not powered for clinical outcomes. Twelve months is short relative to how long people take this, the sample was small, and it did not demonstrate lifespan or disease outcomes.
The FDA-approved label carries a boxed warning covering immunosuppression, increased susceptibility to infection, and the possible development of lymphoma and other malignancies.1Transplant recipients on chronic full-dose immunosuppression.The boxed warning comes from continuous immunosuppressive dosing in transplant patients, which is a different exposure from intermittent dosing in a healthy person. That difference is a reason for caution about extrapolating the risk in either direction, since the reassurance is as unproven as the alarm.
The label documents that safety and efficacy have not been established in liver or lung transplant patients, that sirolimus with tacrolimus was associated with excess mortality and graft loss in de novo liver transplant recipients, and that patients on immunosuppressive therapy are at increased risk of skin cancer.1Transplant populations.Population-specific findings that do not map directly onto healthy adults, but they establish that this molecule has caused serious harm in real clinical use, which is the relevant point for anyone weighing an elective off-label course.
A randomised placebo-controlled study of once-weekly sirolimus alongside a 13-week exercise programme in older adults examined muscle strength and endurance endpoints.4Older adults in a single-centre trial.Small, short and focused on a narrow functional endpoint. It illustrates the state of the human evidence: several small trials probing surrogate and functional measures, none establishing longevity.
Where the evidence stops
This is the offering on the page where the gap between the hope and the evidence is widest. The lifespan data is in mice and other model organisms. The human data consists of small, short trials of safety and surrogate measures. No human study has shown that rapamycin extends lifespan or healthspan in any durable, clinically meaningful way, and the intermittent schedules used in longevity practice have not been studied for safety over the durations people actually take them. Meanwhile the drug is a genuine immunosuppressant with a boxed warning. Anyone considering this should treat it as experimental, and the decision belongs firmly with a physician who knows their full history.
What is inside
Sirolimus (rapamycin)
The sole active. A macrolide that inhibits the mechanistic target of rapamycin (mTOR), specifically the mTORC1 complex, via an intracellular complex with the FKBP-12 binding protein.
Form and route
Oral tablet, taken on an intermittent schedule set by the prescriber.
Sirolimus is orally bioavailable, so the route is unremarkable. The interesting choice is the schedule. Transplant use is daily and continuous, aiming at sustained immunosuppression; the intermittent schedule used off-label is intended to inhibit mTORC1 periodically while allowing recovery in between, on the theory that this preserves the metabolic and autophagy effects while limiting sustained immunosuppression. That theory has not been confirmed in humans, and it is the reason the safety of this schedule is described as unestablished rather than reassuring.
What to expect, and when
There is nothing to feel, which is part of what makes this difficult. The proposed benefits are not perceptible on a day-to-day basis, and the animal evidence they rest on has never been shown to apply to people. What can be perceptible are the side effects: mouth ulcers, changes in blood lipids, impaired wound healing and greater susceptibility to infection are the ones reported in clinical use. Your prescriber decides on laboratory monitoring, and you should report any infection promptly.
Regulatory status
Sirolimus is an FDA-approved drug, but only as an immunosuppressant. Everything about its use in this protocol is off-label: the indication, the intermittent weekly-style schedule, and the healthy population. No regulatory body has approved any drug for longevity. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Anyone with an active infection, or who is at elevated risk of infection. The boxed warning names increased susceptibility to infection, and this is the most immediate practical risk.
Anyone who is immunocompromised for any reason, or taking other immunosuppressive therapy.
Anyone with a current or prior malignancy, or significant skin cancer risk. The boxed warning names lymphoma and other malignancies, and the label notes increased skin cancer risk with limitation of sun and ultraviolet exposure advised.
Anyone with surgery or a procedure planned, or a wound that is healing. Impaired wound healing is a recognised effect of mTOR inhibition.
Anyone with significant hyperlipidaemia, since sirolimus is associated with raised cholesterol and triglycerides, or with significant liver or kidney impairment.
Anyone who is pregnant, breastfeeding, or planning a pregnancy.
Anyone who has not had this conversation properly with a physician who knows their full history. Of everything on this page, this is the offering where that matters most.
Anyone taking strong CYP3A4 inhibitors or inducers, or grapefruit, without a full interaction review; sirolimus exposure is highly sensitive to them.
Source: FDA label, RAPAMUNE (sirolimus), via DailyMed. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
The Burn Protocol Metabolic Support
BURN is a compounded lipotropic injection: a blend of B12 and three nutrient compounds involved in fat and methyl-group metabolism. It is the most modest offering on this page in terms of evidence, and the panel below says so plainly. It is nutrient support prescribed alongside diet and activity, not a weight-loss medication in the sense that the SHED actives are.
We will not tell you that it will. The biochemistry of each ingredient is well established, but the clinical evidence that an injected lipotropic blend changes body weight or body composition is thin, and what exists comes largely from settings where diet and activity were changed at the same time, which makes the injection's own contribution difficult to separate. It is offered as nutrient support alongside a broader plan, not as a weight-loss medication.
What is actually in it? ▾
Four things: methionine, an essential amino acid upstream of the body's main methyl-donor system; inositol, a second messenger in insulin signalling; choline, which is required to package fat for export from the liver; and vitamin B12, a cofactor in energy metabolism and red blood cell formation. Our own protocol copy does not consistently specify which B12 salt form is used, so ask the pharmacy which one is in your preparation.
Why inject it instead of taking a supplement? ▾
For B12 the argument is real: absorption from the gut depends on intrinsic factor and is impaired in a recognisable group of people, so injection bypasses that. For methionine, inositol and choline the case for injecting rather than swallowing is weaker and has not been settled by comparative studies. The blend is compounded sterile under USP standards for sterile preparations.
Is this FDA-approved? ▾
No. There is no FDA-approved lipotropic combination product and no approved indication for this blend, so the whole preparation is compounded and used off-label as nutrient support. Compounded medications are not FDA-approved. If you started this because of fatigue, ask your provider about testing rather than assuming a cause.
MIC + B12 Injection
A compounded intramuscular or subcutaneous injection combining vitamin B12 with methionine, inositol and choline, prescribed as nutrient support alongside diet and activity.
How it is understood to work
Each ingredient here has a real job in how the body handles fat and methyl groups. Choline is needed to package fat for export out of the liver. Methionine feeds the body's main methyl-donor system. Inositol sits in the insulin signalling pathway. B12 is a required cofactor in energy metabolism. What the blend is designed to do is make sure none of those inputs is the thing holding you back. What it is not is an appetite or metabolic drug, and the evidence that combining them changes body composition is thin.
The pharmacology underneath
The individual biochemistry is well established and uncontroversial: cobalamin as a cofactor for methionine synthase and methylmalonyl-CoA mutase; methionine as the substrate for S-adenosylmethionine and thus the principal biological methyl donor; phosphatidylcholine as an obligatory component of hepatic VLDL assembly, which is why choline deficiency produces hepatic steatosis in controlled human depletion studies; inositol phosphates as second messengers downstream of the insulin receptor. What does not follow from any of that is a quantified effect on body weight or body composition in people who are not deficient. The mechanistic chain from cofactor sufficiency to clinical fat loss has not been demonstrated for this combination, and the injectable route has been much less studied than oral supplementation for these compounds.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
Cobalamin's role as a cofactor in energy metabolism, one-carbon metabolism and erythropoiesis is well characterised, as are the consequences of deficiency.1General human physiology and deficiency states.This is evidence about correcting deficiency, not evidence that supplementing a replete person changes body weight. Direct for the biochemistry, extrapolated for anything else.
Choline is an essential nutrient whose deficiency is associated with hepatic fat accumulation, and dietary requirements and deficiency consequences are documented in review.4Human nutrition studies, largely oral intake.Oral dietary intake rather than injection, and hepatic fat rather than body weight. The read-across to an injected blend intended for body composition is indirect.
Methionine's contribution to S-adenosylmethionine production, glutathione biosynthesis and hepatic lipid metabolism is described in review.2Human and preclinical nutritional biochemistry.Mechanistic review rather than a clinical outcome trial, and not specific to an injected combination product.
Inositol isomers act as second messengers in insulin signal transduction, with human clinical data in metabolic contexts.3Clinical studies largely in metabolic and reproductive-endocrine contexts, using oral dosing.Oral dosing and different clinical contexts. Injected inositol as part of a lipotropic blend has not been studied to the same standard.
Where the evidence stops
Be clear-eyed about this one. The biochemistry of each ingredient is solid; the clinical evidence that the combination changes body weight or body composition is not. Most of the supporting literature concerns nutrient physiology, deficiency correction, or oral supplementation, rather than randomised trials of an injected lipotropic blend against placebo with body-composition endpoints. Where such work exists it is small and largely from physician-supervised weight-management settings where diet and activity were also changed, which makes attribution to the injection difficult. This offering is presented as nutrient support alongside a broader plan, and any expectation beyond that is not supported by the evidence.
What is inside
Vitamin B12 (cobalamin)
An essential water-soluble vitamin and a required cofactor in the methylmalonyl-CoA pathway and in one-carbon metabolism supporting DNA synthesis and red blood cell formation. Correcting a genuine deficiency has clear effects; supplementing beyond sufficiency does not have the same evidence base. The protocol page names the blend as containing B12 without always specifying the salt form, so ask your pharmacy which form yours contains.
Methionine
An essential sulphur-containing amino acid, a precursor to S-adenosylmethionine and therefore upstream of a wide range of methylation reactions, and a contributor to glutathione synthesis via the transsulfuration pathway. It is described in the lipotropic literature for its role in hepatic lipid handling.
Inositol
A carbocyclic sugar acting as a second messenger in insulin signal transduction. The published clinical work is mostly on myo- and D-chiro-inositol in metabolic contexts, and mostly oral rather than injected, which is a real gap for an injectable blend.
Choline
An essential nutrient and the precursor of phosphatidylcholine, which is required for hepatic export of lipid as very-low-density lipoprotein. Choline deficiency is associated with hepatic fat accumulation, and this is the clearest mechanistic rationale in the blend.
Form and route
Injection, given on a schedule set by your prescriber.
The rationale for injecting rather than swallowing these compounds is bypassing variable gastrointestinal absorption, which is a genuine consideration for B12 in particular, where absorption depends on intrinsic factor and is impaired in a recognisable set of people. For methionine, inositol and choline the case for injection over oral intake is weaker and has not been established by comparative studies. The blend is compounded sterile under USP standards for sterile preparations.
What to expect, and when
Expect this to work as a supporting piece rather than a driver. It is dosed on a schedule rather than titrated. Any change in how you feel is difficult to separate from the diet and activity changes that accompany it, and the honest position is that we cannot tell you which is responsible. If you started this because of fatigue, ask your provider about testing rather than assuming.
Regulatory status
This is a compounded lipotropic blend. There is no FDA-approved lipotropic combination product and no FDA-approved indication for this blend, so the entire preparation is compounded and used off-label as nutrient support. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Anyone with a known allergy or hypersensitivity to any component of the blend, or to a preservative or excipient used in it.
Anyone with Leber hereditary optic neuropathy or a related optic neuropathy, where cyanocobalamin specifically has historically been cautioned against; ask your prescriber which B12 form your preparation uses.
People with significant kidney impairment, who should discuss the load of these compounds with their prescriber before starting.
Anyone who is pregnant or breastfeeding, without discussing it with their clinician first, since a compounded injectable blend has not been characterised for use in pregnancy.
Anyone expecting this to substitute for evaluation of fatigue, low energy or unexplained weight change. Those warrant a clinical work-up, and this is not one.
Source: No FDA label exists for this compounded combination; these are drawn from the component nutrient literature and general compounded-injectable precautions rather than from an approved label. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
The Desire Protocol Sexual Wellness
DESIRE covers the sexual-wellness offerings a prescriber may consider after an intake review. Most of them are built on PDE5 inhibitors — sildenafil, tadalafil and vardenafil — which share one mechanism: they slow the enzyme that breaks down the blood-flow signal produced during sexual stimulation, and the labels are explicit that they do nothing in the absence of that stimulation. A second group acts on central pathways instead, using the melanocortin agonist bremelanotide and, in some preparations, oxytocin. Several offerings are compounded combinations that no FDA-approved product matches; where that is the case, the evidence below describes the individual actives studied separately, not the combination, and says so.
No. Every offering here that contains a PDE5 inhibitor is absolutely contraindicated with any form of organic nitrate, because the combination can cause a dangerous drop in blood pressure. The same applies to guanylate cyclase stimulators such as riociguat. Caution also applies with alpha-blockers and other antihypertensives. Tell your provider every medication you take, including anything you use only occasionally.
Why do some of these combine two PDE5 inhibitors? ▾
The rationale offered is pairing a faster-acting agent with a longer-acting one. You should know what that rationale is not: the approved labels do not contemplate taking two PDE5 inhibitors together, no adequate published trial has tested these specific combinations, and additive vasodilation with a greater drop in blood pressure is the predictable risk. Two actives is not automatically two independent mechanisms, because both act on the same enzyme.
What is different about the bremelanotide options? ▾
Almost everything is different from the approved product. Bremelanotide is FDA-approved as a subcutaneous autoinjector for acquired, generalised hypoactive sexual desire disorder in premenopausal women, and that is the population the RECONNECT trials studied. A nasal spray is a different route with no published bioequivalence to the approved injector, and use in men is off-label. It also raises blood pressure transiently, which is why uncontrolled hypertension and known cardiovascular disease are contraindications on the approved label.
Is the apomorphine in VAST an approved medicine for this? ▾
Not in the United States, and not for this. Sublingual apomorphine for erectile dysfunction was never approved here; the application was withdrawn after an advisory committee raised concerns about hypotension and syncope. Apomorphine is approved in the United States only for off episodes in Parkinson's disease, by a different route and at a much higher clinical exposure, where its label carries severe nausea warnings and a contraindication with 5HT3 antagonists. It acts as a central dopamine agonist, a different pathway from the blood-flow enzyme the other two actives work on.
Tadalafil ODT
Tadalafil in a tablet that dissolves in the mouth. It is the long-window PDE5 inhibitor, prescribed either before the moment or as a low daily dose.
Sildenafil ODT
Sildenafil in a tablet that dissolves in the mouth. It is the original PDE5 inhibitor and the shortest-acting of the three used in this protocol.
Sildenafil + Tadalafil Combo ODT
A compounded troche containing two PDE5 inhibitors, sildenafil and tadalafil, in one dissolving tablet.
Epiq Chew
A compounded chewable gum containing two PDE5 inhibitors, tadalafil and vardenafil, together with vitamin D3 and vitamin K2.
VAST
A compounded sublingual tablet containing apomorphine alongside two PDE5 inhibitors, tadalafil and vardenafil. Apomorphine is a central dopamine agonist, a different pathway from the blood-flow enzyme the other two act on.
Bremelanotide Nasal Spray
Bremelanotide, a melanocortin receptor agonist, compounded as a nasal spray. Bremelanotide is FDA-approved as a subcutaneous autoinjector for one specific condition in premenopausal women; a nasal spray is a different route.
Olympus
A compounded sublingual tablet containing two peptides, bremelanotide and oxytocin. Neither is approved for sexual function in the form used here.
Olympus Peak
A compounded sublingual tablet containing bremelanotide, oxytocin and tadalafil — the two peptides from Olympus plus a PDE5 inhibitor.
How it is understood to work
An erection depends on blood flow into the penis, and that blood flow depends on a signalling molecule called cGMP. An enzyme called PDE5 breaks cGMP down. Tadalafil slows that enzyme, so the signal lasts longer. Sexual stimulation is still required — the label is explicit that PDE5 inhibition has no effect without it.
The pharmacology underneath
During sexual stimulation, nitric oxide released from nerve terminals and endothelial cells drives cGMP synthesis in cavernosal smooth muscle, producing relaxation and increased inflow. Tadalafil inhibits PDE5, the enzyme that degrades cGMP, raising cGMP concentrations locally. The label states plainly that because sexual stimulation is required to initiate the local release of nitric oxide, PDE5 inhibition has no effect in its absence. The mean terminal half-life is 17.5 hours in healthy subjects, and the label notes the same PDE5 effect on cGMP is also observed in smooth muscle outside the penis, which is the origin of the blood-pressure interactions. What is inferred rather than measured for our preparation is the absorption profile: the label figures come from the reference tablet, not from a compounded orally disintegrating form.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
In two primary US trials of on-demand tadalafil 20 mg, the IIEF Erectile Function domain rose 6.9 and 9.3 points from baseline versus -0.2 and 0.3 on placebo, and successful-intercourse rates (SEP3) rose 34 and 44 percentage points versus 5 and 4 on placebo (all p<.001).1402 men with erectile dysfunction of various severities and causes, mean age 59 (range 27 to 87).Same active and same oral route, but the trials used the reference film-coated tablet at a stated dose, not a compounded orally disintegrating form; absorption from a troche has not been shown equivalent.
The label describes an on-demand development programme of 22 trials of up to 24 weeks involving over 4,000 patients, plus a separate once-daily programme of three trials in 853 patients at doses of 2.5 to 10 mg.1Men with erectile dysfunction, including subgroups with diabetes and post-radical-prostatectomy patients.Direct for the active and the oral route; the dosage form differs, and the daily and on-demand programmes are separate bodies of evidence that should not be read across to each other.
A network meta-analysis of 82 randomized trials (47,626 patients for efficacy; 72 trials and 20,325 patients for adverse events) compared PDE5 inhibitors against placebo and each other, and reported trade-offs between efficacy and adverse events across starting doses rather than a single best agent.2Men with erectile dysfunction across 82 randomized controlled trials.Pooled reference-product tablets at labeled doses; no compounded orally disintegrating arm was included, and the analysis compares agents rather than dosage forms.
European Association of Urology guidance describes PDE5 inhibitors as first-line pharmacotherapy for erectile dysfunction and sets out on-demand versus daily dosing strategies and contraindication management.3Guideline synthesis for men with erectile dysfunction.A guideline, not a trial, and written around approved products. It carries no recommendation about compounded dosage forms.
Where the evidence stops
Every efficacy number above comes from the reference brand tablet at a labeled dose. The active is the same and the route is the same, but the dosage form is not, and no published bioequivalence study comparing a compounded orally disintegrating tadalafil with the reference tablet was identified. Onset, peak level and duration could differ.
What is inside
Tadalafil
Phosphodiesterase type 5 (PDE5) inhibitor — the sole active. The label describes a mean terminal half-life of 17.5 hours, which is why it is described as the long-window option.
Form and route
Orally disintegrating tablet that dissolves in the mouth, taken before the moment or on a daily schedule as the prescriber directs.
An orally disintegrating troche dissolves in the mouth without water. The rationale is practical rather than pharmacokinetic: discretion, no swallowing a tablet, and no glass of water in the moment. No published bioequivalence study comparing a compounded orally disintegrating form of these actives with the reference tablets was identified, so onset and total exposure may differ from the numbers in the label.
What to expect, and when
Response varies widely. In the trials above, roughly half to two thirds of attempts ended in successful intercourse on active drug, and a substantial minority of men saw little change. Headache, flushing, nasal congestion, indigestion and back or muscle ache are the common side effects. Whether tadalafil is appropriate for you at all, and in which schedule, is your prescriber's decision.
Regulatory status
Compounded tadalafil in an orally disintegrating form is not an FDA-approved product; the reference brand tablet containing the same active is. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Do not use with any form of nitrate medicine, whether taken regularly or only now and then. The reference brand labels state this combination is contraindicated because PDE5 inhibitors potentiate the blood-pressure-lowering effect of nitrates.
Do not use with a guanylate cyclase stimulator such as riociguat. The label states PDE5 inhibitors may potentiate the hypotensive effects of these medicines.
Alpha-blockers, other blood-pressure medicines and substantial alcohol can combine with a PDE5 inhibitor to lower blood pressure enough to cause symptomatic hypotension or fainting. Tell your prescriber every medicine and supplement you take.
Not appropriate if sexual activity is inadvisable because of your cardiovascular status. The label directs prescribers to weigh cardiac risk before treating erectile dysfunction at all.
Stop and seek medical attention for sudden loss of vision in one or both eyes, which could be a sign of non-arteritic anterior ischemic optic neuropathy (NAION). The label advises caution in anyone with a history of NAION or a crowded optic disc.
Stop and seek prompt medical attention for a sudden decrease or loss of hearing.
Seek emergency treatment for an erection lasting longer than four hours. The label advises caution in people predisposed to priapism, including sickle cell anemia, multiple myeloma or leukemia, or an anatomical deformation of the penis.
Not for anyone with a known serious hypersensitivity to the active ingredient or to any component of the preparation.
Source: FDA label, CIALIS (tadalafil), SPL v52, effective 2026-06-03. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
Sexual stimulation releases nitric oxide in the penis, which raises a signalling molecule called cGMP and relaxes the smooth muscle so blood flows in. Sildenafil slows the enzyme that breaks cGMP down. It does nothing on its own — the label states it has no effect in the absence of sexual stimulation.
The pharmacology underneath
Nitric oxide released during sexual stimulation activates guanylate cyclase, raising cGMP in cavernosal smooth muscle and producing relaxation and inflow. Sildenafil inhibits PDE5, which degrades that cGMP. The label notes sildenafil has no direct relaxant effect on isolated human corpus cavernosum — the whole effect is amplification of an existing signal. Mean absolute bioavailability of the reference tablet is 41 percent (range 25 to 63), maximum plasma concentrations are reached in a median 60 minutes fasted, and both sildenafil and its active metabolite have terminal half-lives of about four hours. A high-fat meal delays the time to peak by a mean of 60 minutes and lowers the peak. Absorption from a compounded orally disintegrating form is inferred, not measured.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
The label describes 21 randomized, double-blind, placebo-controlled trials of up to six months, at doses of 25, 50 and 100 mg, in more than 3,000 patients, with statistically significant improvement over placebo in all 21 studies on the co-primary IIEF questions on achieving and maintaining erections.1Men aged 19 to 87 with erectile dysfunction of organic, psychogenic and mixed causes, mean duration five years.Same active and same oral route, but the reference film-coated tablet at labeled doses, not a compounded orally disintegrating form.
In the network meta-analysis of starting doses, sildenafil 50 mg had the greatest efficacy of the agents compared but also the highest rate of overall adverse events — the analysis frames PDE5 selection as a trade-off rather than a ranking.282 randomized trials, 47,626 patients for the efficacy analysis.Reference products at labeled starting doses. No compounded orally disintegrating arm; conclusions about a 50 mg tablet do not transfer to a different dosage form at a compounded strength.
European Association of Urology guidance positions PDE5 inhibitors as first-line pharmacotherapy and details on-demand dosing and contraindication management, including the absolute nitrate contraindication.3Guideline synthesis for men with erectile dysfunction.A guideline built on approved products; it makes no statement about compounded dosage forms.
A narrative review of PDE5 non-response reports that the efficacy of PDE5 inhibitors is about 70 percent, and that it is significantly lower in difficult-to-treat subpopulations.4Review of published PDE5 inhibitor experience; not a pooled quantitative estimate.This is a narrative review figure, not a meta-analytic estimate, and it describes approved products in their labeled forms.
Where the evidence stops
The whole evidence base is the reference tablet at labeled doses. Sildenafil absorption is already variable in the label itself — bioavailability ranges from 25 to 63 percent and food shifts the peak by an hour — so the additional uncertainty introduced by an unstudied compounded dosage form sits on top of a drug whose exposure already varies a great deal between people.
What is inside
Sildenafil
Phosphodiesterase type 5 (PDE5) inhibitor — the sole active. The label describes a terminal half-life of about four hours for sildenafil and its active metabolite, which is why it is described as the on-demand option.
Form and route
Orally disintegrating tablet that dissolves in the mouth, taken before activity.
An orally disintegrating troche dissolves in the mouth without water. The rationale is practical rather than pharmacokinetic: discretion, no swallowing a tablet, and no glass of water in the moment. No published bioequivalence study comparing a compounded orally disintegrating form of these actives with the reference tablets was identified, so onset and total exposure may differ from the numbers in the label.
What to expect, and when
Sildenafil is the shortest-acting of the three PDE5 inhibitors in this protocol. Timing matters more than with tadalafil, and a heavy meal beforehand may delay it. Headache, flushing, indigestion, nasal congestion and altered colour vision are the common side effects. A substantial minority of men do not respond adequately to any single PDE5 inhibitor.
Regulatory status
Compounded sildenafil in an orally disintegrating form is not an FDA-approved product; the reference brand tablet containing the same active is. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Do not use with any form of nitrate medicine, whether taken regularly or only now and then. The reference brand labels state this combination is contraindicated because PDE5 inhibitors potentiate the blood-pressure-lowering effect of nitrates.
Do not use with a guanylate cyclase stimulator such as riociguat. The label states PDE5 inhibitors may potentiate the hypotensive effects of these medicines.
Alpha-blockers, other blood-pressure medicines and substantial alcohol can combine with a PDE5 inhibitor to lower blood pressure enough to cause symptomatic hypotension or fainting. Tell your prescriber every medicine and supplement you take.
Not appropriate if sexual activity is inadvisable because of your cardiovascular status. The label directs prescribers to weigh cardiac risk before treating erectile dysfunction at all.
Stop and seek medical attention for sudden loss of vision in one or both eyes, which could be a sign of non-arteritic anterior ischemic optic neuropathy (NAION). The label advises caution in anyone with a history of NAION or a crowded optic disc.
Stop and seek prompt medical attention for a sudden decrease or loss of hearing.
Seek emergency treatment for an erection lasting longer than four hours. The label advises caution in people predisposed to priapism, including sickle cell anemia, multiple myeloma or leukemia, or an anatomical deformation of the penis.
Not for anyone with a known serious hypersensitivity to the active ingredient or to any component of the preparation.
Source: FDA label, VIAGRA (sildenafil citrate), SPL v6, effective 2023-11-17. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
Both actives slow the same enzyme, PDE5, so that the blood-flow signal produced during sexual stimulation lasts longer. They differ in how long they stay in the body. Because they act on the same target, putting them together is not the same as combining two different mechanisms.
The pharmacology underneath
Sildenafil and tadalafil are both competitive inhibitors of PDE5 and both raise cGMP in cavernosal smooth muscle by the same route. Their pharmacokinetics differ — roughly a four-hour terminal half-life for sildenafil and its active metabolite versus 17.5 hours for tadalafil — which is the pharmacokinetic rationale usually offered for pairing them. What is inferred rather than measured is everything about the pair: neither label contemplates concurrent PDE5 use, no interaction study of the two together was identified, and the effect of blocking one enzyme with two inhibitors at once has not been characterised in a published trial. The predictable class consequence is additive systemic vasodilation, because PDE5 inhibition also occurs in vascular smooth muscle outside the penis.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
Tadalafil 20 mg on demand raised the IIEF Erectile Function domain by 6.9 and 9.3 points and successful-intercourse rates (SEP3) by 34 and 44 percentage points over baseline in the two primary US trials (n=402), versus small placebo changes.1Men with erectile dysfunction, mean age 59.Tadalafil alone, as the reference tablet at a labeled dose. Not this combination, not this dosage form.
Sildenafil showed statistically significant improvement over placebo in all 21 of its randomized controlled trials, at 25, 50 and 100 mg, in more than 3,000 patients.2Men aged 19 to 87 with erectile dysfunction.Sildenafil alone, as the reference tablet at labeled doses. Not this combination, not this dosage form.
The 82-trial network meta-analysis compared PDE5 inhibitors head to head and against placebo and framed the choice as a trade-off between efficacy and adverse events. Its comparisons are between single agents; it did not evaluate two PDE5 inhibitors taken together.347,626 patients across 82 randomized trials.The largest comparative dataset available still contains no arm in which two PDE5 inhibitors were given together, which is the specific question this offering raises.
Both reference labels state that PDE5 inhibitors potentiate the hypotensive effects of nitrates and of guanylate cyclase stimulators, and advise caution with alpha-blockers and antihypertensives because the combination can lower blood pressure enough to cause fainting.1Label safety statements, drawn from clinical pharmacology studies in the reference programmes.These are single-agent statements. Neither label addresses what happens when a second PDE5 inhibitor is added, so the blood-pressure risk of the pair is inferred from the class, not measured.
Where the evidence stops
The approved labels do not contemplate taking two PDE5 inhibitors at the same time, and no adequate published randomized trial of this specific pairing was identified. The predictable pharmacologic consequence of combining two drugs from the same class is additive vasodilation and a larger fall in blood pressure, not a larger benefit. Read the evidence below as evidence for each active taken on its own, at its own labeled dose, in its own dosage form — nothing here measures the pair together.
What is inside
Sildenafil
PDE5 inhibitor. Studied and labeled as a single agent with a terminal half-life of about four hours.
Tadalafil
PDE5 inhibitor acting on the same enzyme by the same mechanism, with a mean terminal half-life of 17.5 hours. Because both actives inhibit the same enzyme, their contribution in this combination is not independent, and no trial of the pair was identified.
Form and route
Orally disintegrating troche that dissolves in the mouth, taken on demand.
An orally disintegrating troche dissolves in the mouth without water. The rationale is practical rather than pharmacokinetic: discretion, no swallowing a tablet, and no glass of water in the moment. No published bioequivalence study comparing a compounded orally disintegrating form of these actives with the reference tablets was identified, so onset and total exposure may differ from the numbers in the label.
What to expect, and when
Timing and duration are the reasons this pairing is compounded, and neither has been measured for the pair. Side effects common to the class — headache, flushing, nasal congestion, indigestion, back or muscle ache — may be more likely when two agents of the same class are taken at once. Whether a two-agent troche is appropriate for you is entirely your prescriber's decision.
Regulatory status
This is a compounded combination of two separate prescription actives in a single dosage form. It is not an FDA-approved product, and no FDA-approved product combines two PDE5 inhibitors. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Do not use with any form of nitrate medicine, whether taken regularly or only now and then. The reference brand labels state this combination is contraindicated because PDE5 inhibitors potentiate the blood-pressure-lowering effect of nitrates.
Do not use with a guanylate cyclase stimulator such as riociguat. The label states PDE5 inhibitors may potentiate the hypotensive effects of these medicines.
Alpha-blockers, other blood-pressure medicines and substantial alcohol can combine with a PDE5 inhibitor to lower blood pressure enough to cause symptomatic hypotension or fainting. Tell your prescriber every medicine and supplement you take.
Not appropriate if sexual activity is inadvisable because of your cardiovascular status. The label directs prescribers to weigh cardiac risk before treating erectile dysfunction at all.
Stop and seek medical attention for sudden loss of vision in one or both eyes, which could be a sign of non-arteritic anterior ischemic optic neuropathy (NAION). The label advises caution in anyone with a history of NAION or a crowded optic disc.
Stop and seek prompt medical attention for a sudden decrease or loss of hearing.
Seek emergency treatment for an erection lasting longer than four hours. The label advises caution in people predisposed to priapism, including sickle cell anemia, multiple myeloma or leukemia, or an anatomical deformation of the penis.
Not for anyone with a known serious hypersensitivity to the active ingredient or to any component of the preparation.
Because this preparation contains two PDE5 inhibitors, the blood-pressure cautions above apply with more weight, not less. Do not add any other PDE5 inhibitor — including a separately prescribed sildenafil, tadalafil, vardenafil or avanafil — to this preparation.
Source: FDA labels, CIALIS (tadalafil), SPL v52, effective 2026-06-03, and VIAGRA (sildenafil citrate), SPL v6, effective 2023-11-17. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
The two active medicines slow the same enzyme, PDE5, so the blood-flow signal produced during sexual stimulation lasts longer. The two vitamins are nutritional ingredients in the blend; they are not the reason the preparation is prescription-only, and there is no trial showing what they add here.
The pharmacology underneath
Tadalafil and vardenafil are both competitive PDE5 inhibitors raising cGMP in cavernosal smooth muscle by the identical route, differing mainly in half-life (17.5 hours versus roughly four to five hours) and in ancillary cautions. Because they share a target, their combination is not mechanistically additive in the way two different pathways would be, and the class effect on vascular smooth muscle outside the penis is what drives the shared hypotension warnings. Vitamin D3 is a secosteroid that undergoes hepatic and renal hydroxylation to calcitriol and acts through the vitamin D receptor; vitamin K2 is a cofactor for gamma-carboxylation of vitamin K-dependent proteins. Neither has a characterised role in the erectile pathway, and no pharmacokinetic or clinical study of this four-ingredient chewable was identified.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
In four major double-blind, randomized, placebo-controlled fixed-dose trials of vardenafil in 2,431 men, the IIEF Erectile Function domain rose from a mean baseline of about 13 to 18, 21 and 21 at 5, 10 and 20 mg respectively, against 15 on placebo in the North American trial (p<0.0001), with the European trial (n=803) confirming the result.1Men aged 20 to 83, mean age 57, including diabetes and post-prostatectomy subgroups.Vardenafil alone, as an oral tablet at labeled doses. Not this combination, not a chewable gum, and not co-administered with a second PDE5 inhibitor.
Tadalafil 20 mg on demand raised SEP3 successful-intercourse rates by 34 and 44 percentage points from baseline versus 5 and 4 on placebo in the two primary US trials (n=402).2Men with erectile dysfunction, mean age 59.Tadalafil alone, as the reference tablet at a labeled dose. Not this combination and not a chewable form.
The 82-trial network meta-analysis compared PDE5 inhibitors including tadalafil and vardenafil against placebo and one another, and reported trade-offs between efficacy and adverse events rather than a single superior agent or a superior combination.347,626 patients across 82 randomized trials of single agents.No arm combined two PDE5 inhibitors, so the specific question raised by this preparation is unanswered by the largest comparative dataset available.
The vardenafil label reports that a single 10 mg dose produced a placebo-subtracted mean QTcF change of 5 msec, and that co-administration with gatifloxacin 400 mg produced an additive change of 9 msec. The label states the clinical impact of these QT changes is unknown and advises that people with congenital QT syndrome or on class IA or III antiarrhythmics avoid vardenafil.1Healthy volunteers (n=44) in a postmarketing QT study.A surrogate electrocardiographic endpoint in healthy volunteers, not a clinical outcome, and measured for vardenafil alone rather than in this blend.
Where the evidence stops
Two of the four ingredients have substantial single-agent evidence and two have essentially none in this context. Beyond that, the approved labels do not contemplate concurrent PDE5 inhibitor use, no published trial of tadalafil plus vardenafil was identified, and no bioavailability data for a chewable gum containing either active was identified. The predictable consequence of two same-class actives is additive vasodilation and a larger blood-pressure effect.
What is inside
Tadalafil
PDE5 inhibitor. The long-half-life member of the class, with a mean terminal half-life of 17.5 hours per the reference label.
Vardenafil
PDE5 inhibitor acting on the same enzyme, with a terminal half-life of about four to five hours per the reference label. Its label carries a QT caution the other PDE5 inhibitors do not.
Vitamin D3 (cholecalciferol)
Included in the compounded blend as a nutritional ingredient. No trial substantiating a contribution of vitamin D3 to erectile function in this combination was identified; the evidence for its contribution here is limited.
Vitamin K2
Included in the compounded blend, conventionally alongside vitamin D3 for calcium handling. No trial substantiating a contribution of vitamin K2 to erectile or sexual function was identified; the evidence for its contribution here is limited.
Form and route
Chewable gum, taken daily or as directed by the prescriber.
A chew avoids swallowing a tablet and needs no water. The rationale is adherence and convenience rather than pharmacokinetics. Chewing may begin some absorption across the oral mucosa, but no published study characterised the absorption of tadalafil or vardenafil from this chewable form, so the exposure achieved is not established.
What to expect, and when
Class side effects — headache, flushing, nasal congestion, indigestion, back or muscle ache — may be more likely when two same-class actives are taken together. The vitamins are unlikely to produce a noticeable effect on sexual function. Whether a daily two-PDE5 chewable is appropriate for you is your prescriber's decision.
Regulatory status
This is a compounded four-ingredient chewable preparation. It is not an FDA-approved product, no FDA-approved product combines two PDE5 inhibitors, and no FDA-approved product combines a PDE5 inhibitor with vitamin D3 and K2. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Do not use with any form of nitrate medicine, whether taken regularly or only now and then. The reference brand labels state this combination is contraindicated because PDE5 inhibitors potentiate the blood-pressure-lowering effect of nitrates.
Do not use with a guanylate cyclase stimulator such as riociguat. The label states PDE5 inhibitors may potentiate the hypotensive effects of these medicines.
Alpha-blockers, other blood-pressure medicines and substantial alcohol can combine with a PDE5 inhibitor to lower blood pressure enough to cause symptomatic hypotension or fainting. Tell your prescriber every medicine and supplement you take.
Not appropriate if sexual activity is inadvisable because of your cardiovascular status. The label directs prescribers to weigh cardiac risk before treating erectile dysfunction at all.
Stop and seek medical attention for sudden loss of vision in one or both eyes, which could be a sign of non-arteritic anterior ischemic optic neuropathy (NAION). The label advises caution in anyone with a history of NAION or a crowded optic disc.
Stop and seek prompt medical attention for a sudden decrease or loss of hearing.
Seek emergency treatment for an erection lasting longer than four hours. The label advises caution in people predisposed to priapism, including sickle cell anemia, multiple myeloma or leukemia, or an anatomical deformation of the penis.
Not for anyone with a known serious hypersensitivity to the active ingredient or to any component of the preparation.
Vardenafil carries a caution the other two do not: the label advises that people with congenital QT syndrome, or taking class IA or class III antiarrhythmics, avoid vardenafil.
Because this preparation contains two PDE5 inhibitors, the nitrate contraindication and the alpha-blocker and blood-pressure cautions apply with more weight. Do not add any other PDE5 inhibitor to it.
The reference vardenafil orally disintegrating product contains phenylalanine, which matters for anyone with phenylketonuria. Ask the pharmacy about the excipients in this specific preparation.
Source: FDA labels, CIALIS (tadalafil), SPL v52, effective 2026-06-03, and Vardenafil Hydrochloride Tablets, SPL v9, effective 2026-07-15. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
Two of the three actives slow the same blood-flow enzyme in the penis. The third, apomorphine, acts in the brain on dopamine signalling rather than on blood flow. That is genuinely a different pathway — but the apomorphine evidence for sexual function comes from an old sublingual product that was never approved in the United States, and no study of these three together was identified.
The pharmacology underneath
Tadalafil and vardenafil are both competitive PDE5 inhibitors raising cavernosal cGMP by the identical route; combining them is same-target, not complementary. Apomorphine is pharmacologically distinct: a dopamine agonist whose proposed pro-erectile action is central, at oxytocinergic neurons of the paraventricular nucleus, with the erectile response then descending through spinal pathways. The US reference label for apomorphine states its precise mechanism in Parkinson's disease is unknown and attributes it to post-synaptic D2-type receptor stimulation in the caudate-putamen; that label is for a subcutaneous product at Parkinson's doses and says nothing about erectile function. The apomorphine dose and route studied for erectile dysfunction — sublingual, 2 to 6 mg — correspond to a product that is not marketed in the United States. Nothing about the three-way pharmacokinetics or the combined haemodynamic effect of this preparation has been measured.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
In an 8-week multicenter double-blind trial, 569 men were randomized to dose-optimized sublingual apomorphine, fixed 5 or 6 mg doses, or placebo. Across apomorphine groups, 48 to 53 percent of patients achieved and maintained an erection firm enough for intercourse versus 35 percent on placebo, and 45 to 51 percent of attempts resulted in intercourse versus 33 percent (p<=0.001). Nausea was the most common side effect and was dose related.1569 men with erectile dysfunction.The sublingual apomorphine product studied here was never approved in the United States and is no longer marketed anywhere. The dose range and formulation are not the US approved product, and the trial studied apomorphine alone, not with two PDE5 inhibitors.
A systematic review and meta-analysis of nine randomized controlled trials of sublingual apomorphine (2 to 6 mg, 4 to 8 weeks) found apomorphine better than placebo in all studies reporting successful intercourse attempts, by 6 to 27 percentage points, though the difference was not statistically significant in a post-radical-prostatectomy population and erectile function score differences were not clinically relevant in diabetic and post-prostatectomy subgroups. Discontinuation for adverse events was higher on apomorphine, particularly at higher doses.2Nine randomized controlled trials of men with erectile dysfunction; evidence search closed January 2019.All trials used the sublingual formulation that was never US-approved. The effect size is modest, subgroup results were inconsistent, and no trial combined apomorphine with a PDE5 inhibitor.
Vardenafil raised the IIEF Erectile Function domain from a mean baseline of about 13 to 18, 21 and 21 at 5, 10 and 20 mg versus 15 on placebo (p<0.0001) in a 762-patient North American trial, confirmed in a 803-patient European trial.3Men aged 20 to 83 with erectile dysfunction, mean age 57.Vardenafil alone as an oral tablet at labeled doses, not sublingual, not in this three-active preparation.
Tadalafil 20 mg on demand raised SEP3 successful-intercourse rates by 34 and 44 percentage points from baseline versus 5 and 4 on placebo in the two primary US trials (n=402).4Men with erectile dysfunction, mean age 59.Tadalafil alone as the reference tablet at a labeled dose, not sublingual, not in this three-active preparation.
The US apomorphine label contraindicates concomitant 5HT3 antagonists including ondansetron, granisetron, dolasetron, palonosetron and alosetron, citing reports of profound hypotension and loss of consciousness, and reports that 98 percent of patients in the domestic clinical studies were premedicated with an antiemetic — with 31 percent still experiencing nausea and 11 percent vomiting.5Patients with advanced Parkinson's disease receiving subcutaneous apomorphine at Parkinson's doses.A different indication, a different route and much higher clinical exposure than a sublingual erectile dysfunction dose. The contraindication and the nausea burden are nonetheless the best US regulatory characterisation of the molecule available.
Where the evidence stops
Two separate problems stack here. First, the apomorphine evidence for sexual function is old, modest in size, and comes from a sublingual product that was never approved in the United States and is no longer marketed — so it describes a route and dose that are not the US approved product, whose approved use is Parkinson's off episodes. Second, tadalafil and vardenafil are two inhibitors of the same enzyme; the approved labels do not contemplate concurrent PDE5 use, no adequate published trial of that pairing was identified, and additive vasodilation and hypotension are the predictable risk. No study of all three actives together was identified at all.
What is inside
Apomorphine
Non-ergoline dopamine agonist. The reference US label describes high in vitro affinity for the dopamine D4 receptor and moderate affinity for D2, D3 and D5. In the erectile dysfunction literature the proposed site is central — dopaminergic signalling in the hypothalamic paraventricular nucleus — which is a different pathway from PDE5 inhibition. Its US approval is for Parkinson's off episodes, not for sexual function.
Tadalafil
PDE5 inhibitor with a mean terminal half-life of 17.5 hours per the reference label.
Vardenafil
PDE5 inhibitor acting on the same enzyme as tadalafil, terminal half-life about four to five hours, and carrying a QT caution the other PDE5 inhibitors do not.
Form and route
Sublingual dissolving tablet, taken roughly 20 to 30 minutes before activity.
The sublingual route is the one the apomorphine erectile dysfunction literature used, because apomorphine has poor and erratic oral bioavailability and extensive first-pass metabolism, so swallowing it is not a practical route. For the two PDE5 inhibitors the sublingual route is a formulation convenience rather than a pharmacokinetic necessity, and their absorption from this form has not been characterised in a published study.
What to expect, and when
Nausea is the most consistently reported effect of sublingual apomorphine and was dose-related in the trials above; discontinuation for adverse events was higher on apomorphine than placebo. The PDE5 class side effects — headache, flushing, nasal congestion, back or muscle ache — may also occur, and three actives that all lower blood pressure may combine. There is no published trial of this three-active preparation, so nobody can tell you what to expect from it specifically. This is a prescriber's judgement call, not a product with an established response profile.
Regulatory status
This is a compounded three-active sublingual preparation and is not an FDA-approved product. Apomorphine is FDA-approved in the United States only for Parkinson's disease off episodes; it has never been approved in the United States for erectile dysfunction, in any form. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Do not use with any form of nitrate medicine, whether taken regularly or only now and then. The reference brand labels state this combination is contraindicated because PDE5 inhibitors potentiate the blood-pressure-lowering effect of nitrates.
Do not use with a guanylate cyclase stimulator such as riociguat. The label states PDE5 inhibitors may potentiate the hypotensive effects of these medicines.
Alpha-blockers, other blood-pressure medicines and substantial alcohol can combine with a PDE5 inhibitor to lower blood pressure enough to cause symptomatic hypotension or fainting. Tell your prescriber every medicine and supplement you take.
Not appropriate if sexual activity is inadvisable because of your cardiovascular status. The label directs prescribers to weigh cardiac risk before treating erectile dysfunction at all.
Stop and seek medical attention for sudden loss of vision in one or both eyes, which could be a sign of non-arteritic anterior ischemic optic neuropathy (NAION). The label advises caution in anyone with a history of NAION or a crowded optic disc.
Stop and seek prompt medical attention for a sudden decrease or loss of hearing.
Seek emergency treatment for an erection lasting longer than four hours. The label advises caution in people predisposed to priapism, including sickle cell anemia, multiple myeloma or leukemia, or an anatomical deformation of the penis.
Not for anyone with a known serious hypersensitivity to the active ingredient or to any component of the preparation.
Vardenafil carries a caution the other two do not: the label advises that people with congenital QT syndrome, or taking class IA or class III antiarrhythmics, avoid vardenafil.
Do not use with a 5HT3 antagonist antiemetic such as ondansetron, granisetron, dolasetron or palonosetron, or with alosetron. The US apomorphine label makes this an absolute contraindication after reports of profound hypotension and loss of consciousness.
Apomorphine can cause severe nausea and vomiting, sudden onset of sleep during daily activities, daytime somnolence, syncope and orthostatic hypotension, falls, hallucinations and psychotic-like behaviour, impulse-control problems, and QTc prolongation. These are label warnings for the approved Parkinson's product.
Not for anyone with hypersensitivity to apomorphine or to sulfites, including sodium metabisulfite — the US label describes angioedema and anaphylaxis.
Because this preparation contains two PDE5 inhibitors plus a dopamine agonist that itself lowers blood pressure, the hypotension cautions above apply with more weight, not less.
Source: FDA labels, APOKYN (apomorphine hydrochloride) injection, SPL v21, effective 2024-10-10; CIALIS (tadalafil), SPL v52, effective 2026-06-03; and Vardenafil Hydrochloride Tablets, SPL v9, effective 2026-07-15. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
Bremelanotide acts on receptors in the brain that are involved in sexual response, rather than on blood flow in the genitals. The approved label is candid that the exact mechanism is unknown. It also acts on a receptor found on skin pigment cells, which is why skin darkening is a listed risk.
The pharmacology underneath
Bremelanotide is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. It non-selectively activates melanocortin receptors in the order MC1R, MC4R, MC3R, MC5R, MC2R; MC4R-expressing neurons are widespread in the central nervous system and MC4R is thought to be the subtype relevant to sexual response. The label states the mechanism by which the drug improves hypoactive sexual desire disorder is unknown, and attributes the pigmentation risk to MC1R on melanocytes. All of the approved pharmacokinetic and safety characterisation is for subcutaneous injection. Peptides are generally poorly absorbed across mucosa, and nasal absorption of peptides is characteristically rapid and variable; no published bioequivalence or bioavailability study comparing a compounded intranasal bremelanotide with the approved subcutaneous autoinjector was identified, so the exposure achieved by a spray is not established.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
The two identical phase 3 RECONNECT trials randomized 1,267 premenopausal women 1:1 to 24 weeks of subcutaneous bremelanotide 1.75 mg as needed or placebo. Bremelanotide produced statistically significant increases in the FSFI desire-domain score (integrated treatment difference 0.35, p<.001) and reductions in desire-related distress on FSDS-DAO item 13 (integrated -0.33, p<.001). Nausea, flushing and headache each occurred in 10 percent or more of bremelanotide patients in both studies.11,267 premenopausal women with acquired, generalized hypoactive sexual desire disorder; 85.6 percent white, mean age 39.Different route (subcutaneous autoinjector, not nasal spray), and a different population from most of the men this offering is prescribed for. The endpoints are patient-reported desire and distress scales, not an erectile or performance outcome.
The approved label reports the same trials in its own terms: mean FSFI desire-domain change from baseline 0.5 and 0.6 on bremelanotide versus 0.2 on placebo, and mean FSDS-DAO item 13 change -0.7 versus -0.4, on scales running 1.2 to 6.0 and 0 to 4 respectively.2The modified intent-to-treat populations of Study 1 (n=313 versus 315) and Study 2 (n=282 versus 288).These are the absolute magnitudes behind the statistical significance, and they are small on the scales used. They describe subcutaneous dosing in premenopausal women, not a nasal spray and not men.
In a randomized crossover study, 19 men with erectile dysfunction who self-reported response to sildenafil or vardenafil received 25 mg sildenafil plus 7.5 mg intranasal PT-141 (bremelanotide), 25 mg sildenafil plus intranasal placebo, or double placebo. The erectile response measured by RigiScan during visual sexual stimulation was significantly greater with the combination than with sildenafil alone, and no new adverse events were seen.319 men with erectile dysfunction who were self-reported responders to a PDE5 inhibitor.Very small, uses a device-measured surrogate (RigiScan penile rigidity during visual stimulation) rather than intercourse outcomes, studies subtherapeutic doses of both agents in combination rather than bremelanotide alone, and the intranasal formulation studied is not a currently marketed product.
A regulatory development review records that bremelanotide reached first approval as a self-administered, on-demand subcutaneous therapy, developed by Palatin Technologies and licensed to AMAG Pharmaceuticals for the North American filing.4Regulatory and development history, not a clinical trial.Establishes that the route that reached approval is subcutaneous. It says nothing about the performance or safety of a compounded nasal spray.
Where the evidence stops
The pivotal evidence is subcutaneous, in premenopausal women, against patient-reported desire and distress scales, and the effect sizes are small in absolute terms. Our preparation differs on route with no published bioequivalence, and when prescribed for men it also differs on population, on indication and on the outcome anyone is hoping for. The intranasal data that exist in men are a 19-person surrogate-endpoint crossover study and one larger trial that now carries a published Expression of Concern.
What is inside
Bremelanotide
Melanocortin receptor agonist — the sole active. The approved label describes non-selective activation of several receptor subtypes with MC1R and MC4R binding most relevant at therapeutic doses, and states that the mechanism by which it improves hypoactive sexual desire disorder is unknown.
Form and route
Nasal spray, one spray roughly 45 minutes before activity.
The 45-minute timing follows the dosing instruction in the approved subcutaneous label. The practical rationale for a spray is that it avoids an injection. The pharmacokinetic rationale usually offered is that nasal mucosa allows a peptide to enter the circulation without passing through the gut, but nasal peptide absorption is characteristically rapid and variable between people and between doses, and no published study established what fraction of a dose is absorbed from this preparation.
What to expect, and when
In the pivotal trials the average change in desire and distress scores was small and the trials ran 24 weeks. Nausea was reported by 40 percent of patients and improved for most with the second dose. Because the route here is different and unstudied, onset and intensity may not match the approved product. Whether this is appropriate for you at all is your prescriber's decision.
Regulatory status
Compounded intranasal bremelanotide is not an FDA-approved product. The approved product, VYLEESI, is a subcutaneous autoinjector indicated only for acquired, generalized hypoactive sexual desire disorder in premenopausal women; its label states explicitly that it is not indicated in postmenopausal women or in men, and not indicated to enhance sexual performance. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Not for anyone with uncontrolled hypertension or known cardiovascular disease. The approved label makes this an absolute contraindication.
Not recommended for anyone at high risk for cardiovascular disease. The label directs prescribers to consider cardiovascular risk before starting and to ensure blood pressure is well controlled.
Expect a transient increase in blood pressure and a reduction in heart rate after each dose. The label reports maximal increases of 6 mmHg systolic and 3 mmHg diastolic peaking 2 to 4 hours after dosing, with heart rate down up to 5 beats per minute, usually back to baseline within 12 hours.
Nausea is common. The label reports it in 40 percent of patients receiving up to eight monthly doses, requiring anti-emetic therapy in 13 percent and leading 8 percent to stop treatment.
Focal hyperpigmentation, including on the face, gums and breasts, was reported in 1 percent of patients on up to eight doses per month, and in 38 percent after eight consecutive daily doses. Risk is higher with darker skin and with daily dosing, and resolution after stopping was not confirmed in all patients.
Do not take more than one dose in 24 hours. The label sets this limit specifically to avoid more pronounced blood-pressure effects.
The approved product is not indicated in postmenopausal women, is not indicated in men, and is not indicated to enhance sexual performance. Any use outside that indication is off-label and is the prescriber's judgement.
Source: FDA label, VYLEESI (bremelanotide) injection, SPL v1, effective 2025-11-13. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
Both ingredients are peptides that act in the brain rather than on blood flow in the genitals. Bremelanotide acts on melanocortin receptors; oxytocin acts on oxytocin receptors involved in social and sexual response. There is no published study of the two together, and the oxytocin evidence in this setting is thin.
The pharmacology underneath
Bremelanotide is a cyclic heptapeptide alpha-MSH analogue whose MC4R activity in central nervous system neurons is the presumed route to its effect; the approved label states the mechanism is unknown. Oxytocin is a nine-amino-acid neuropeptide acting at the oxytocin receptor, a G-protein-coupled receptor found in uterine and mammary smooth muscle peripherally and in limbic and hypothalamic circuits centrally. Intranasal administration is the route used in the human central-effects literature, on the premise that some peptide reaches the brain directly; imaging studies show dose-varying effects on amygdala and striatal reactivity that differ between women and men. Neither peptide has published bioavailability data for a compounded sublingual tablet. Peptides are generally poorly absorbed across mucosa and are degraded by peptidases, so the exposure achieved by this form is not established, and the combined effect of the two has not been measured at all.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
The two RECONNECT phase 3 trials randomized 1,267 premenopausal women to 24 weeks of subcutaneous bremelanotide 1.75 mg or placebo, with statistically significant integrated improvements in the FSFI desire domain (0.35, p<.001) and in desire-related distress (-0.33, p<.001).11,267 premenopausal women with acquired, generalized hypoactive sexual desire disorder, mean age 39.Different route (subcutaneous autoinjector, not a sublingual tablet), different population when prescribed to men, and a self-reported desire endpoint rather than a performance outcome. The trial studied bremelanotide alone, without oxytocin.
In a 22-week randomized, double-blind, placebo-controlled crossover trial, 30 pre- and postmenopausal women with sexual dysfunction self-administered intranasal oxytocin 32 IU or placebo within 50 minutes before intercourse for 8 weeks each. FSFI scores rose 26 percent on oxytocin and 31 percent on placebo; there was no statistically significant treatment, sequence or interaction effect.230 pre- and postmenopausal women with sexual dysfunction, at a single academic medical centre.This is the most directly relevant randomized human evidence located for oxytocin and sexual function, and it did not separate from placebo. It also used the intranasal route in women, not a sublingual tablet, and not in men.
In a double-blind, placebo-controlled crossover fMRI study, 90 healthy women received intranasal oxytocin at 6, 12 or 24 IU. Oxytocin altered amygdala reactivity to fearful faces and striatal responses to happy faces, and the direction of these effects differed significantly between women and men compared with the authors' earlier male cohort.390 healthy women, compared against a previously published male cohort.A brain-imaging surrogate of social-cognitive processing in healthy volunteers, not a sexual-function outcome and not a clinical endpoint. It shows the effect is sex-dependent, which argues against reading female data across to men.
The approved oxytocin product is an injection for obstetric use and carries a prominent notice that it is not indicated for elective induction of labor because the available data are inadequate to evaluate the benefit-to-risk considerations.4Obstetric patients; the label's contraindications are entirely obstetric and surgical.Completely different route, dose, indication and population. The label offers no safety characterisation whatsoever for a sublingual tablet used for sexual function, which is itself the point.
Where the evidence stops
One of the two peptides has real pivotal evidence but only by a different route, in a different population, for a different endpoint; the other has essentially no positive controlled human evidence for this use — the single randomized crossover trial located did not separate from placebo. No study of the two peptides together was identified, and no bioavailability data exist for either in a sublingual tablet. Read this as two off-label ingredients in an unstudied dosage form.
What is inside
Bremelanotide
Melanocortin receptor agonist. The approved label describes non-selective melanocortin receptor activation with MC1R and MC4R most relevant at therapeutic doses, and states the mechanism of benefit in hypoactive sexual desire disorder is unknown.
Oxytocin
Nonapeptide included in the compounded blend for its proposed central effects on social and sexual response. Its only US approval is as an injection for obstetric use. The human evidence for oxytocin and sexual function is small and, in the one randomized crossover trial located, did not separate from placebo. The evidence for its contribution in this combination is limited.
Form and route
Sublingual tablet, one tablet under the tongue before activity.
A sublingual tablet dissolves under the tongue. The practical rationale is that it avoids a needle and avoids swallowing. The pharmacokinetic rationale usually offered for peptides is that some transmucosal absorption bypasses the gut and first-pass metabolism, but no published bioavailability study of these peptides in this tablet was identified, and peptides are generally poorly absorbed by mouth.
What to expect, and when
There is no published trial of this preparation, so no honest expectation curve exists for it. What can be said is that the bremelanotide component in its approved form produced small average changes in desire scores over 24 weeks and caused nausea in 40 percent of patients, and that the one randomized trial of intranasal oxytocin for sexual function did not separate from placebo. This is a prescriber's judgement call.
Regulatory status
This is a compounded two-peptide sublingual tablet and is not an FDA-approved product. Bremelanotide is approved only as a subcutaneous autoinjector for premenopausal women with hypoactive sexual desire disorder. Oxytocin is approved in the United States only as an injection for obstetric use. Neither approval covers a sublingual tablet, and neither covers this use. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Not for anyone with uncontrolled hypertension or known cardiovascular disease. The approved bremelanotide label makes this an absolute contraindication.
Not recommended for anyone at high risk for cardiovascular disease. Bremelanotide transiently raises blood pressure — maximal increases of 6 mmHg systolic and 3 mmHg diastolic peaking 2 to 4 hours after each dose — and lowers heart rate by up to 5 beats per minute.
Nausea is common with bremelanotide — 40 percent of patients in the approved product's trials, with 13 percent needing an anti-emetic and 8 percent stopping treatment.
Focal hyperpigmentation of the face, gums or breasts was reported with bremelanotide, more often with darker skin and with frequent dosing, and did not resolve in all patients after stopping.
Do not take more than one dose in 24 hours. The approved bremelanotide label sets this limit to avoid more pronounced blood-pressure effects.
Oxytocin at obstetric doses acts on uterine smooth muscle. Anyone who is pregnant, might be pregnant, or is breastfeeding should not use this preparation without discussing it with their prescriber first.
Not for anyone with a known hypersensitivity to either peptide or to any component of the tablet.
Source: FDA labels, VYLEESI (bremelanotide) injection, SPL v1, effective 2025-11-13, and PITOCIN (oxytocin) injection, SPL v16, effective 2026-05-06. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
Two of the three actives are peptides acting in the brain; the third, tadalafil, acts on blood flow in the penis by slowing an enzyme. That combination genuinely spans two different pathways, unlike pairing two PDE5 inhibitors. What has not been studied is the three of them together, in a tablet, at whatever doses this preparation contains.
The pharmacology underneath
Tadalafil raises cavernosal cGMP by inhibiting PDE5, and the label is explicit that this has no effect without sexual stimulation. Bremelanotide activates central melanocortin receptors, MC4R being the subtype implicated in sexual response, though the approved label states the mechanism of benefit is unknown. Oxytocin acts at the oxytocin receptor, with the human central-effects literature using the intranasal route and reporting sex-dependent effects on amygdala and striatal reactivity. Three points are inferred rather than measured: the absorption of a small molecule and two peptides from a single sublingual tablet, the pharmacokinetic interaction among them, and the combined haemodynamic effect — bremelanotide transiently raises blood pressure while tadalafil lowers it, and no study has characterised what those opposing effects do together.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
Tadalafil 20 mg on demand raised the IIEF Erectile Function domain by 6.9 and 9.3 points and SEP3 successful-intercourse rates by 34 and 44 percentage points from baseline versus small placebo changes in the two primary US trials (n=402, all p<.001), within a programme of 22 trials and over 4,000 patients.1402 men with erectile dysfunction in the primary US trials, mean age 59.Tadalafil alone, as the reference oral tablet at a labeled dose. Not this three-active preparation and not a sublingual tablet.
The two RECONNECT phase 3 trials randomized 1,267 premenopausal women to 24 weeks of subcutaneous bremelanotide 1.75 mg or placebo, with statistically significant integrated improvements in FSFI desire (0.35, p<.001) and in desire-related distress (-0.33, p<.001), and nausea, flushing and headache each in 10 percent or more.21,267 premenopausal women with acquired, generalized hypoactive sexual desire disorder, mean age 39.Different route (subcutaneous), different population when prescribed to men, self-reported desire endpoints rather than performance outcomes, and bremelanotide alone rather than in this blend.
A 22-week randomized, double-blind, placebo-controlled crossover trial of intranasal oxytocin 32 IU before intercourse in 30 women with sexual dysfunction found FSFI increases of 26 percent on oxytocin and 31 percent on placebo, with no statistically significant treatment, sequence or interaction effect.330 pre- and postmenopausal women with sexual dysfunction.The closest randomized evidence for the oxytocin component, and it was null. Different route, different population, and oxytocin alone.
In a randomized crossover study, 19 men with erectile dysfunction received 25 mg sildenafil plus 7.5 mg intranasal bremelanotide, sildenafil plus intranasal placebo, or double placebo. RigiScan-measured erectile response during visual sexual stimulation was significantly greater with the combination than with sildenafil alone, with no new adverse events.419 men with erectile dysfunction who were self-reported PDE5 responders.The only located human evidence for combining bremelanotide with a PDE5 inhibitor. Very small, a device-measured surrogate rather than an intercourse outcome, subtherapeutic doses, a different PDE5 inhibitor (sildenafil, not tadalafil), a different bremelanotide route (intranasal, not a sublingual tablet), and no oxytocin.
The bremelanotide label reports a transient rise in blood pressure of up to 6 mmHg systolic and 3 mmHg diastolic peaking 2 to 4 hours post-dose. The tadalafil label warns that combining a PDE5 inhibitor with alpha-blockers, antihypertensives or substantial alcohol may lead to hypotension.5Label safety statements from the two separate approved programmes.The two actives push blood pressure in opposite directions and no study has characterised their combined haemodynamic effect. Neither label contemplates the other drug.
Where the evidence stops
Each active has been studied alone, by a route that is not this route, and in most cases in a population that is not this population. The one study that combined a melanocortin agonist with a PDE5 inhibitor enrolled 19 men, used a surrogate rigidity endpoint, used subtherapeutic doses, used a different PDE5 inhibitor and a different bremelanotide route, and contained no oxytocin. Nothing published characterises this three-active sublingual tablet, including the combined blood-pressure effect of an agent that raises blood pressure and an agent that lowers it.
What is inside
Bremelanotide
Melanocortin receptor agonist. The approved label describes MC1R and MC4R activation as most relevant at therapeutic doses and states the mechanism of its benefit in hypoactive sexual desire disorder is unknown.
Oxytocin
Nonapeptide included in the compounded blend for proposed central effects. Approved in the United States only as an obstetric injection. The randomized human evidence for sexual function is minimal and did not separate from placebo in the one crossover trial located; the evidence for its contribution in this combination is limited.
Tadalafil
PDE5 inhibitor — the one active here with a direct approved erectile dysfunction indication and a large trial base, with a mean terminal half-life of 17.5 hours per the reference label.
Form and route
Sublingual tablet, one tablet under the tongue before activity.
A sublingual tablet dissolves under the tongue. The practical rationale is that it avoids a needle and avoids swallowing. The pharmacokinetic rationale usually offered for peptides is that some transmucosal absorption bypasses the gut and first-pass metabolism, but no published bioavailability study of these peptides in this tablet was identified, and peptides are generally poorly absorbed by mouth.
What to expect, and when
The tadalafil component has a well-characterised response profile in its approved oral tablet form; the other two do not, in this form or this population. Nausea, headache, flushing, nasal congestion and back or muscle ache are all plausible from the individual components. Because the blood-pressure effects of the components run in opposite directions and have never been studied together, blood-pressure history is central to whether a prescriber considers this appropriate at all.
Regulatory status
This is a compounded three-active sublingual tablet and is not an FDA-approved product. Bremelanotide is approved only as a subcutaneous autoinjector for premenopausal women; oxytocin is approved only as an obstetric injection; tadalafil is approved as an oral tablet. No approved product combines any two of them, and none is approved as a sublingual tablet. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Do not use with any form of nitrate medicine, whether taken regularly or only now and then. The reference brand labels state this combination is contraindicated because PDE5 inhibitors potentiate the blood-pressure-lowering effect of nitrates.
Do not use with a guanylate cyclase stimulator such as riociguat. The label states PDE5 inhibitors may potentiate the hypotensive effects of these medicines.
Alpha-blockers, other blood-pressure medicines and substantial alcohol can combine with a PDE5 inhibitor to lower blood pressure enough to cause symptomatic hypotension or fainting. Tell your prescriber every medicine and supplement you take.
Not appropriate if sexual activity is inadvisable because of your cardiovascular status. The label directs prescribers to weigh cardiac risk before treating erectile dysfunction at all.
Stop and seek medical attention for sudden loss of vision in one or both eyes, which could be a sign of non-arteritic anterior ischemic optic neuropathy (NAION). The label advises caution in anyone with a history of NAION or a crowded optic disc.
Stop and seek prompt medical attention for a sudden decrease or loss of hearing.
Seek emergency treatment for an erection lasting longer than four hours. The label advises caution in people predisposed to priapism, including sickle cell anemia, multiple myeloma or leukemia, or an anatomical deformation of the penis.
Not for anyone with a known serious hypersensitivity to the active ingredient or to any component of the preparation.
Not for anyone with uncontrolled hypertension or known cardiovascular disease. The approved bremelanotide label makes this an absolute contraindication, and it sits alongside the tadalafil cardiovascular caution rather than replacing it.
Not recommended for anyone at high risk for cardiovascular disease. This preparation contains one active that transiently raises blood pressure and another that lowers it, and their combined effect has not been studied.
Nausea is common with bremelanotide — reported by 40 percent of patients in the approved product's trials.
Focal hyperpigmentation of the face, gums or breasts was reported with bremelanotide and did not resolve in all patients after stopping.
Do not take more than one dose in 24 hours. The approved bremelanotide label sets this limit specifically to avoid more pronounced blood-pressure effects.
Oxytocin at obstetric doses acts on uterine smooth muscle. Anyone who is pregnant, might be pregnant, or is breastfeeding should not use this preparation without discussing it with their prescriber first.
Source: FDA labels, CIALIS (tadalafil), SPL v52, effective 2026-06-03; VYLEESI (bremelanotide) injection, SPL v1, effective 2025-11-13; and PITOCIN (oxytocin) injection, SPL v16, effective 2026-05-06. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
The Crown Protocol Hair
CROWN is a set of four compounded formulas for pattern hair loss, built around two mechanism families. One family reduces DHT, the androgen that gradually miniaturises sensitive follicles — finasteride blocks one of the two enzymes that produce it, dutasteride blocks both, and spironolactone blunts androgen signalling by a different route. The other is minoxidil, a vasodilator studied for its effect on the hair cycle. Three of the four formulas are oral tablets and one is a nightly topical solution; every one of them is compounded, none is an FDA-approved product, and the route matters more here than anywhere else in the catalogue — the FDA-approved minoxidil for hair loss is topical, and the FDA-approved oral minoxidil is an antihypertensive that carries a boxed warning.
What does the FDA's 2025 alert on compounded topical finasteride and minoxidil mean for Scalp Solution? ▾
In April 2025 the FDA issued a risk alert about compounded topical finasteride and minoxidil products sold through telemedicine platforms, citing adverse event reports. It is directly relevant here and worth reading before you start. Two things follow from it. Compounded topical concentrations are not standardised between pharmacies, so one product is not interchangeable with another. And minimal systemic absorption is not the same as none: published work reports topical finasteride suppresses serum DHT less than the oral tablet does, but it still suppresses it measurably.
Why use oral minoxidil when the approved product for hair is topical? ▾
The FDA-approved minoxidil products for hair loss are topical. Oral minoxidil is approved only as an antihypertensive, and at those blood-pressure doses its label carries a boxed warning for pericardial effusion and for worsening angina. Hair-loss use is off-label at a small fraction of that dose, which is the whole safety argument. Be aware that the low-dose safety evidence is largely observational and shorter than the period people actually take it, so this is a decision to make with a prescriber rather than an established equivalence.
Can women take Cedar? ▾
No. Cedar contains finasteride, which is contraindicated in women who are or may become pregnant because it can affect the development of a male fetus, and the label also warns that women who are or may be pregnant should not handle crushed or broken tablets. Willow is the finasteride-free formula and Ivy is the dutasteride-based one; your provider decides which, if any, is appropriate.
Why is Ivy aimed at women 45 and over? ▾
Because of dutasteride's half-life, which is measured in weeks rather than the hours that finasteride's is. A drug that lingers that long carries a different set of considerations for anyone who might become pregnant, and that is the reason for the age framing. Dutasteride is also not FDA-approved for hair loss in the United States, though 0.5 mg oral dutasteride is approved for male androgenetic alopecia in South Korea and Japan. Use here is off-label and compounded.
Cedar — Men
A once-daily oral tablet for men that pairs a DHT blocker with oral minoxidil in one compounded capsule instead of two separate products.
Ivy — Women 45+
A once-daily oral tablet for women 45 and over that pairs dutasteride, a dual DHT blocker, with low-dose oral minoxidil.
Willow — Women under 45
A once-daily oral tablet for women under 45 that pairs low-dose oral minoxidil with spironolactone. It contains no finasteride and no dutasteride.
Scalp Solution
A nightly topical solution applied to the scalp, combining minoxidil and finasteride with tretinoin in a single 1 mL application.
How it is understood to work
Male-pattern hair loss is driven largely by DHT, a hormone made from testosterone, which gradually shrinks sensitive follicles. Finasteride is designed to reduce how much DHT the body makes. Minoxidil comes at the same problem from the other side — it widens small blood vessels and is studied for its effect on the growth phase of the hair cycle. One tablet is intended to cover both angles.
The pharmacology underneath
Finasteride inhibits Type II 5-alpha-reductase, the isozyme concentrated in hair follicles, prostate and liver, which the label says accounts for roughly two-thirds of circulating DHT. Enzyme turnover is slow, with a Type II enzyme-complex half-life of about 30 days, so the pharmacodynamic effect long outlasts the plasma half-life. Minoxidil is a prodrug converted to minoxidil sulfate, which opens ATP-sensitive potassium channels and dilates arterioles; the connection between that vascular action and hair-cycle changes is described in the literature as incompletely characterised rather than settled. The label for finasteride is explicit that the relative contributions of scalp versus serum DHT reduction to the treatment effect have not been defined. For oral minoxidil there is no FDA-approved hair-loss label at all, so the dose-response relationship at hair-loss doses is inferred from observational practice rather than measured in registration trials.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
Three double-blind, randomized, placebo-controlled 12-month studies in 1879 men with mild to moderate androgenetic alopecia reported a 107-hair difference from placebo at 12 months within a 1-inch diameter circle, widening to a 277-hair difference at 5 years. At 12 months, 14 percent of finasteride-treated men had any decrease in hair count from baseline versus 58 percent on placebo.1Men aged 18 to 41, 88 percent Caucasian, with mild to moderate but not complete vertex or anterior mid-scalp hair loss.Different product and different composition. This is the single-active brand tablet at 1 mg; Cedar is a compounded tablet that also contains minoxidil and biotin. No trial has tested that combination tablet. The age band studied is also narrower than the men who present for treatment, and efficacy in bitemporal recession was not established.
The FDA label for oral minoxidil tablets carries a boxed warning stating that minoxidil tablets contain the powerful antihypertensive agent minoxidil, which may produce serious adverse effects, that it can cause pericardial effusion occasionally progressing to tamponade, and that angina pectoris may be exacerbated. Indications and Usage restricts the tablet to hypertension that is symptomatic or associated with target organ damage and not manageable with maximum doses of a diuretic plus two other antihypertensives.2Adults with severe, refractory hypertension — the only population the oral tablet is approved for.Dose and indication. That boxed warning was written for antihypertensive dosing, which is many times the low dose used off-label for hair. No FDA label exists for oral minoxidil at hair-loss doses, so there is no approved safety text for the dose we actually dispense.
A retrospective multicenter study of 1404 patients treated with low-dose oral minoxidil for at least 3 months reported hypertrichosis as the most frequent adverse effect at 15.1 percent, with systemic effects of lightheadedness 1.7 percent, fluid retention 1.3 percent, tachycardia 0.9 percent, headache 0.4 percent, periorbital edema 0.3 percent and insomnia 0.2 percent. Overall 1.7 percent of patients discontinued because of adverse effects and no life-threatening adverse effects were observed.31404 patients, 943 women (67.2 percent) and 461 men (32.8 percent), mean age 43, treated for any type of alopecia across multiple international centres.Study design and product. The authors name the limitations themselves: retrospective design and no control group. It is a safety series, not an efficacy trial, it mixes alopecia types, it is mostly women while Cedar is for men, and it studied oral minoxidil on its own rather than a combination tablet. Minimum exposure was three months, which is short relative to the years people take hair medication.
A review of oral minoxidil as a primary treatment for hair loss identified 17 studies covering 634 patients in total across androgenetic alopecia, telogen effluvium, lichen planopilaris, alopecia areata and other conditions. The authors state that larger randomized studies comparing different doses with standardized objective measurements will be needed to clarify the best treatment protocol.4634 patients pooled across 17 heterogeneous studies, mixed sexes and mixed diagnoses.Evidence quality rather than route. This is a narrative review of small and mostly uncontrolled studies, not a randomized trial base, and the authors explicitly flag that the optimal dose is not yet defined. It also does not address the combination with finasteride in one tablet.
A review of biotin for hair loss found 18 reported cases of biotin use for hair and nail changes; in all of them the patient had an underlying pathology causing poor hair or nail growth. The authors conclude there is a lack of sufficient evidence for supplementation in healthy individuals.6Case reports and trials in people with biotin deficiency, brittle nail syndrome or uncombable hair syndrome.Population. The reported benefit sits in people with a deficiency or a specific hair-shaft pathology, not in men with androgenetic alopecia. Biotin's contribution inside this compounded tablet is not established, and high-dose biotin can also interfere with some laboratory immunoassays, which is worth mentioning to a prescriber before blood work.
Where the evidence stops
The strongest evidence here belongs to a different product. Finasteride 1 mg has a large randomized trial base, but as a single-active tablet in men 18 to 41. Oral minoxidil for hair has no randomized registration evidence at all — its safety picture comes from retrospective cohorts, and its only FDA label is for a much higher antihypertensive dose that carries a boxed warning. Nothing published tests Cedar as dispensed: one compounded tablet containing finasteride, minoxidil and biotin together.
What is inside
Finasteride
Type II 5-alpha-reductase inhibitor. The label describes it as a competitive and specific inhibitor of Type II 5-alpha-reductase, the intracellular enzyme that converts testosterone into DHT, producing about 65 percent suppression of serum DHT within 24 hours of a 1 mg oral dose.
Minoxidil
Vasodilator prescribed off-label at low oral doses to support hair growth. In its FDA-approved oral form it is an antihypertensive, and in its FDA-approved hair-loss form it is topical — neither of those is what this tablet is.
Biotin
Included in the compounded tablet on a keratin-support rationale. The evidence for biotin in people who are not biotin-deficient is limited: the published review found 18 reported cases, and in every one the patient had an underlying pathology causing poor hair or nail growth. Its contribution inside this blend is not established.
Form and route
Oral tablet, once daily.
The reason is practical rather than pharmacokinetic. Both actives can be delivered orally in one unit, which removes the twice-daily topical application that the minoxidil topical label requires and that the oral minoxidil literature repeatedly cites as the main reason people stop. The trade is real: an oral route means systemic exposure to both drugs rather than exposure concentrated at the scalp.
What to expect, and when
Slow, and not the same for everyone. The finasteride trials assessed hair count at 6 and 12 months and reported maximum improvement in hair count during the first two years, with investigator-rated change visible in a subset as early as 3 months. Increased shedding early on is commonly described in dermatology practice and is not a reason to expect a particular endpoint. The label also shows what happens on stopping: men switched from finasteride to placebo had their hair-count increase reverse over the following 12 months. Individual responses vary and the prescriber decides whether to continue, adjust or stop.
Regulatory status
Cedar is a compounded multi-ingredient oral tablet and is not an FDA-approved product; the reference brand products are single-active and, for minoxidil, the FDA-approved hair-loss form is topical rather than oral. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Women who are or may become pregnant. The finasteride label lists pregnancy as a contraindication because inhibiting the conversion of testosterone to DHT may cause abnormalities of the external genitalia of a male fetus.
Women who are or may be pregnant should not handle crushed or broken finasteride tablets, because of possible absorption and the potential risk to a male fetus. A compounded tablet does not necessarily carry the protective coating that FDA-approved finasteride tablets have.
Anyone with a known hypersensitivity to finasteride, to minoxidil, or to any component of the preparation.
Anyone with pheochromocytoma — the oral minoxidil label lists it as a contraindication because minoxidil may stimulate catecholamine secretion from the tumor.
Anyone with heart disease without discussing it with the prescriber first. The minoxidil topical label says to ask a doctor before use if you have heart disease, and to stop use and ask a doctor if chest pain, rapid heartbeat, faintness or dizziness occurs, if sudden unexplained weight gain occurs, or if the hands or feet swell.
Men who need PSA testing interpreted without adjustment. Finasteride decreases serum PSA, and the label states that any confirmed increase in PSA while on treatment may signal prostate cancer and should be evaluated even if the value is still in the normal range. The label also carries a warning that 5-alpha-reductase inhibitors may increase the risk of high-grade prostate cancer.
Source: FDA label, PROPECIA (finasteride), SPL v9, effective 2024-10-14; FDA label, MINOXIDIL tablets USP (oral), SPL v5, effective 2026-02-09; FDA label, MENS ROGAINE EXTRA STRENGTH UNSCENTED (minoxidil 5 percent topical), SPL v5, effective 2024-09-06. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
Finasteride blocks one of the two enzymes that make DHT. Dutasteride is designed to block both, including the one that is also active in skin. Low-dose oral minoxidil is added for the growth side. The tablet is aimed at women 45 and over, where the hormonal picture behind thinning is different from that in younger women.
The pharmacology underneath
Dutasteride inhibits both the type 1 and type 2 isoforms of 5-alpha-reductase, whereas finasteride is roughly 100-fold selective for type 2. The pharmacokinetic fact that matters most for this offering is duration: the label states the terminal elimination half-life of dutasteride is approximately 5 weeks at steady state, lengthening with age from about 170 hours in men aged 20 to 49 to about 300 hours in men over 70, and that serum concentrations remain detectable long after the last dose. The label also instructs that patients should not donate blood until 6 months after their last dose. For a woman of childbearing potential that long tail is the entire risk conversation, because the drug is contraindicated in pregnancy on the basis of inhibited development of male fetal external genitalia — stopping the tablet does not clear it quickly. This is a direct reason the offering is positioned at 45 and over, though age alone is not a pregnancy test and the prescriber makes that assessment.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
The dutasteride label states the product is indicated for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate, that it is contraindicated for use in pregnancy, and that dutasteride is not indicated for use in women. Warnings add that women who are pregnant or may be pregnant should not handle the capsules, and that patients should not donate blood until 6 months after the last dose.1Men with symptomatic benign prostatic hyperplasia.Indication and population, both. Nothing in the US label covers hair loss, and nothing in it covers women. Every use in Ivy is off-label on two axes at once.
Dutasteride 0.5 mg was approved in Korea in 2009 for treating androgenetic alopecia in men. A retrospective analysis of 99 Korean men treated for at least 5 years reported investigator-assessed improvement in 89.9 percent and prevention of progression in 93.9 percent.299 Korean men aged 18 and over with androgenetic alopecia, treated at a single hospital.Country, sex and design. The approval is Korean, not American. The patients are men. The analysis is retrospective and single-centre with no control group, and it studied dutasteride alone rather than the combination tablet.
Japan's regulator approved dutasteride under the brand Zagallo for male pattern hair loss (androgenetic alopecia) in men only, distinct from the dutasteride product approved there for benign prostatic hyperplasia. The 2015 review document records that indication.3Japanese men with androgenetic alopecia.Country and sex again. Two national regulators have approved dutasteride for hair loss, both for men only, and neither is the FDA. It remains unapproved for any hair indication in the United States and unapproved for women anywhere located.
A network meta-analysis set out to compare dutasteride, finasteride and minoxidil monotherapy for pattern hair loss in adult women, drawing on 13 trials. The 10 regimens it was able to rank were finasteride and minoxidil regimens only. The authors open by noting that evidence on the relative effectiveness of these drugs is far less for women than for men.4Adult women with pattern hair loss, pooled across 13 trials.This is the gap, stated by the evidence itself. A meta-analysis built to include dutasteride in women could not rank a single dutasteride regimen. There is no comparable randomized base for dutasteride in women, and Ivy should not be presented as though there were.
A retrospective multicenter safety study of low-dose oral minoxidil in 1404 patients, 67.2 percent of them women, reported hypertrichosis in 15.1 percent as the most common adverse effect, systemic effects including lightheadedness 1.7 percent, fluid retention 1.3 percent and tachycardia 0.9 percent, and discontinuation for adverse effects in 1.7 percent.51404 patients across international trichology centres, majority women, mean age 43, treated at least 3 months for any alopecia.Design and product. Retrospective, uncontrolled, mixed diagnoses, minimum three months of exposure, and oral minoxidil alone rather than combined with dutasteride in one tablet. Facial hypertrichosis at roughly one in seven is the effect women most often notice and it belongs in the counselling conversation.
The FDA label for oral minoxidil tablets carries a boxed warning that the tablet can cause pericardial effusion, occasionally progressing to tamponade, and that angina pectoris may be exacerbated, and restricts the product to refractory hypertension.6Adults with severe hypertension not manageable on a diuretic plus two other antihypertensives.Dose. The boxed warning describes antihypertensive dosing, far above the low doses used off-label for hair. There is no FDA label for oral minoxidil at hair-loss doses, and the low-dose reassurance rests on observational cohorts of limited duration rather than on trials.
Where the evidence stops
Dutasteride's hair-loss evidence is in men, and its regulatory approvals for hair loss are in Korea and Japan, for men. The women's literature is thin enough that a network meta-analysis designed to include dutasteride could not rank one dutasteride regimen. On top of that sits the minoxidil problem: an oral route whose only label is an antihypertensive one with a boxed warning. Ivy therefore combines two off-label uses, neither of which has been trialled in the combination or the population it is dispensed for.
What is inside
Dutasteride
Dual 5-alpha-reductase inhibitor. The label describes it as a competitive and specific inhibitor of both the type 1 and type 2 isoenzymes, forming a stable enzyme complex from which dissociation is extremely slow. Type 1 is the isozyme also active in skin and liver, which is the pharmacological argument for using it rather than finasteride.
Minoxidil
Vasodilator prescribed off-label at low oral doses to support hair growth. Its FDA-approved hair-loss form is topical and its FDA-approved oral form is an antihypertensive.
Biotin
Included in the compounded tablet on a keratin-support rationale. The evidence for biotin in people who are not biotin-deficient is limited: the published review found 18 reported cases, and in every one the patient had an underlying pathology causing poor hair or nail growth. Its contribution inside this blend is not established.
Form and route
Oral tablet, once daily.
One unit for two actives, which removes the twice-daily topical routine. Dutasteride's very long half-life also means once-daily oral dosing produces stable exposure rather than peaks — the same property that makes it slow to clear if it needs to be stopped.
What to expect, and when
Assessment windows in the hair-loss literature run at 6 and 12 months, and the Korean long-term data was collected over 5 years. Hypertrichosis, meaning hair growth where it is not wanted, was reported in about 15 percent of patients on low-dose oral minoxidil and is the effect most often raised by women. Because dutasteride clears slowly, both any effect and any adverse effect take longer to settle after a change than they would with a shorter-acting drug. Individual responses vary and the prescriber decides on continuation.
Regulatory status
Both actives are off-label here: dutasteride is FDA-approved for benign prostatic hyperplasia in men and is not approved for hair loss in the United States or for use in women at all, and oral minoxidil is FDA-approved only as an antihypertensive — the compounded tablet itself is not an FDA-approved product. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Women who are pregnant or may become pregnant. The dutasteride label lists pregnancy as a contraindication because the drug may cause harm to a male fetus; in animal studies it inhibited development of male fetal external genitalia. The approximately 5-week terminal half-life means exposure persists well after the last dose.
Women who are pregnant or may be pregnant should not handle the capsules, according to the label, because of potential risk to a male fetus.
Anyone with previously demonstrated, clinically significant hypersensitivity — including serious skin reactions or angioedema — to dutasteride or another 5-alpha-reductase inhibitor, or hypersensitivity to minoxidil or any component of the preparation.
Blood donors within 6 months of the last dose. The label instructs patients not to donate blood until 6 months after their last dose of dutasteride, so that a pregnant recipient does not receive it.
Anyone with pheochromocytoma, which the oral minoxidil label lists as a contraindication.
Anyone with heart disease, fluid-retention problems or unexplained rapid heartbeat without prescriber review first. Stop and seek advice if chest pain, rapid heartbeat, faintness or dizziness occurs, if there is sudden unexplained weight gain, or if the hands or feet swell.
Source: FDA label, DUTASTERIDE capsules (dutasteride), SPL v3, effective 2025-09-11; FDA label, MINOXIDIL tablets USP (oral), SPL v5, effective 2026-02-09; FDA label, MENS ROGAINE EXTRA STRENGTH UNSCENTED (minoxidil 5 percent topical), SPL v5, effective 2024-09-06. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
This is the formula for women who should not take a 5-alpha-reductase inhibitor. Spironolactone is a blood-pressure drug that also blunts androgen signalling, which is why clinicians use it off-label for hormone-driven hair and skin concerns in women. Low-dose oral minoxidil covers the growth side. Because spironolactone affects potassium, the prescriber decides whether blood work is needed.
The pharmacology underneath
Spironolactone antagonises the mineralocorticoid receptor and, less potently, the androgen receptor, and it has some effect on androgen synthesis — the antiandrogenic actions are the basis for off-label dermatologic use in women and are not described as an indication anywhere in the label. The pharmacologically important consequence is potassium: the label states spironolactone can cause hyperkalemia, that the risk is increased by impaired renal function, potassium supplementation, potassium-containing salt substitutes or drugs that raise potassium such as ACE inhibitors and angiotensin receptor blockers, and that serum potassium should be monitored within 1 week of initiation or titration and regularly thereafter. Whether that monitoring cadence is necessary at the low doses used in dermatology in otherwise healthy young women is an open clinical question rather than a settled one, and it is the prescriber's call. Minoxidil contributes a separate cardiovascular action — vasodilation with reflex fluid retention and tachycardia at antihypertensive doses.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
The spironolactone label lists indications for NYHA Class III-IV heart failure with reduced ejection fraction, add-on treatment of hypertension, management of edema in cirrhosis and nephrotic syndrome, and primary hyperaldosteronism. It is contraindicated in hyperkalemia, Addison's disease and concomitant use of eplerenone, and warns that serum potassium should be monitored within 1 week of initiation or titration and regularly thereafter.1Adults with cardiovascular, hepatic and renal conditions.Indication. Nothing in the approved labelling addresses hair. Use for pattern hair loss in women is entirely off-label, and the safety architecture in the label was designed around patients on cardiac and renal drug regimens rather than around healthy young women.
An observational pilot study of 100 women with Sinclair stage 2 to 5 pattern hair loss treated with a once-daily capsule of oral minoxidil 0.25 mg plus spironolactone 25 mg reported a mean reduction in hair loss severity score of 0.85 at 6 months and 1.3 at 12 months, and a mean reduction in hair shedding score of 2.6 at 12 months. Mean blood pressure change was -4.52 mmHg systolic and -6.48 mmHg diastolic. Side effects were seen in 8 women, described as generally mild; no patient developed hyperkalemia or any other blood test abnormality. Two women discontinued because of urticaria.2100 women, mean age 48.4 (range 18 to 80), mean baseline severity Sinclair 2.79, mean duration of diagnosis 6.5 years, at a single Australian clinic.Design first: the author labels it prospective, uncontrolled, open-label and observational, with no placebo group and no blinded assessment. Population second: mean age was 48, older than Willow's under-45 target. Endpoint third: the outcomes are clinician-scored severity and shedding scales, not photographic hair counts. This is the closest published match to Willow's combination, and it is a pilot.
A randomized, evaluator-blinded trial in 120 non-menopausal women with mild-to-moderate female pattern hair loss compared 5 percent topical minoxidil alone, topical minoxidil plus oral spironolactone 80 to 100 mg daily, and topical minoxidil plus microneedling over 24 weeks. Hair density increased more in the minoxidil plus spironolactone group than in minoxidil alone (p = 0.009), while hair shaft diameter increased in all three groups with no significant difference between them.3115 of 120 non-menopausal Chinese women with clinically confirmed Sinclair class II-III hair loss, normal blood hormone levels and regular menstrual cycles, at a single centre in Beijing.Route and dose, both large. The minoxidil was topical 5 percent, not an oral tablet. The spironolactone dose was 80 to 100 mg daily, several times higher than the doses typically used in the oral hair combination, which materially changes the hyperkalemia and menstrual-irregularity risk profile. Single-centre, single-ethnicity, non-menopausal cohort, 24 weeks.
A network meta-analysis of monotherapy for female pattern hair loss ranked 10 regimens drawn from 13 trials. All ranked regimens were finasteride or minoxidil; no spironolactone regimen appears among them. The authors note that evidence on relative effectiveness in women is far less developed than in men.4Adult women with pattern hair loss.Absence of comparative data. Spironolactone was not part of the ranked comparison, so there is no head-to-head basis for placing it against minoxidil or a 5-alpha-reductase inhibitor in women. Willow's spironolactone component rests on off-label practice and small studies, not on comparative trial evidence.
The FDA label for oral minoxidil tablets carries a boxed warning stating that the tablet can cause pericardial effusion, occasionally progressing to tamponade, and that angina pectoris may be exacerbated. A separate retrospective multicenter series of 1404 patients on low-dose oral minoxidil, 67.2 percent women, reported hypertrichosis in 15.1 percent, fluid retention in 1.3 percent, tachycardia in 0.9 percent and discontinuation for adverse effects in 1.7 percent.5For the label: adults with refractory hypertension. For the series: 1404 mostly female patients treated at least 3 months for any alopecia.Dose for the boxed warning — it describes antihypertensive dosing far above hair-loss doses. Design for the series — retrospective, uncontrolled, short minimum exposure. Neither describes oral minoxidil combined with spironolactone in one tablet, and both drugs lower blood pressure, so the combination is not simply the sum of two independent risks.
Where the evidence stops
The one published study that actually matches Willow's combination is an uncontrolled open-label pilot of 100 women at a single clinic, with a mean age of 48 — older than the under-45 group this tablet is built for — using clinician-scored scales rather than hair counts. Everything else is either a different route, a much higher spironolactone dose, or a drug label written for cardiovascular medicine. Both actives lower blood pressure, which is a combination effect the individual studies do not isolate.
What is inside
Minoxidil
Vasodilator prescribed off-label at low oral doses to support hair growth. Its FDA-approved hair-loss form is topical; its FDA-approved oral form is an antihypertensive.
Spironolactone
Aldosterone antagonist with antiandrogenic activity. The label describes the approved mechanism as competitive binding at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. The antiandrogenic effect that clinicians use off-label in hair and hirsutism is a secondary property, not the labelled mechanism.
Biotin
Included in the compounded tablet on a keratin-support rationale. The evidence for biotin in people who are not biotin-deficient is limited: the published review found 18 reported cases, and in every one the patient had an underlying pathology causing poor hair or nail growth. Its contribution inside this blend is not established.
Form and route
Oral tablet, once daily.
Spironolactone has no topical form that reaches the follicle in a way anyone has substantiated, so systemic dosing is the only route for that active. Combining it with oral minoxidil in one unit is a practical adherence decision, and it is exactly what the 100-woman pilot capsule did.
What to expect, and when
The 100-woman pilot measured change at 6 and 12 months, with shedding scores moving before severity scores. Mean blood pressure fell by roughly 4 to 6 mmHg in that study, which most people do not notice but some do. Hypertrichosis was reported in about 15 percent of patients on low-dose oral minoxidil in the larger safety series. Spironolactone can also cause menstrual irregularity and breast tenderness. Whether potassium needs checking, and how often, is the prescriber's decision based on your history and other medications. Individual responses vary.
Regulatory status
Both actives are off-label for hair: spironolactone is FDA-approved as an aldosterone antagonist for heart failure, hypertension, edema and primary hyperaldosteronism, and oral minoxidil is FDA-approved only as an antihypertensive — the compounded tablet is not an FDA-approved product. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Anyone with hyperkalemia, Addison's disease, or taking eplerenone. Those are the three contraindications listed in the spironolactone label.
Women who are pregnant or planning pregnancy without prescriber review. The label states that based on mechanism of action and animal findings spironolactone may affect sex differentiation of the male fetus during embryogenesis, that rat studies report feminization of male fetuses, and that spironolactone should be avoided in pregnant women or the potential risk to a male fetus discussed.
Anyone taking potassium supplements, potassium-containing salt substitutes, ACE inhibitors, angiotensin receptor blockers or other drugs that raise potassium, without prescriber review and potassium monitoring. The label warns concomitant use can lead to severe hyperkalemia.
Anyone with impaired renal function, significant volume depletion, or on lithium, without prescriber review. The label warns of hypotension and worsening renal function, and of increased risk of lithium toxicity.
Anyone with pheochromocytoma, which the oral minoxidil label lists as a contraindication, or a known hypersensitivity to minoxidil, spironolactone or any component of the preparation.
Anyone with heart disease, unexplained rapid heartbeat or swelling without prescriber review first. Stop and seek advice if chest pain, rapid heartbeat, faintness or dizziness occurs, if there is sudden unexplained weight gain, or if the hands or feet swell.
Source: FDA label, ALDACTONE (spironolactone), SPL v25, effective 2025-11-28; FDA label, MINOXIDIL tablets USP (oral), SPL v5, effective 2026-02-09; FDA label, MENS ROGAINE EXTRA STRENGTH UNSCENTED (minoxidil 5 percent topical), SPL v5, effective 2024-09-06. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
Same two drug families as the tablets, delivered onto the scalp instead of swallowed. The idea is to put the medicine where the follicles are and reduce how much reaches the rest of the body. Tretinoin is included to help the solution absorb, which is what allows a nightly rather than twice-daily routine.
The pharmacology underneath
Applied topically, finasteride reaches the follicular unit and inhibits Type II 5-alpha-reductase locally, but some crosses into the circulation. In the phase III trial of a standardised topical finasteride spray, maximum plasma finasteride concentrations were more than 100 times lower than with the oral tablet, and the reduction from baseline in mean serum DHT was 34.5 percent with topical versus 55.6 percent with oral — a real and measured reduction in systemic exposure, and clear evidence that systemic exposure still occurs. Topical minoxidil is converted to minoxidil sulfate in the scalp, which is the pharmacological argument for a topical route for that active specifically. Tretinoin is included to increase percutaneous absorption of minoxidil; that rationale is stated in the literature, and the trial testing it showed equivalence of a once-daily combined solution to twice-daily minoxidil rather than a superior result. One thing does not carry over from the trial data at all: compounded topical concentrations, vehicles and application volumes are not standardised across pharmacies, so the pharmacokinetics measured for one commercial spray cannot be assumed for a different compounded solution.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
FDA issued a compounding risk alert stating that absorption of finasteride through the skin into the bloodstream is expected, and that reports describe adverse events consistent with those reported for approved oral finasteride products — erectile dysfunction, anxiety, suicidal ideation, brain fog, depression, fatigue, insomnia, decreased libido and testicular pain — following use of compounded topical products with finasteride alone or in combination with other active ingredients. There were 32 cases reported to the FDA Adverse Event Reporting System between 2019 and 2024. Most reports state the adverse events continued to persist after product discontinuation. FDA also notes that compounded topical finasteride products do not have the coating that prevents transfer during handling, raising the risk of inadvertent exposure to others, specifically females.1US consumers using compounded topical finasteride, including products obtained through telemedicine platforms, some in combination with minoxidil.Direct: same active, same route, same compounded product class, and FDA names finasteride combined with minoxidil and telemedicine platforms specifically. This is the most on-point safety document that exists for this offering, and it cuts against the reassurance the current site copy offers.
A phase III, randomized, double-blind, double-dummy trial of topical finasteride spray solution in 458 randomized men over 24 weeks reported a change from baseline in target area hair count of 20.2 hairs versus 6.7 with placebo (p less than 0.001), numerically similar to oral finasteride. Maximum plasma finasteride concentrations were more than 100 times lower and the reduction from baseline in mean serum DHT was 34.5 percent with topical versus 55.6 percent with oral. Incidence and type of adverse events did not differ meaningfully between topical finasteride and placebo, and no serious adverse events were treatment related.2458 randomized adult male outpatients with androgenetic alopecia at 45 sites in Europe; 323 completed, 446 evaluated for safety.Product and composition. This tested a single-active, standardised, industrially manufactured 0.25 percent spray — not a compounded solution containing minoxidil and tretinoin alongside finasteride. It is men only, 24 weeks only, and the DHT figure is a surrogate endpoint rather than a clinical safety outcome. The pharmacokinetics of that spray do not transfer to a differently compounded product at an unstated concentration.
The FDA-approved topical minoxidil label directs applying 1 mL with the dropper 2 times a day directly onto the scalp in the hair loss area, states results may occur at 2 months with twice a day usage and that some men may need at least 4 months before seeing results, and warns that this product will not work for all men. It is labelled for the vertex only and states it is not intended for frontal baldness or a receding hairline.3Men aged 18 and over with vertex-pattern hair loss, over-the-counter use.Dosing frequency and composition. The approved regimen is twice daily; Scalp Solution is applied nightly. The approved product is minoxidil alone; ours adds finasteride and tretinoin. The approved indication is the vertex; nothing in that label supports use on the frontal scalp or hairline.
A randomized, double-blind comparative trial in 31 men aged 28 to 45 with Hamilton-Norwood type III-V androgenetic alopecia compared a combined 5 percent minoxidil plus 0.01 percent tretinoin solution applied once daily at night against 5 percent minoxidil applied twice daily over the study period. Total hair count and non-vellus hair count increased in both groups, with no statistically significant differences between the two groups in the macrophotographic variables or in subjective assessments.431 men at a single centre in Korea.This substantiates the once-nightly convenience rationale for including tretinoin and nothing more. It is small, single-centre, contains no finasteride, and its result is a non-difference rather than a benefit. It does not show that tretinoin makes the solution more potent.
The postmarketing section of the finasteride label lists sexual dysfunction that continued after discontinuation of treatment, including erectile dysfunction, libido disorders, ejaculation disorders and orgasm disorders, male infertility and poor seminal quality, testicular pain, male breast cancer, breast tenderness and enlargement, and under Nervous System / Psychiatric: depression, suicidal ideation and behavior. In the 12-month controlled trials the drug-related rates were decreased libido 1.8 percent versus 1.3 percent on placebo, erectile dysfunction 1.3 percent versus 0.7 percent, and ejaculation disorder 1.2 percent versus 0.7 percent.5Men in the finasteride 1 mg trials, plus voluntary postmarketing reports of uncertain population size.Route. These are oral-tablet data. But FDA's compounding alert states the compounded topical reports describe adverse events consistent with the oral profile and that most persisted after stopping — so the oral label is the closest available description of what topical finasteride adverse events look like, not a set of risks the topical route avoids.
Where the evidence stops
The efficacy and pharmacokinetic evidence comes from a standardised commercial single-active spray tested in men for 24 weeks. What we dispense is a compounded multi-active solution at a concentration that is not standardised across pharmacies. Between those two things sits FDA's own alert about this exact product class, which reports adverse events consistent with oral finasteride, most of them persisting after discontinuation. Lower systemic exposure than the oral tablet is measured and defensible. No systemic exposure is not, and FDA says absorption into the bloodstream is expected.
What is inside
Minoxidil
The one active here with an FDA-approved hair-loss labelling precedent. The approved topical product is labelled at 5 percent for men and 2 percent for women, applied 1 mL twice daily to the vertex.
Finasteride
Type II 5-alpha-reductase inhibitor, applied topically to reduce DHT at the follicle. FDA states that absorption of finasteride through the skin into the bloodstream is expected — topical application lowers systemic exposure, it does not remove it.
Tretinoin
Retinoid included on the stated rationale that it increases percutaneous absorption of minoxidil. The one randomized comparison located found once-daily minoxidil plus tretinoin performed comparably to twice-daily minoxidil alone in 31 men, with no significant difference between groups — which supports a convenience argument, not a potency argument.
Form and route
Topical solution to the scalp, 1 mL nightly.
Genuinely pharmacokinetic for finasteride: the phase III data show maximum plasma concentrations more than 100 times lower and roughly 34.5 percent versus 55.6 percent serum DHT reduction compared with the oral tablet. For minoxidil the topical route is where the FDA-approved hair-loss labelling actually sits. Tretinoin is included so the solution can be applied once nightly rather than twice daily. What the topical route adds rather than removes is transfer risk — FDA specifically warns about inadvertent exposure to others, particularly women, because compounded topical products do not have the coating that protects handlers of finasteride tablets.
What to expect, and when
The FDA-approved topical minoxidil label says results may occur at 2 months with twice-daily use, that some men need at least 4 months, and that the product will not work for all men. The topical finasteride trial measured its primary endpoint at 24 weeks with a significant difference visible at 12 weeks. Local reactions — irritation, redness, dryness or scaling, stinging and burning — are named by FDA as risks of topical finasteride. Individual responses vary and the prescriber decides on continuation.
Regulatory status
There is no FDA-approved topical finasteride product of any kind, alone or in combination, so this entire preparation is compounded and off-label; FDA states plainly that compounded drugs are not FDA-approved, meaning the agency has not evaluated their safety, effectiveness or quality before marketing. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Women who are or may become pregnant. Finasteride is contraindicated in pregnancy because it may cause abnormalities of the external genitalia of a male fetus, and FDA warns that compounded topical products carry a greater potential for inadvertent exposure to others, specifically females, through transfer of applied product.
Households where a pregnant woman may contact the treated scalp, bedding, pillow or the applied product before it dries, without discussing handling precautions with the prescriber. Unlike coated finasteride tablets, a compounded topical has nothing preventing contact with the active.
Anyone with a known hypersensitivity to finasteride, minoxidil, tretinoin or any component of the preparation.
Anyone whose scalp is red, inflamed, infected, irritated or painful, who is using other medicines on the scalp, whose hair loss is sudden or patchy, or who does not know the reason for their hair loss. Those are all Do Not Use entries in the FDA-approved topical minoxidil label.
Anyone with heart disease without prescriber review, and anyone who develops chest pain, rapid heartbeat, faintness or dizziness, sudden unexplained weight gain, or swelling of the hands or feet, who should stop and seek advice.
Anyone who has not been told about, or does not accept, the possibility of sexual and psychiatric adverse effects. FDA reports that consumers said they were told there was no risk because the product was topical, and that in most reports the effects persisted after stopping.
Source: FDA compounding risk alert on compounded topical finasteride products, content current as of 2025-04-22; FDA label, PROPECIA (finasteride), SPL v9, effective 2024-10-14; FDA label, MENS ROGAINE EXTRA STRENGTH UNSCENTED (minoxidil 5 percent topical), SPL v5, effective 2024-09-06. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
The Reclaim Protocol LDN Therapy
RECLAIM is a single compounded offering: naltrexone at a small fraction of the strength used in addiction medicine, titrated upward over the first month by the prescriber. Low-dose naltrexone is prescribed entirely off-label, and its proposed mechanisms — a brief opioid-receptor blockade followed by compensatory endorphin signalling, and antagonism at Toll-like receptor 4 on glial cells — are hypotheses supported by preclinical work rather than established human pharmacology. The published human research is small trials and pilot studies in specific diagnoses. This page describes what the medication is and what the research does and does not show; it is not a claim that low-dose naltrexone is a therapy for any specific illness.
Low-dose naltrexone is used far below the 50 mg dose at which naltrexone is FDA-approved, and the flex-dose design exists so your prescriber can start low and step up gradually. Titrating slowly is how tolerability is managed, and it lets you and your provider find the smallest dose that suits you rather than starting at a fixed one.
Why do vivid dreams happen early on? ▾
Vivid dreams and some sleep disturbance are among the most commonly reported effects in the first weeks of low-dose naltrexone, and they are usually described in the literature as settling with time or with a change in dose timing. That is a description of what tends to be reported, not a prediction for you. Tell your provider if it persists or bothers you, because the timing of the dose can often be adjusted.
Can I take this if I use opioid pain medication? ▾
No, and this one matters more than any other item on this page. Naltrexone is contraindicated in anyone taking opioid analgesics, anyone currently dependent on opioids including those on methadone or buprenorphine, and anyone in acute opioid withdrawal, because it can precipitate withdrawal and it blocks the effect of opioid pain relief. Tell every clinician you see that you take it, especially before surgery or in an emergency.
Is low-dose naltrexone FDA-approved? ▾
Naltrexone is FDA-approved at 50 mg for alcohol and opioid use disorder. Low-dose use is entirely off-label and compounded, and compounded medications are not FDA-approved. The proposed mechanisms, a transient opioid receptor blockade with rebound endorphin signalling and an anti-inflammatory effect through TLR4 on microglia, are hypotheses supported mainly by preclinical work. Human evidence consists of small trials and pilot studies, and nothing here should be read as a therapy directed at any specific illness.
LDN Flex-Dose
One nightly compounded tablet of naltrexone at a small fraction of the addiction-medicine strength, started at 0.5 mg and raised in provider-set steps toward 4.5 mg.
How it is understood to work
The same molecule used in addiction medicine, at a small fraction of that strength, for a completely different purpose. Two mechanisms have been proposed for the low dose. One is that a brief block of opioid receptors is followed by the body increasing its own endorphin signalling. The other involves glial cells, the immune-signalling cells of the nervous system. Both are hypotheses under active study. The dose starts low and rises slowly because that is how the effects and side effects are managed.
The pharmacology underneath
Naltrexone is a competitive opioid receptor antagonist. The label records that although well absorbed orally it undergoes significant first-pass metabolism with oral bioavailability estimates from 5 to 40 percent, that peak plasma levels of naltrexone and its active metabolite 6-beta-naltrexol occur within one hour, and that mean elimination half-lives are approximately 4 hours for naltrexone and 13 hours for 6-beta-naltrexol. Those short half-lives are the pharmacokinetic basis of the low-dose hypothesis: a brief period of receptor occupancy followed by clearance, with the proposed consequence of compensatory upregulation of endogenous opioid signalling. The second proposed mechanism is antagonism at Toll-like receptor 4 on microglia, reducing pro-inflammatory glial signalling. Both are described in the review literature as proposed mechanisms supported by preclinical work; neither has been demonstrated in humans, and no human study has established a dose-response relationship across the 0.5 to 4.5 mg range. The label pharmacokinetics were also measured at 50 mg and above, not at these doses.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
The naltrexone label states the product is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids, and that it has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. It is contraindicated in patients receiving opioid analgesics, patients currently dependent on opioids including those maintained on methadone or buprenorphine, patients in acute opioid withdrawal, anyone who has failed the naloxone challenge test or has a positive urine screen for opioids, and anyone with a history of sensitivity to naltrexone.1Adults being treated for alcohol dependence or opioid dependence, at 50 mg.Dose and purpose. The approved label describes a 50 mg tablet used in addiction medicine. LDN Flex-Dose is roughly one tenth to one hundredth of that strength, prescribed for an entirely different reason. The label's own statement that no therapeutic benefit has been shown outside addiction management is the honest starting point, not evidence for the low dose.
A small randomized, double-blind, placebo-controlled, counterbalanced crossover trial of 4.5 mg daily oral naltrexone in 31 women with fibromyalgia reported a 28.8 percent reduction in baseline daily pain on active drug versus 18.0 percent on placebo (p = 0.016), with improved general satisfaction with life (p = 0.045) and improved mood (p = 0.039) but no improvement in fatigue or sleep. Thirty-two percent of participants met the study's response criterion versus 11 percent on placebo (p = 0.05). The authors describe the evidence as preliminary and call for parallel-group randomized controlled trials.231 women with fibromyalgia at a single US academic centre.Condition and size. This is a specific diagnosis, a crossover design in 31 people at one site, and the authors themselves call the evidence preliminary. Nuvari does not present LDN as a treatment for fibromyalgia or any other named condition, and this row should not be read as though it did. The dose studied, 4.5 mg, is the top of the titration range rather than where treatment starts.
A Cochrane systematic review of low-dose naltrexone for induction of remission in Crohn's disease identified 2 randomized trials totalling 46 participants. In the adult trial, 30 percent (5 of 18) of LDN-treated patients achieved clinical remission at 12 weeks versus 18 percent (3 of 16) on placebo, a difference that was not statistically significant (risk ratio 1.48, 95 percent confidence interval 0.42 to 5.24).334 adults and 12 children with active Crohn's disease.This is a negative result and it belongs on the page for that reason. The entire randomized evidence base in Crohn's disease is 46 people across two trials and the difference did not reach statistical significance. It is a caution against reading small positive signals in other conditions as established.
A single-centre, double-masked, placebo-controlled crossover pilot of 4.5 mg nightly naltrexone for 8 weeks in multiple sclerosis enrolled 80 subjects, of whom 60 completed. It reported improvements on mental-health quality-of-life measures — 3.3 points on the SF-36 Mental Component Summary (p = 0.04), 6 points on the Mental Health Inventory (p less than 0.01), 1.6 points on the Pain Effects Scale (p = 0.04) — and no serious adverse events. The authors record that a high dropout rate and data management errors substantially reduced the trial's statistical power.480 enrolled adults with clinically definite multiple sclerosis at one US centre.Endpoint and power. The outcomes are self-reported quality-of-life scales, not disease activity, over 8 weeks, in a pilot the authors describe as underpowered. Again a specific diagnosis, and again not a basis for any general claim.
Two peer-reviewed reviews describe the pharmacology proposed for naltrexone at low doses — brief transient modulation of opioid receptors and activity at glial cells — and how it is used in clinical practice. Both state that the human evidence remains preliminary and based on small studies and call for larger trials. A third peer-reviewed evaluation of low-dose naltrexone in chronic pain and inflammation reports that it is generally well tolerated and that the evidence base is still developing.5Narrative and systematic reviews of the published low-dose naltrexone literature.Evidence type. These are reviews of a preliminary literature, not trials. They establish that a mechanism has been proposed and is being studied; they do not establish that it operates in humans or that any clinical outcome follows from it.
Where the evidence stops
Every human trial of low-dose naltrexone located is small, single-centre and tied to a specific diagnosis, and the largest randomized evidence base in any one condition — Crohn's disease — totals 46 people and did not reach statistical significance. The proposed mechanisms are supported by preclinical work and have not been demonstrated in humans. Nothing here supports presenting LDN as a treatment for any condition, and this page does not.
What is inside
Naltrexone, low dose
Opioid receptor antagonist. The sole active. At the approved 50 mg strength the label describes it as a pure opioid antagonist that markedly attenuates or completely blocks the subjective effects of opioids. At 0.5 to 4.5 mg the proposed mechanism is different and is a hypothesis rather than an established pharmacology.
Form and route
Oral tablet, one nightly, titrated from 0.5 mg toward 4.5 mg in provider-set steps.
Oral is the only practical route at these strengths, and the reason for the slow ramp is tolerability rather than pharmacokinetics: vivid dreams and lighter sleep are the effects most commonly reported early, which is why the dose starts at the bottom of the range and moves only when the provider decides. Nightly dosing matches how the published low-dose studies dosed. Because no manufacturer makes a tablet at these strengths, compounding is the only way to produce the dose at all.
What to expect, and when
The first month is a titration month rather than a treatment month. Vivid dreams and lighter sleep are the most commonly reported early effects and often ease as the dose settles; headache and nausea are also reported, usually during titration. Where the published studies measured anything, they measured it over 8 to 12 weeks. Anything people notice tends to arrive gradually. Individual responses vary, and whether to continue, adjust or stop is the prescriber's decision.
Regulatory status
Naltrexone is FDA-approved at 50 mg for alcohol dependence and blockade of exogenously administered opioids; no manufacturer makes a commercial product at 0.5 to 4.5 mg, so low-dose naltrexone is compounded, prescribed entirely off-label, and is not an FDA-approved product. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Anyone receiving opioid analgesics, in any form. Naltrexone blocks opioid analgesia, so pain relief that would normally work may not.
Anyone currently dependent on opioids, including anyone maintained on an opioid agonist such as methadone or a partial agonist such as buprenorphine. Naltrexone precipitates withdrawal in anyone physically dependent on opioids.
Anyone in acute opioid withdrawal, anyone who has failed the naloxone challenge test, or anyone with a positive urine screen for opioids.
Anyone with a history of sensitivity to naltrexone or any component of the preparation.
Anyone unable to tell every treating clinician and emergency responder that they take it. The label describes a management plan for emergency pain control in someone on naltrexone that involves regional analgesia, conscious sedation, non-opioid analgesics or general anaesthesia, and warns that if opioid analgesia is required the amount needed may be greater than usual and the resulting respiratory depression deeper and more prolonged.
Anyone who should not risk hepatic injury without monitoring. The label's Hepatotoxicity warning records cases of hepatitis and clinically significant liver dysfunction associated with naltrexone exposure during the clinical development programme and in the postmarketing period, and advises patients to seek medical attention if they experience symptoms of acute hepatitis.
Source: FDA label, Naltrexone Hydrochloride tablets USP 50 mg, SPL v1, effective 2026-07-31. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
The Ignite Protocol NAD+
IGNITE offers compounded nicotinamide adenine dinucleotide by two routes: a twice-weekly subcutaneous injection and a daily sublingual tablet. The biology is well described — NAD+ carries electrons through cellular energy metabolism and is consumed by sirtuins and PARP enzymes, and measured tissue levels decline with age. The clinical evidence is a different matter, and the gap between the two is the point of this page. Almost every human study showing a rise in NAD+ used an oral precursor, nicotinamide riboside or nicotinamide mononucleotide, rather than NAD+ itself, and the only peer-reviewed human pharmacokinetic data on NAD+ comes from a single intravenous infusion pilot in 11 men. No NAD+ drug product is FDA-approved for any indication.
There is essentially no published bioavailability data for sublingual NAD+, so we cannot tell you it is. There is a pharmacological reason for the doubt: NAD+ is a large, charged dinucleotide, and molecules of that size and charge cross mucosal membranes poorly. The sublingual form exists for people who do not want an injection, and that is the honest basis for choosing it.
What does the NAD+ research actually show? ▾
Less than the enthusiasm around it suggests, and much of it is about something adjacent. A large share of the human literature studies NAD+ precursors such as nicotinamide riboside and nicotinamide mononucleotide rather than NAD+ itself, which is a real gap, because a precursor and the molecule are not the same intervention. The direct human work on administered NAD+ is early, small and largely focused on measuring what happens to NAD+ metabolites rather than on clinical outcomes.
Is NAD+ FDA-approved? ▾
No. There is no FDA-approved NAD+ drug product, so both the injection and the sublingual form are compounded and used off-label, and compounded medications are not FDA-approved.
Will it give me more energy? ▾
We are not going to promise that. NAD+ has well-described roles in cellular metabolism, and research describes those roles clearly, but controlled human evidence for outcomes like energy, cognition or ageing is early and limited. If persistent fatigue is what brought you here, it deserves a clinical evaluation rather than an assumption, and this is not a substitute for one.
NAD+ Injection
A compounded subcutaneous injection of nicotinamide adenine dinucleotide, the coenzyme cells use in energy metabolism and in several repair pathways, self-administered twice weekly.
NAD+ Sublingual
A compounded daily tablet of nicotinamide adenine dinucleotide that dissolves under the tongue — the needle-free route, and the one with the least published data behind it.
How it is understood to work
NAD+ is a molecule every cell uses to turn food into usable energy, and it is also consumed by the enzymes involved in cellular repair. Measured levels of it decline with age. This protocol is designed to supply it directly. What is well described is the biology. What is far less established is what supplying it from outside does in a person, and that distinction is the honest state of the field.
The pharmacology underneath
NAD+ is the electron carrier in glycolysis, the citric acid cycle and oxidative phosphorylation, and a required substrate for sirtuin deacylases and for PARP enzymes in DNA damage response. The decline of tissue NAD+ with age and its links to sirtuin function are well described in the review literature, largely from cell and animal work. What that mechanism does not establish is the pharmacology of injecting the intact dinucleotide. NAD+ is a large, doubly charged molecule of about 663 g/mol, and the only peer-reviewed human pharmacokinetic study located — an intravenous infusion pilot — found NAD+ was rapidly cleared from plasma with measurable changes in downstream metabolites, which is consistent with extracellular degradation to precursors rather than intact cellular uptake. Almost every human study showing a rise in NAD+ used an oral PRECURSOR, nicotinamide riboside or nicotinamide mononucleotide, not NAD+ itself. Subcutaneous administration twice weekly has no published pharmacokinetic characterisation at all, so the dosing interval is a practice convention rather than a measured one.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
A pilot study of intravenous NAD+ at 750 mg infused over 6 hours in 11 men measured the plasma and urine NAD+ metabolome and found NAD+ was rapidly cleared from plasma with measurable changes in downstream metabolites. The authors note that the clinical evidence base for intravenous NAD+ remains limited.111 men, a single pilot cohort.Route, dose, duration and size, all four. This is a 6-hour intravenous infusion; we dispense a twice-weekly subcutaneous self-injection. Eleven men is a pilot, the endpoint is a metabolite measurement rather than any clinical outcome, and there is no comparable pharmacokinetic study of the subcutaneous route.
A systematic review of 10 randomized controlled trials covering 489 participants on NAD and NADH supplementation reported that these were generally well tolerated, with common side effects including muscle pain, sleep disturbance and headache. The authors flag heterogeneity and limited high-quality efficacy data.2489 participants pooled across 10 randomized trials in mixed clinical conditions.Form and route. The pooled trials cover NAD and NADH supplementation across heterogeneous conditions and routes, predominantly oral, not compounded subcutaneous NAD+ injection. The tolerability finding travels reasonably well; the efficacy picture does not travel at all, because the authors state the efficacy data is limited and heterogeneous.
A randomized, double-blind, placebo-controlled crossover trial in 24 healthy adults aged 55 to 79 found that 1000 mg per day of oral nicotinamide riboside for 6 weeks was well tolerated and raised whole-blood NAD+ by approximately 60 percent.324 healthy middle-aged and older adults.This is the precursor-versus-NAD+ gap in its clearest form. The molecule studied is nicotinamide riboside, not NAD+; the route is oral, not injected; the endpoint is a blood NAD+ concentration, a surrogate, not a symptom or a function. It shows that a precursor can raise measured NAD+. It says nothing about what injecting NAD+ does.
A first-in-human pharmacokinetic study of oral nicotinamide riboside at 100, 300 and 1000 mg demonstrated dose-dependent elevation of the blood NAD+ metabolome. A separate first published human safety study of oral nicotinamide mononucleotide at single doses of 100, 250 and 500 mg in 10 healthy Japanese men reported no significant adverse effects with dose-dependent rises in downstream NAD+ metabolites.4Healthy adult volunteers; 10 men in the nicotinamide mononucleotide study.Same gap, twice. Both are oral precursors, both use metabolite surrogates rather than clinical endpoints, and the nicotinamide mononucleotide study was a single-dose safety study in 10 people. Neither studied NAD+ and neither studied an injection.
Compounded preparations are governed under the federal human drug compounding framework, and FDA's interim policy describes how 503A pharmacies may compound using bulk drug substances while the formal bulks list is being developed. There is no FDA-approved NAD+ drug product, and FDA has not evaluated the safety, effectiveness or quality of any compounded NAD+ preparation.5Not applicable — regulatory framework.Regulatory rather than clinical. This is the status of the product itself: compounded under an enforcement framework, not approved under an evidence review.
Where the evidence stops
The mechanism literature is strong and almost entirely preclinical. The human literature is about precursors taken orally, not NAD+ given by injection. The single peer-reviewed human pharmacokinetic study of injected NAD+ used a 6-hour intravenous infusion in 11 men and found rapid plasma clearance. Nothing published characterises twice-weekly subcutaneous NAD+, so both the dose interval and any expected effect are extrapolations from adjacent research rather than measurements of this product.
What is inside
Nicotinamide adenine dinucleotide (NAD+)
The sole active. A dinucleotide coenzyme that cycles between NAD+ and NADH in cellular redox reactions and is consumed as a substrate by sirtuins and PARP enzymes. Injected directly rather than given as a precursor — which is also why almost none of the published human outcome research applies to it.
Form and route
Subcutaneous self-injection, twice weekly, shipped cold-packed with supplies.
The pharmacological argument is that NAD+ is a large, charged dinucleotide, which makes oral absorption of the intact molecule questionable, so an injected route bypasses the gut and first-pass metabolism entirely. That argument is sound as far as it goes. What it does not establish is what happens after injection — the one human infusion study found rapid plasma clearance, consistent with breakdown to precursors before cellular uptake. Twice weekly is a practical dosing convention, not a schedule derived from published pharmacokinetics.
What to expect, and when
Be sceptical of timelines here, including our own. No published trial of injected NAD+ has measured energy, focus or any longevity endpoint against placebo, so there is no evidence-based schedule of what happens when. The one human infusion study measured metabolites over hours, and the pooled supplementation trials reported tolerability rather than benefit. What you can expect is a routine, provider review, and an honest conversation about whether to continue. Individual responses vary.
Regulatory status
There is no FDA-approved NAD+ drug product for any indication, so this preparation is compounded at a 503A pharmacy and is not FDA-approved — FDA has not evaluated its safety, effectiveness or quality. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Anyone expecting an FDA-approved medicine. No NAD+ drug product is approved for any indication, so there is no approved contraindication list, no approved dose and no approved labelling for this preparation. The screening points below come from the prescriber and from the published literature, not from a label.
Anyone who is pregnant, may become pregnant, or is breastfeeding. Injected NAD+ has not been studied in pregnancy or lactation and there is no safety data to draw on.
Anyone with a known hypersensitivity to NAD+ or to any excipient in the compounded preparation.
Anyone unable to self-inject safely, to maintain sterile technique, or to store the vial as directed. A compounded sterile injection carries handling and infection risk that an oral product does not, and injection-site reactions are the most predictable adverse effect.
Anyone who has not discussed their existing conditions and medications with the prescriber. In the pooled randomized trials of NAD and NADH supplementation the commonly reported side effects were muscle pain, sleep disturbance and headache.
Anyone looking for a therapy directed at a specific medical diagnosis. This is not a substitute for diagnosis or for a physician's judgment, and NAD+ is not offered here for any disease.
Source: No FDA label exists for any NAD+ drug product. Screening points are drawn from Gindri IM et al., Am J Physiol Endocrinol Metab 2024 (pooled tolerability), from the absence of pregnancy and lactation data, and from general sterile-compounding practice under 21 CFR Part 216.. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
Same molecule as the injection, without the needle. It dissolves under the tongue, where the idea is that it is absorbed directly into the bloodstream rather than being broken down in the gut and liver. That is the rationale. It has not been demonstrated for NAD+, and this route should not be presented as equivalent to the injection.
The pharmacology underneath
The sublingual rationale is that absorption across the oral mucosa bypasses first-pass hepatic metabolism. That reasoning holds for small lipophilic molecules. NAD+ is neither: it is a dinucleotide of about 663 g/mol carrying negative charge at physiological pH, which is unfavourable for passive diffusion across a membrane. The only direct human comparison of sublingual against oral administration in this family that we located used nicotinamide mononucleotide, not NAD+, and found no significant difference in blood NAD+ between the two routes — only the terminal catabolites 2PY and 4PY differed. No published study characterises how much intact NAD+ reaches the circulation from a sublingual tablet, how quickly, or how it compares with an injection. That is not a nuance to be smoothed over; it is the central fact about this offering.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
A randomized two-period crossover trial in 14 healthy adult men compared single-dose sublingual and oral nicotinamide mononucleotide over 60 minutes. The incremental area under the curve was significantly higher for the terminal catabolites 2PY and 4PY after sublingual administration, but there were no significant differences in blood concentrations of nicotinamide mononucleotide, nicotinamide or NAD+ between the two routes. The authors state the metabolic origin of the catabolite increases could not be distinguished.114 healthy adult Japanese men; study conducted by employees of a food and health company.Molecule, endpoint and duration. The molecule is nicotinamide mononucleotide, a precursor, not NAD+. Blood NAD+ — the measure that matters most for this comparison — did not differ significantly between routes. Sampling ran only 60 minutes. This is the closest evidence available to a sublingual bioavailability claim for this family, and it does not support one for NAD+.
A search of the published human literature for sublingual NAD+ pharmacokinetics or bioavailability returned no study of NAD+ administered sublingually in humans. The only peer-reviewed human pharmacokinetic data on NAD+ itself comes from an intravenous infusion pilot in 11 men, in which NAD+ was rapidly cleared from plasma.2Not applicable — this is an absence of evidence, recorded as a finding.The gap is total. There is no human bioavailability data for sublingual NAD+ to compare against anything. Any implication that the sublingual tablet delivers what the injection delivers is unsupported, and the injection's own human data is a single 11-man infusion pilot.
NAD+ is recorded as molecular formula C21H27N7O14P2 with a molecular weight of 663.4 g/mol — a large dinucleotide carrying two phosphate groups. Size and charge of this order are unfavourable for passive transmucosal absorption of the intact molecule.3Not applicable — chemical property.This is pharmacological reasoning, not a measurement of this product. It explains why sublingual absorption of intact NAD+ is questionable; it does not prove that none occurs. The measurement that would settle it has not been published.
The human studies showing a measurable rise in blood NAD+ used oral precursors: 1000 mg per day of nicotinamide riboside for 6 weeks raised whole-blood NAD+ by approximately 60 percent in 24 healthy adults aged 55 to 79, and single oral doses of nicotinamide mononucleotide produced dose-dependent rises in downstream NAD+ metabolites in 10 healthy men.424 healthy older adults; 10 healthy Japanese men.Molecule and route again. Precursors given orally are the intervention with human data behind it. NAD+ given sublingually is not that intervention, and the results of one cannot be read across to the other.
A systematic review of 10 randomized controlled trials with 489 participants on NAD and NADH supplementation reported these were generally well tolerated, with muscle pain, sleep disturbance and headache among common side effects, while flagging heterogeneity and limited high-quality efficacy data.5489 participants across 10 randomized trials in mixed conditions.Form and route. Predominantly oral supplementation across heterogeneous conditions rather than a compounded sublingual NAD+ tablet. It is the best available tolerability signal for this family and it is not efficacy evidence.
Where the evidence stops
There is no published human study of sublingual NAD+ bioavailability. That single sentence is the most important thing on this page. Everything else here is adjacent — a precursor molecule, a different route, a 60-minute sampling window, or a tolerability review of mixed oral products. This offering is chosen for convenience and needle avoidance, and it should be presented that way rather than as pharmacologically equivalent to the injection.
What is inside
Nicotinamide adenine dinucleotide (NAD+)
The sole active. Same molecule as the injection, delivered across the oral mucosa instead. Whether a meaningful amount of the intact dinucleotide crosses that membrane has not been established in any published human study we could find.
Form and route
Sublingual tablet, once daily, dissolved under the tongue; ships and stores at room temperature.
The honest answer is practical, not pharmacokinetic: it avoids a needle, avoids cold-chain shipping, and is easier to keep to daily than a twice-weekly self-injection. The usual sublingual rationale — bypassing first-pass hepatic metabolism — is theoretically attractive but unverified for a molecule this large and this charged, and the one direct sublingual-versus-oral human comparison in this family found no difference in blood NAD+.
What to expect, and when
There is no evidence-based timeline for this route, because no human study has measured what a sublingual NAD+ tablet delivers or what follows from it. The pooled randomized data on NAD and NADH supplementation reports tolerability rather than benefit, with muscle pain, sleep disturbance and headache among the reported side effects. What to expect is a daily routine and a provider review of whether it is worth continuing. Individual responses vary.
Regulatory status
There is no FDA-approved NAD+ drug product for any indication, so this preparation is compounded at a 503A pharmacy and is not FDA-approved — FDA has not evaluated its safety, effectiveness or quality. The sublingual route in particular has no published human bioavailability data for NAD+ that we were able to locate. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Anyone expecting an FDA-approved medicine or a route with established bioavailability. No NAD+ drug product is approved for any indication and no published human study characterises sublingual NAD+ absorption, so there is no approved contraindication list and no established dose.
Anyone who is pregnant, may become pregnant, or is breastfeeding. Sublingual NAD+ has not been studied in pregnancy or lactation.
Anyone with a known hypersensitivity to NAD+ or to any excipient in the compounded tablet, including its flavouring or sweetener.
Anyone with mouth ulceration, oral mucositis or another condition affecting the oral mucosa, without prescriber review — the delivery site is the mucosa itself.
Anyone choosing this route because they were told it delivers the same exposure as the injection. It has not been shown to, and no one should choose between the two on that basis.
Anyone looking for a therapy directed at a specific medical diagnosis. This is not a substitute for diagnosis or for a physician's judgment.
Source: No FDA label exists for any NAD+ drug product and no human sublingual NAD+ pharmacokinetic study was located. Screening points are drawn from Wakabayashi J et al., Sci Rep 2026 (sublingual versus oral nicotinamide mononucleotide), Gindri IM et al., Am J Physiol Endocrinol Metab 2024 (pooled tolerability), and the absence of pregnancy and lactation data.. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
The Glow Protocol Skin
GLOW is a set of six prescription topical formulas, each compounded by a licensed 503A pharmacy after a provider reviews your intake. They share a family of mechanisms rather than a single one: retinoids that speed how quickly surface skin cells turn over, tyrosinase inhibitors that slow the enzyme step in pigment production, and anti-inflammatory agents that calm the reaction that follows. Every formula here is a multi-active compound, and compounded medications are not FDA-approved; the evidence below is drawn from the single agents and, where one exists, from an approved brand product built on the same idea.
Why does hydroquinone have to be cycled rather than used continuously? ▾
Prolonged uninterrupted use of hydroquinone is associated with exogenous ochronosis, a paradoxical darkening of the skin that is difficult to resolve, and the FDA has described this occurring after unmonitored long-term use even at low concentrations. Non-prescription hydroquinone also lost its route to market when the CARES Act reformed the OTC monograph process in 2020, and the FDA has issued warning letters over unapproved products. The enforced cycling in these formulas exists for that reason, and also because the topical corticosteroids in some of them carry their own risks of skin thinning and visible vessels with extended use.
Have these combinations been tested as combinations? ▾
No. There are no clinical trials of these specific multi-active formulas at these specific concentrations. The evidence on this page is per-ingredient, drawn largely from single-agent or two-agent studies. The closest approved precedent is a triple combination product for melasma, and even that is an analogy rather than a match, because it used a different corticosteroid from the one in our formulas. Every Glow formula is compounded, and compounded medications are not FDA-approved.
Can I use these while pregnant or breastfeeding? ▾
Discuss it with your clinician before you do, and expect the answer to be cautious. The tretinoin-containing formulas carry pregnancy warnings on the reference label. Stella+ contains estriol, an estrogen. Flawless contains spironolactone, which has antiandrogenic effects relevant to a male fetus. None of these compounded combinations has been characterised for use in pregnancy.
What is the concern with the estriol in Stella+? ▾
Estriol is an estrogen and is not an FDA-approved drug in the United States. FDA-approved estrogen products carry class warnings derived from the Women's Health Initiative covering endometrial cancer, cardiovascular risk, breast cancer and probable dementia. Low-concentration estriol applied to the face is not the same exposure as systemic estrogen therapy, but the published facial studies are small and short and were not designed to answer questions about systemic absorption or endometrial safety. Anyone with a history of an estrogen-sensitive cancer, undiagnosed abnormal vaginal bleeding or a blood clot should raise it before starting.
Stella+
A nightly compounded cream that pairs a prescription retinoid with a copper peptide, a topical estrogen and niacinamide. It is aimed at fine lines and firmness in skin going through hormonal transition.
Diamond Delux
A nightly compounded cream combining a pigment-blocking agent, a prescription retinoid and a topical corticosteroid, dispensed in limited cycles. It is aimed at dark spots and post-acne marks.
Diamond Delux Plus
The same nightly triple-combination idea as Diamond Delux with a second tyrosinase inhibitor, kojic acid, added. It is aimed at stubborn pigment and melasma.
Tretinoin TAAN
A nightly compounded cream built around prescription tretinoin, with azelaic acid and niacinamide alongside it. It is aimed at texture, congestion and dullness.
Luminance
A nightly compounded cream that pairs two tyrosinase inhibitors with azelaic acid and a low-potency corticosteroid, dispensed in limited cycles. It is aimed at uneven tone and dullness across the face rather than at discrete spots.
Flawless
A nightly compounded cream that takes three drugs normally given as tablets, metformin, progesterone and spironolactone, and delivers them topically alongside azelaic acid. It is aimed at hormonal breakouts along the jaw and chin.
How it is understood to work
Tretinoin speeds up how fast the outer layer of skin renews itself, which is why texture and fine lines are the endpoints it has been studied for. Niacinamide is studied for helping the skin barrier hold on to water and for evening out tone. GHK-Cu is a small copper-carrying peptide; most of what is known about it comes from laboratory work, not from trials in people. Estriol is a weak estrogen, included because skin behaves differently as hormones shift, though that specific use has not been tested in a controlled trial at this concentration.
The pharmacology underneath
Tretinoin activates the RAR-alpha, RAR-beta and RAR-gamma nuclear receptors. The RENOVA label is candid that it has not been established whether tretinoin's clinical effects are mediated through retinoic acid receptor activation, through irritation, or both; it also notes that in human skin, adequate data have not been provided to show an increase in desmosine, hydroxyproline or elastin mRNA. Transdermal absorption of tretinoin from topical formulations has ranged from 1 percent to 31 percent of the applied dose depending on whether skin is healthy or inflamed. Niacinamide increases biosynthesis of ceramides and other stratum corneum lipids, which is the mechanistic basis for its barrier claims. GHK-Cu's proposed actions on matrix remodeling and gene expression are described mainly in vitro and ex vivo, and a controlled clinical test of a copper tripeptide product did not separate it from control. Estriol is a low-potency estrogen receptor ligand; systemic absorption from a facial cream at low concentration has not been characterised in a way we can cite, which is itself the point a prescriber has to weigh.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
In five controlled trials of RENOVA (tretinoin cream) 0.02%, 324 evaluable patients on tretinoin were compared with 332 on vehicle over 24 weeks. For fine wrinkling in lightly pigmented subjects (n=279 vs n=280), moderate improvement was seen in 10 percent on tretinoin versus 3 percent on vehicle, mild improvement in 15 percent versus 9 percent, and minimal improvement in 35 percent versus 27 percent. Two of the five trials demonstrated efficacy for fine wrinkling; none of the pairs demonstrated it for coarse wrinkling, mottled hyperpigmentation, tactile roughness or laxity.1Adults with photodamaged facial skin, Fitzpatrick I-III in four trials and IV-VI in one, all on a comprehensive skin care and sun avoidance program.Different product. This is single-agent tretinoin cream 0.02% from an FDA-approved brand, not our four-active compound, and the trial required a full sunscreen and sun-avoidance program alongside it. In the single-centre study of 107 darkly pigmented subjects, fewer improved on tretinoin (29 percent) than on vehicle (43 percent), which the label attributes to the small size of that study.
A double-blind split-face randomized trial in 27 patients compared 4 percent niacinamide cream on one side of the face with 4 percent hydroquinone cream on the other for eight weeks. Good to excellent improvement was reported in 44 percent of patients on the niacinamide side versus 55 percent on the hydroquinone side.2Adults with melasma.Different endpoint and different concentration. This measured pigment in melasma, not fine lines or firmness, and it tested niacinamide alone at 4 percent rather than as one of four actives in a compounded cream. It says nothing about what niacinamide contributes inside Stella+.
A controlled clinical study of a topical copper tripeptide complex applied after CO2 laser resurfacing in 13 patients found no statistically significant difference between groups in the resolution of erythema, and objective evaluation found no significant improvement in wrinkles or overall skin quality. Patient-reported satisfaction was higher in the copper tripeptide group.3Thirteen patients following CO2 laser facial resurfacing.This is the only controlled clinical read we could find on a topical copper peptide product, it is very small, it was in post-laser skin rather than untreated aging skin, and the objective result was null. We are including a negative finding rather than a supportive one because we could not substantiate a positive controlled result for GHK-Cu in this setting.
The published regenerative and protective actions attributed to GHK-Cu are described predominantly from in vitro, ex vivo and gene-expression data, including effects on extracellular matrix components in cultured fibroblasts, rather than from randomized clinical endpoints in human facial skin.4Cell and tissue models, with narrative reference to small cosmetic studies.Preclinical and mechanistic only. A change in gene expression in a cell culture is a surrogate, not a clinical outcome, and it does not translate to a claim about lines or firmness on a face.
FDA states that many marketed compounded 'bioidentical' hormone products are not FDA-approved, and the National Academies report FDA commissioned recommended that FDA's Pharmacy Compounding Advisory Committee review a list of compounded bioidentical hormone substances, including estriol, as candidates for the Difficult to Compound list. There is no FDA-approved drug product containing estriol in the United States.5Regulatory and policy review, not a clinical trial.There is no efficacy evidence at all for topical facial estriol at low concentration for lines or firmness that we could substantiate. This active is in the formula on a prescriber's clinical judgment, not on trial data.
Where the evidence stops
There is no clinical trial of GHK-Cu plus estriol plus tretinoin plus niacinamide at these concentrations in one cream. Everything above is read across from single agents, and two of the four actives, GHK-Cu and estriol, have essentially no controlled human efficacy data for this use. The only well-evidenced active here is tretinoin, and even its own FDA label limits the demonstrated benefit to fine wrinkling, states in capital letters that the product does not remove wrinkles or repair sun-damaged skin, and notes that no two of five trials demonstrated benefit on coarse wrinkling, mottled hyperpigmentation, roughness or laxity.
What is inside
GHK-Cu (copper tripeptide-1)
A copper-binding tripeptide included in the compounded blend. Most of its published data is laboratory and gene-expression work rather than controlled clinical trials, and the evidence for its contribution in this combination is limited.
Estriol
A topical estrogen included for skin in hormonal transition. Estriol is not an FDA-approved drug substance in the United States, and there is no controlled trial of facial estriol at this concentration in this blend.
Tretinoin
A prescription retinoid that binds retinoic acid nuclear receptors in skin cells. This is the active with the strongest label-level evidence in the formula.
Niacinamide
Vitamin B3 amide, studied for barrier support and for pigment evenness. Its role here is supportive rather than primary.
Form and route
Topical cream, pea-size, applied nightly to the face.
Nightly dosing is the convention for retinoids because tretinoin and the skin's response to it are both affected by ultraviolet light, and because the label directs a sunscreen of SPF 15 or greater in the morning. Compounding the four actives into one base is a practical and adherence decision, not a pharmacokinetic one: it makes a single step out of what would otherwise be several products. Topical delivery is chosen so exposure is concentrated in the skin, though the tretinoin label documents that a measurable fraction of a topical dose is absorbed through the skin, so 'topical' should not be read as 'no systemic exposure'.
What to expect, and when
Retinoid trials in this indication ran 24 weeks before the reported readouts, so this is a slow category, not a fast one. Early weeks commonly bring dryness, peeling, redness or stinging as skin adjusts, and the tretinoin label directs using less product, applying less often, or pausing if irritation is significant. Response varies a great deal between people: in the tretinoin trials, 40 percent of treated patients showed no change in fine wrinkling at 24 weeks, and so did 58 percent on vehicle. Daily broad-spectrum sunscreen is part of the protocol, not an optional extra. Whether this formula suits you at all is your prescriber's decision.
Regulatory status
Stella+ is a four-active compounded cream that is not FDA-approved, and one of its actives, estriol, is not the active ingredient in any FDA-approved drug product in the United States. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Pregnancy, or if you are trying to become pregnant. The tretinoin label states plainly not to use it if you are pregnant or attempting to become pregnant, and to contact your physician immediately if you become pregnant during use.
Anyone with known, suspected or a history of breast cancer, or a known or suspected estrogen-dependent tumour. This is a contraindication on the reference estrogen label and applies to the estriol in this formula.
Undiagnosed abnormal vaginal bleeding, which is a contraindication on the reference estrogen label and needs a physician's evaluation first.
A history of blood clots in the legs or lungs, stroke or heart attack, or a known clotting disorder. These are contraindications on the reference estrogen label. The estrogen class boxed warning also covers endometrial cancer, cardiovascular disorders, breast cancer and probable dementia.
Eczematous or sunburned skin. Tretinoin has been reported to cause severe irritation on eczematous skin, and the label says not to use it until sunburn has fully recovered.
Anyone taking a medicine that increases sun sensitivity, such as thiazides, tetracyclines, fluoroquinolones, phenothiazines or sulfonamides, because of the possibility of augmented phototoxicity.
Known sensitivity to any component of the formula.
Source: FDA label, RENOVA (tretinoin), SPL v14, effective 2026-02-24, together with the estrogen class warnings and contraindications on FDA label, Estradiol Vaginal Cream 0.01% (estradiol), SPL v3, effective 2026-04-13. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
Pigment in skin is made by an enzyme called tyrosinase. Hydroquinone slows that enzyme down, so less new pigment is made while you use it. The retinoid speeds up how quickly the surface layer sheds, which helps move existing pigment out and helps the other ingredients get in. The steroid is there to keep the first two from making the skin red and sore. That last part is also why the formula is used in limited cycles: steroids on facial skin are not meant for continuous long-term use.
The pharmacology underneath
Hydroquinone's depigmenting action is enzymatic inhibition at the tyrosine-to-DOPA step plus suppression of other melanocyte metabolic processes; the hydroquinone label notes that exposure to sunlight or ultraviolet light causes repigmentation of bleached areas, which is why sun protection is mandatory rather than advisory. Tretinoin acts through RAR nuclear receptors and increases epidermal turnover. Triamcinolone acetonide is a mid-potency topical corticosteroid; the analogous FDA-approved triple product's label warns that systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal, plus Cushing's syndrome, hyperglycemia and glucosuria while on treatment. The three-agent design traces to Kligman and Willis's 1975 depigmenting formula, which used hydroquinone 5 percent, tretinoin 0.1 percent and dexamethasone 0.1 percent, a different steroid at different strengths from anything dispensed today.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
Two adequate and well-controlled trials in 641 subjects compared TRI-LUMA (fluocinolone acetonide 0.01 percent, hydroquinone 4 percent, tretinoin 0.05 percent) with each of the three possible two-ingredient combinations, applied nightly for 8 weeks. Treatment success, defined as a melasma severity score of zero, was reached in 38 percent on the triple versus 15 percent on hydroquinone plus tretinoin in trial 1 (n=85 and n=83), and 13 percent versus 4 percent in trial 2 (n=76 and n=75).1Subjects aged 21 to 75 with Fitzpatrick skin types I-IV and moderate to severe facial melasma; approximately 66 percent white and 98 percent female.Different corticosteroid and different product. Tri-Luma uses fluocinolone acetonide 0.01 percent; Diamond Delux uses triamcinolone. Tri-Luma is an FDA-approved fixed-combination product tested as manufactured; our formula is compounded. This is an analogy for the design of the formula, not evidence for the formula itself. The Tri-Luma label also states that safety and efficacy in Fitzpatrick skin types V and VI have not been studied, and that the product is not indicated for maintenance treatment.
A 12-month open-label study of hydroquinone 4 percent, tretinoin 0.05 percent and fluocinolone acetonide 0.01 percent reported the safety and efficacy profile of that fixed triple combination over a year of use in melasma.2Adults with melasma treated over 12 months.Different steroid again, and a different use pattern from ours. Long duration in that study does not license continuous use of our compound: FDA's approved triple product is indicated only for short-term treatment and explicitly not for maintenance, and our protocol runs in 12-week maximum cycles for that reason.
The hydroquinone 4 percent label describes depigmentation as reversible, directs that the product be discontinued if no improvement is seen after 2 months of treatment, and warns that hydroquinone may produce exogenous ochronosis, a gradual blue-black darkening of the skin, adding that the majority of patients developing this condition are Black but that it may also occur in Caucasians and Hispanics.3Label population for prescription hydroquinone 4 percent cream in hyperpigmented conditions such as chloasma, melasma, freckles and senile lentigines.Direct for the hydroquinone component's mechanism and its risks, but the label describes a single-agent 4 percent cream applied twice daily. Our formula is applied once nightly as part of a multi-active compound, so the exposure pattern is not identical.
Kligman and Willis's original 1975 depigmenting formula combined hydroquinone 5 percent, tretinoin 0.1 percent and dexamethasone 0.1 percent in a hydrophilic ointment, applied daily for five to seven weeks.4A small 1975 investigation in adults, pre-dating modern trial standards.Historical precedent only. Different steroid, higher concentrations of both hydroquinone and tretinoin than anything dispensed now, no control group by current standards, and a different endpoint. It explains where the idea came from; it does not substantiate our product.
A review of adverse effects of topical corticosteroid use describes local effects including skin atrophy, striae, telangiectasia, purpura, perioral dermatitis and acneiform eruptions, and notes that with prolonged use, hypothalamic-pituitary-adrenal axis suppression and adrenal insufficiency can occur and can take months to recover after treatment stops.5Narrative and clinical review of topical corticosteroid safety across indications.Not specific to triamcinolone on the face in a pigment formula. It is the general class evidence that justifies cycling this product rather than using it continuously.
Where the evidence stops
The single biggest limitation is that the trials that support this design were run on a different product. Tri-Luma is a manufactured, FDA-approved fixed combination containing fluocinolone acetonide, and its 38 percent and 13 percent clearing rates belong to that product at those exact concentrations. Diamond Delux substitutes triamcinolone and is compounded to a prescription, so its concentrations, vehicle and stability are not the ones that were tested. No trial has been run on this combination.
What is inside
Hydroquinone
The pigment-lightening agent. It inhibits the enzymatic oxidation of tyrosine to DOPA and suppresses other melanocyte metabolic processes, producing depigmentation the label describes as reversible.
Tretinoin
A prescription retinoid included to speed epidermal turnover, which helps disperse pigment and improves penetration of the other actives.
Triamcinolone acetonide
A topical corticosteroid included to blunt the irritation that hydroquinone and tretinoin cause together. It is the reason this formula is cycled rather than used continuously.
Form and route
Topical cream, applied nightly, in cycles of no more than 12 weeks.
Nightly application matches the approved triple product's directions, which specify a thin film once daily at least 30 minutes before bedtime, in part because tretinoin and pigment biology are both light-sensitive. The 12-week cycle cap exists for two separate safety reasons, not one: prolonged hydroquinone exposure carries the risk of exogenous ochronosis, a gradual blue-black darkening that the label says should prompt discontinuation, and prolonged topical corticosteroid exposure on facial skin carries the risk of atrophy, telangiectasia, striae and steroid-driven perioral dermatitis, plus HPA-axis suppression with extensive use. FDA's approved triple product is indicated only for short-term treatment and is explicitly not indicated for maintenance.
What to expect, and when
The comparable trials ran 8 weeks before their primary readout, and even then a minority of subjects reached complete clearing: 38 percent in one trial and 13 percent in the other, on the approved product. The hydroquinone label directs discontinuing if there is no improvement after 2 months. Pigment lightening from hydroquinone is described on the label as reversible, and ultraviolet exposure causes repigmentation, so daily broad-spectrum sun protection is part of the treatment rather than an add-on. Irritation, redness, dryness and mild burning are common early. Melasma commonly recurs after the approved triple product is stopped. Individual response varies widely and treatment is your prescriber's decision.
Regulatory status
Diamond Delux is a compounded triple-combination cream and is not FDA-approved; FDA states that Tri-Luma is currently the only FDA-approved drug containing hydroquinone, and Tri-Luma uses a different corticosteroid at a fixed concentration. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Pregnancy, or if you are trying to become pregnant. The tretinoin label directs against use in pregnancy, and the hydroquinone label states that the safety of topical hydroquinone use during pregnancy has not been established.
Anyone who has developed exogenous ochronosis, the gradual blue-black darkening of skin that hydroquinone can produce. The label directs discontinuing treatment and consulting a physician if it occurs.
Continuous, uninterrupted long-term use. The corticosteroid carries the risk of skin atrophy, telangiectasia, striae and perioral dermatitis, and systemic absorption of topical corticosteroids can produce reversible HPA-axis suppression. This is why the protocol cycles.
Eczematous, broken or sunburned skin, and anyone taking a photosensitising medicine such as a thiazide, tetracycline, fluoroquinolone, phenothiazine or sulfonamide.
Anyone with a prior sensitivity or allergic reaction to hydroquinone, tretinoin, a corticosteroid, or any component of the formula.
Children 12 and under, for whom the safety of topical hydroquinone has not been established.
Source: FDA label, HYDROQUINONE 4% (hydroquinone), SPL v5, effective 2026-07-10, and FDA label, RENOVA (tretinoin), SPL v14, effective 2026-02-24, with corticosteroid class warnings from FDA label, TRI-LUMA (fluocinolone acetonide, hydroquinone and tretinoin), SPL v18, effective 2024-10-24. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
This is Diamond Delux with a second pigment-blocker added. Both hydroquinone and kojic acid slow the same enzyme, tyrosinase, that skin uses to make pigment. The retinoid keeps the surface layer turning over so existing pigment moves out and the other ingredients get in. The steroid keeps the combination from being too irritating. Adding a second blocker is a reasonable idea on paper, but no study has tested whether stacking them on top of one another adds anything.
The pharmacology underneath
Hydroquinone and kojic acid both act at tyrosinase, the rate-limiting enzyme in melanogenesis, so the two actives converge on the same step rather than on complementary steps; whether that produces additive benefit or mainly additive irritation has not been tested for this pairing. Tretinoin acts through RAR nuclear receptors and increases epidermal turnover. Triamcinolone acetonide is a mid-potency topical corticosteroid, and the analogous approved triple product's label documents that systemic absorption of topical corticosteroids can produce reversible HPA-axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal. Hydroquinone's depigmentation is described on the label as reversible, with ultraviolet exposure causing repigmentation.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
In two controlled trials totalling 641 subjects, the FDA-approved triple combination of fluocinolone acetonide 0.01 percent, hydroquinone 4 percent and tretinoin 0.05 percent applied nightly for 8 weeks reached complete clearing of melasma in 38 percent of subjects versus 15 percent on hydroquinone plus tretinoin in trial 1, and 13 percent versus 4 percent in trial 2.1Adults aged 21 to 75, Fitzpatrick skin types I-IV, with moderate to severe facial melasma.Different product and a different number of actives. That trial tested three ingredients with fluocinolone acetonide; this formula has four ingredients and uses triamcinolone. It is an analogy for the triple-combination architecture only, and it says nothing about what kojic acid adds.
A systematic review of topical and systemic melasma therapies that screened 174 randomized or controlled clinical trials assigned kojic acid a grade A recommendation for melasma, and reported that kojic acid carried a relatively low irritation risk of 5.3 percent compared with 50.9 percent for hydroquinone-containing combination therapy.2Pooled melasma trial populations across the reviewed literature.The kojic acid evidence comes from studies of kojic acid alone or in cosmetic pairings, not as a fourth ingredient added to a hydroquinone-plus-retinoid-plus-steroid compound. Note also the direction of the irritation figures: hydroquinone-containing combinations were the higher-irritation arm.
A split-face, evaluator-blinded randomized pilot study of a topical cosmetic containing alpha-arbutin 5 percent and kojic acid 2 percent versus triple combination cream found no significant difference between the two in melanin index or melasma area and severity score, though physician-assessed improvement favoured the triple combination cream.3A small pilot population with melasma, split-face design.Different comparator and different formulation. Kojic acid was paired with alpha-arbutin in a cosmetic, not added to a prescription triple. The study is a pilot and the primary instrument-based endpoints did not separate the groups.
The hydroquinone 4 percent label warns that hydroquinone may produce exogenous ochronosis, a gradual blue-black darkening of the skin, and directs discontinuing the product if no improvement is seen after 2 months of treatment.4Label population for prescription hydroquinone 4 percent cream.Direct for the hydroquinone component, but the label covers a single-agent 4 percent cream used twice daily rather than once-nightly use inside a four-active compound.
Where the evidence stops
Adding a fourth active makes the read-across weaker, not stronger. The only trials that resemble this design tested three ingredients, with a different corticosteroid, at fixed manufactured concentrations. There is no study of hydroquinone plus kojic acid plus tretinoin plus triamcinolone, and because hydroquinone and kojic acid inhibit the same enzyme, it is not established that the second one adds benefit rather than adding irritation. Anyone reading the trial numbers above should read them as belonging to a different product.
What is inside
Hydroquinone
The primary pigment-lightening agent, inhibiting the enzymatic oxidation of tyrosine to DOPA and suppressing other melanocyte metabolic processes.
Kojic acid
A second tyrosinase inhibitor added to the blend. It has trial-level support as a melasma agent in its own right, but there is no study of it added on top of a hydroquinone triple combination, so its incremental contribution here is not established.
Tretinoin
A prescription retinoid included to increase epidermal turnover and improve penetration of the depigmenting actives.
Triamcinolone acetonide
A topical corticosteroid included to reduce the irritation caused by the other three actives. It is one of the two reasons this formula is cycled.
Form and route
Topical cream, applied nightly, in cycles of no more than 12 weeks.
Nightly dosing follows the approved triple product's directions, which specify a thin film once daily at least 30 minutes before bedtime. The 12-week cap is a safety limit with two distinct drivers: prolonged hydroquinone use carries the exogenous ochronosis risk described on its label, and prolonged facial corticosteroid use carries atrophy, telangiectasia, striae and perioral dermatitis, plus HPA-axis suppression with extensive use. FDA's approved triple product is indicated for short-term treatment and is explicitly not indicated for maintenance.
What to expect, and when
The comparable trials read out at 8 weeks, with complete clearing in a minority of subjects on the approved product. The hydroquinone label directs stopping if there is no improvement after 2 months. Because two tyrosinase inhibitors are stacked here, irritation, redness, dryness and stinging may be more noticeable than with the three-active version, and the systematic review data show hydroquinone-containing combinations sit at the higher end of irritation risk. Depigmentation is reversible and ultraviolet exposure causes repigmentation, so daily broad-spectrum sun protection is part of the treatment. Response varies widely between individuals, and suitability is your prescriber's decision.
Regulatory status
Diamond Delux Plus is a four-active compounded cream and is not FDA-approved; no approved product combines hydroquinone, kojic acid, tretinoin and a corticosteroid, and kojic acid is not an FDA-approved drug ingredient. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Pregnancy, or if you are trying to become pregnant. The tretinoin label directs against use in pregnancy and the hydroquinone label states that safety in pregnancy has not been established.
Anyone who has developed exogenous ochronosis, the gradual blue-black darkening hydroquinone can produce, which the label says should prompt stopping treatment and consulting a physician.
Continuous long-term use without breaks. The corticosteroid component carries skin atrophy, telangiectasia, striae and perioral dermatitis risk, and systemic absorption of topical corticosteroids can produce reversible HPA-axis suppression.
Eczematous, broken or sunburned skin, or use alongside a photosensitising medicine such as a thiazide, tetracycline, fluoroquinolone, phenothiazine or sulfonamide.
Anyone with a prior sensitivity or allergic reaction to hydroquinone, kojic acid, tretinoin, a corticosteroid, or any component of the formula.
Children 12 and under, for whom the safety of topical hydroquinone has not been established.
Source: FDA label, HYDROQUINONE 4% (hydroquinone), SPL v5, effective 2026-07-10, and FDA label, RENOVA (tretinoin), SPL v14, effective 2026-02-24, with corticosteroid class warnings from FDA label, TRI-LUMA (fluocinolone acetonide, hydroquinone and tretinoin), SPL v18, effective 2024-10-24. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
Tretinoin speeds up the rate at which the outer layer of skin turns over. That is why it is studied for texture and fine lines, and why it can cause peeling and redness in the first several weeks. Azelaic acid does several things at once: it calms inflammation, it affects how cells in the pore lining behave, and it slows the pigment enzyme. Niacinamide supports the skin barrier, which matters when the other two are drying. Put together, the intent is renewal without stripping the barrier, though nobody has tested this exact trio.
The pharmacology underneath
Tretinoin activates RAR-alpha, RAR-beta and RAR-gamma; the label is explicit that it has not been established whether the clinical effects are mediated through receptor activation, irritation, or both. Transdermal absorption of tretinoin from topical formulations has ranged from 1 to 31 percent of applied dose depending on skin condition, so systemic exposure is not zero. Azelaic acid's described actions include antimicrobial activity, modification of follicular epidermal hyperproliferation, control of inflammatory lesions and anti-tyrosinase activity, which is the basis for its use in post-inflammatory hyperpigmentation. Niacinamide increases stratum corneum lipid biosynthesis with enhanced permeability barrier function. The three actives act at different points, which is the rationale for combining them, but that rationale is inferred from single-agent pharmacology rather than measured in this combination.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
In five controlled trials, RENOVA (tretinoin cream) 0.02% was compared with vehicle over 24 weeks in 324 evaluable treated patients and 332 on vehicle. Two of the five trials demonstrated efficacy for mitigation of fine facial wrinkling; for fine wrinkling in lightly pigmented subjects, moderate improvement occurred in 10 percent versus 3 percent on vehicle. No two of the five trials demonstrated efficacy for coarse wrinkling, mottled hyperpigmentation, tactile skin roughness or laxity.1Adults with photodamaged facial skin on a comprehensive skin care and sun avoidance program.Different product and a narrower endpoint than this offering markets. This is single-agent tretinoin cream 0.02%, and the label's own trials did not demonstrate benefit for tactile roughness, which is close to the 'texture' language on the card. Our formula is a compounded three-active cream at concentrations set per prescription.
A comparative study of 20 percent azelaic acid cream versus 4 percent hydroquinone cream in melasma reported comparable therapeutic effect between the two, and a separate 24-week double-blind study in 329 women reported 65 percent good or excellent results with 20 percent azelaic acid cream with no significant difference from 4 percent hydroquinone on overall rating, lesion size or pigmentary intensity.2Adults with melasma, predominantly women.Different concentration, different endpoint and different context. Those trials used azelaic acid at 20 percent as a single agent applied twice daily for pigment, not as one of three actives applied once nightly for texture and congestion. Nothing there measures azelaic acid's contribution inside this blend.
A double-blind split-face randomized trial in 27 melasma patients found good to excellent improvement in 44 percent on 4 percent niacinamide versus 55 percent on 4 percent hydroquinone over eight weeks. Separately, niacinamide has been shown to increase biosynthesis of ceramides and other stratum corneum lipids with enhanced epidermal permeability barrier function.3Adults with melasma for the clinical trial; ex vivo and in vivo barrier studies for the lipid finding.Surrogate and off-endpoint. The barrier lipid finding is a mechanism, not a clinical outcome, and the clinical trial measured melasma pigment rather than texture or congestion. Concentration and monotherapy design both differ from our formula.
A comprehensive review of azelaic acid describes its pharmacological properties and clinical applications across acne, rosacea and hyperpigmentation, and catalogues the formulations in which it has been studied.4Review across azelaic acid's studied indications.A narrative review rather than a trial, and it covers manufactured azelaic acid products at defined strengths. It does not evaluate azelaic acid compounded alongside tretinoin and niacinamide.
Where the evidence stops
The evidence for each active comes from studies of that active alone, usually at a higher concentration and often for a different endpoint than the one this formula targets. Most notably, the tretinoin label's own trials did not demonstrate benefit for tactile roughness, and the azelaic acid data are largely from 20 percent single-agent creams used for pigment. There is no trial of tretinoin plus azelaic acid plus niacinamide in one cream.
What is inside
Tretinoin
The lead active. A prescription retinoid that binds RAR nuclear receptors and increases epidermal turnover. This is the only active in the formula with an FDA-approved reference label.
Azelaic acid
A dicarboxylic acid with antimicrobial activity, an effect on follicular keratinisation, anti-inflammatory activity and anti-tyrosinase activity. Studied as a single agent at 15 and 20 percent; its contribution at compounded strengths inside this blend is not established.
Niacinamide
Vitamin B3 amide, included for barrier support and tone evenness. It increases biosynthesis of ceramides and other stratum corneum lipids. Supportive rather than primary here.
Form and route
Topical cream, pea-size, applied nightly to the face.
Nightly is the standard retinoid schedule because ultraviolet exposure and retinoid-treated skin are a poor combination, and the tretinoin label directs a moisturising sunscreen of SPF 15 or greater in the morning. Combining the three actives in one base is a practical adherence decision rather than a pharmacokinetic one: it collapses three steps into one and lets the pharmacy set concentrations to what a given patient tolerates. Topical delivery keeps exposure concentrated in the skin, though the label documents meaningful transdermal absorption of tretinoin, so it is not a zero-systemic route.
What to expect, and when
Retinoid trials in this category read out at 24 weeks, so patience is part of the protocol. The first several weeks commonly bring dryness, peeling, redness or stinging, and the label directs using less product, applying it less often, or pausing altogether if irritation becomes significant. Using more than directed has not been shown to give faster or better results, and may cause marked redness, peeling or discomfort. Daily broad-spectrum sunscreen is required, not optional. Response varies substantially: in the reference trials, 40 percent of treated patients showed no change in fine wrinkling at 24 weeks. Your prescriber decides whether this formula is appropriate for you.
Regulatory status
Tretinoin TAAN is a three-active compounded cream and is not FDA-approved; the reference brand tretinoin products are approved, but as single-active formulations at fixed strengths. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Pregnancy, or if you are trying to become pregnant. The tretinoin label states directly not to use it if you are pregnant or attempting to become pregnant, and to contact your physician immediately if you become pregnant while using it.
Sunburned skin. The label directs waiting until sunburn has fully recovered before use, and warns of heightened sunburn susceptibility during treatment.
Eczematous skin, on which tretinoin has been reported to cause severe irritation and should be used only with caution.
Anyone taking a medicine known to be a photosensitiser, such as a thiazide, tetracycline, fluoroquinolone, phenothiazine or sulfonamide, because of the possibility of augmented phototoxicity.
Anyone with a history of sensitivity reaction to any component of the formula, which is the label's stated contraindication.
Use around the eyes, mouth, nostrils, angles of the nose or other mucous membranes, where the label warns of severe redness, itching, burning, stinging and peeling.
Source: FDA label, RENOVA (tretinoin), SPL v14, effective 2026-02-24. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
Three of the four actives slow pigment production, by acting on the same enzyme or on the inflammation that drives pigment after irritation. Hydroquinone is the main one; kojic acid and azelaic acid both push in the same direction. The low-potency steroid is there to keep the combination from making skin red and sore, which is also why it cannot be used continuously. Because this formula has no retinoid, it is less irritating than the Diamond formulas but it is applied across the whole face rather than onto individual marks.
The pharmacology underneath
Hydroquinone and kojic acid both inhibit tyrosinase, the rate-limiting enzyme in melanogenesis; azelaic acid also has anti-tyrosinase activity along with anti-inflammatory effects that matter for post-inflammatory hyperpigmentation. The hydroquinone label notes that exposure to sunlight or ultraviolet light causes repigmentation of bleached areas. Hydrocortisone is a low-potency topical corticosteroid; corticosteroid class data document local atrophy, striae, telangiectasia, purpura, perioral dermatitis and acneiform eruptions with prolonged use, and with extensive or prolonged exposure, hypothalamic-pituitary-adrenal axis suppression that can take months to recover after treatment stops. Because three of the four actives converge on the same enzymatic step, the pharmacological rationale for combining them is redundancy and tolerability rather than complementary pathways, and that rationale is inferred, not measured.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
A comparative study of 20 percent azelaic acid cream versus 4 percent hydroquinone cream in melasma reported comparable therapeutic effect, and a 24-week double-blind study in 329 women reported 65 percent good or excellent results with 20 percent azelaic acid, with no significant difference from 4 percent hydroquinone on overall rating, lesion size or pigmentary intensity. Severe adverse effects such as allergic sensitisation or exogenous ochronosis were not observed with azelaic acid.1Adults with melasma, predominantly women.Different formulation and different regimen. Those studies used azelaic acid at 20 percent as a single agent applied twice daily; here it is one of four actives applied once nightly at a compounded concentration. The result also does not tell us whether combining azelaic acid with hydroquinone adds anything over either alone.
A systematic review that screened 174 randomized or controlled clinical trials in melasma assigned kojic acid a grade A recommendation and reported its irritation risk at 5.3 percent, against 50.9 percent for hydroquinone-containing combination therapy.2Pooled melasma trial populations.The grade A recommendation is for kojic acid in the formulations studied, not as a fourth ingredient in this compound. The irritation figures are also a caution rather than a reassurance for us, since our formula is a hydroquinone-containing combination.
The hydroquinone 4 percent label describes reversible depigmentation via inhibition of the enzymatic oxidation of tyrosine to DOPA, directs discontinuing if no improvement is seen after 2 months, warns that hydroquinone may produce exogenous ochronosis, and directs a broad-spectrum sun blocking agent because the product contains no sunscreen and ultraviolet exposure causes repigmentation.3Label population for prescription hydroquinone 4 percent cream in hyperpigmented conditions.Direct for the hydroquinone component's mechanism and safety, but the label covers single-agent 4 percent cream applied twice daily rather than once-nightly use inside a four-active compound.
A review of adverse effects of topical corticosteroid use describes local atrophy, striae, telangiectasia, purpura, perioral dermatitis and acneiform eruptions, and notes that prolonged use can lead to HPA-axis suppression and adrenal insufficiency taking months to recover after treatment stops, with adrenal suppression expected when more than 50 g per week is applied.4Narrative and clinical review of topical corticosteroid safety.Class-level rather than product-specific. Hydrocortisone is at the low-potency end of the class and facial application quantities here are far below 50 g per week, but the local facial effects, particularly perioral dermatitis and telangiectasia, are the reason this formula is cycled.
Where the evidence stops
Every citation above is a single-agent study at a concentration and frequency that differ from what is dispensed here, and three of the four actives target the same enzymatic step, so the individual results cannot simply be added together. There is no trial of azelaic acid plus hydrocortisone plus hydroquinone plus kojic acid. The approved reference point for hydroquinone combination therapy, Tri-Luma, contains a retinoid and a different corticosteroid, so it is not a valid stand-in for this formula either.
What is inside
Azelaic acid
A dicarboxylic acid with anti-tyrosinase, anti-inflammatory and antimicrobial activity. In melasma trials at 20 percent it has performed comparably to 4 percent hydroquinone as a single agent.
Hydrocortisone
A low-potency topical corticosteroid included to reduce irritation from the depigmenting actives. It is one of the two reasons the protocol cycles this formula.
Hydroquinone
The primary pigment-lightening agent, inhibiting the enzymatic oxidation of tyrosine to DOPA and suppressing other melanocyte metabolic processes. Its label describes the depigmentation as reversible.
Kojic acid
A second tyrosinase inhibitor. It has independent melasma trial support, but there is no study of kojic acid added to a hydroquinone-plus-azelaic-acid compound, so its incremental contribution here is not established.
Form and route
Topical cream, applied nightly, in cycles of no more than 12 weeks.
Nightly application avoids daytime ultraviolet exposure, which matters more here than usual: hydroquinone's label states that exposure to sunlight or ultraviolet light causes repigmentation of bleached areas, so treating at night and protecting by day are two halves of the same regimen. The 12-week cycle cap is a safety limit with two separate drivers. Prolonged hydroquinone exposure carries the risk of exogenous ochronosis, a gradual blue-black darkening the label says should prompt discontinuation. Prolonged facial corticosteroid exposure carries atrophy, telangiectasia, striae and steroid-driven perioral dermatitis. Neither risk is theoretical, and continuous long-term use is not recommended.
What to expect, and when
This is a gradual category. The hydroquinone label directs stopping if no improvement is seen after 2 months of treatment. Dryness and fissuring around the nose and under the eyes, redness and stinging are the reported adverse reactions for the hydroquinone component. Because the depigmentation is reversible and ultraviolet exposure causes repigmentation, daily broad-spectrum sun protection is part of the treatment rather than an add-on, and results tend not to hold without it. Response varies widely between individuals and by skin type, and whether this formula is appropriate for you is your prescriber's decision.
Regulatory status
Luminance is a four-active compounded cream and is not FDA-approved. It contains no retinoid, so it is not equivalent to any approved triple-combination product, and hydrocortisone here is a compounded component rather than an approved combination ingredient. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Pregnancy. The hydroquinone label states that the safety of topical hydroquinone use during pregnancy has not been established, and topical hydroquinone should be given to a pregnant woman only if clearly needed.
Anyone who has developed exogenous ochronosis, the gradual blue-black darkening of the skin hydroquinone can produce. The label directs discontinuing treatment and consulting a physician.
Continuous long-term use without breaks. The corticosteroid carries the risk of skin atrophy, telangiectasia, striae and perioral dermatitis on facial skin, and prolonged or extensive topical corticosteroid use can suppress the HPA axis.
Anyone with a prior history of sensitivity or allergic reaction to hydroquinone, kojic acid, azelaic acid, a corticosteroid, or any component of the formula, which is the hydroquinone label's stated contraindication.
Children 12 and under, for whom the safety of topical hydroquinone has not been established.
Use on skin that shows itching, vesicle formation or an excessive inflammatory response on a sensitivity test. The label advises a patch test on unbroken skin checked at 24 hours before starting, and says further treatment is not advised if those reactions appear.
Source: FDA label, HYDROQUINONE 4% (hydroquinone), SPL v5, effective 2026-07-10, with corticosteroid class warnings from the published review of adverse effects of topical corticosteroid use. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
Hormonal breakouts along the jaw and chin are driven partly by how skin responds to androgens. Spironolactone blocks some of that androgen signal, which is why the tablet form is used for adult acne in women. Metformin is included on the idea that insulin signalling feeds the same pathway. Progesterone is included on a hormonal rationale. Azelaic acid does the more conventional work: calming inflammation, affecting the pore lining and reducing bacteria. The important caveat is that three of these four are drugs designed to be swallowed, and putting them on skin is a different question from taking them.
The pharmacology underneath
Spironolactone is an aldosterone receptor antagonist that also antagonises the androgen receptor and reduces androgen-driven sebum production, which is the mechanistic basis for oral use in adult female acne. Topical spironolactone is intended to act locally at the pilosebaceous unit with less systemic exposure, and small trials have tested 5 percent gel and 5 percent cream on that premise. Metformin activates AMP-activated protein kinase and reduces hepatic gluconeogenesis systemically; the topical rationale rests on local effects on insulin signalling and inflammation described in laboratory and animal work rather than on human acne outcomes. Progesterone's role in the pilosebaceous unit is complex and we could not source acne outcome data for topical application. Azelaic acid's actions are antimicrobial, comedolytic through effects on follicular keratinisation, anti-inflammatory and anti-tyrosinase. Systemic absorption from a compounded facial cream containing spironolactone, metformin and progesterone has not been characterised in a way we can cite, which is a prescriber consideration rather than a settled question.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
A double-blind randomized controlled trial of 5 percent topical spironolactone gel versus placebo in 78 patients with mild to moderate acne (38 on spironolactone, 40 on placebo) found a statistically significant difference in total lesion count between groups, but no statistically significant difference in the acne severity index.1Patients with mild to moderate acne vulgaris.Different form and different population framing. This tested a 5 percent gel as a single agent, not spironolactone compounded with three other actives in a cream, and it enrolled mild to moderate acne generally rather than hormonal jawline acne or a PCOS population. The primary severity endpoint was not met.
A pilot clinical trial of 5 percent spironolactone cream applied twice daily for 8 weeks in 15 patients with mild to moderate acne assessed changes in open and closed comedones, inflammatory papules and global grading, along with skin biometric measures.2Fifteen patients with mild to moderate acne vulgaris.Pilot scale with 15 patients and no control arm of the kind that would support an efficacy claim. Twice-daily dosing at 5 percent as a single agent, which is not our regimen.
A systematic review and meta-analysis of randomized placebo-controlled trials with trial sequential analysis found oral spironolactone efficacious for acne in women. Separately, a meta-analysis comparing oral and topical spironolactone in acne examined effectiveness and safety across both routes.3Women with acne vulgaris in the oral analysis; mixed populations across the route comparison.This is the crucial gap for this offering. The strong evidence is for oral spironolactone at systemic doses, and it does not transfer to a compounded topical cream. Route, dose and systemic exposure all differ, and we are explicitly not offering the oral drug. The systemic evidence must not be read as support for the topical product.
A systematic review following PRISMA standards of human clinical studies of topical metformin concluded that while topical metformin has shown promising results in animal studies, there is limited data on its effectiveness in humans.4Human clinical studies of topical metformin across dermatologic indications including acne.The review's own conclusion is the gap. Human evidence for topical metformin is limited, and what exists is not at the level of an adequately powered acne trial in a defined population. This active is here on a mechanistic rationale, not on outcome data.
A comprehensive update on hormonal therapies for acne describes the current evidence base for androgen-directed acne treatment, and the treatments with established support in that literature are systemic: combined oral contraceptives and oral spironolactone.5Review of hormonal acne management, predominantly in women.The established hormonal acne treatments in this literature are oral. We could not find controlled acne outcome evidence for topical progesterone at all, so that active is included on a compounding rationale without trial support.
Where the evidence stops
The single biggest limitation is route substitution. Spironolactone's strong evidence in acne is oral and systemic; the topical evidence is a small placebo-controlled trial that missed its severity endpoint and a 15-patient pilot. Metformin's human topical evidence is described by its own systematic review as limited. Topical progesterone has essentially no acne outcome evidence we could locate. Reading the oral spironolactone literature across to this cream would be the most likely error a reader makes on this page, and it would be wrong.
What is inside
Azelaic acid
A dicarboxylic acid with antimicrobial activity, an effect on follicular epidermal hyperproliferation, anti-inflammatory activity and anti-tyrosinase activity. This is the active in the formula with the most conventional topical acne evidence.
Metformin
An oral antidiabetic drug included topically on an insulin-sensitisation rationale. A systematic review of human studies of topical metformin concluded there is limited data on its effectiveness in humans, so its contribution here is not established.
Progesterone
Included in the compounded blend on a hormonal rationale. We could not find controlled acne outcome evidence for topical progesterone, so the evidence for its contribution in this combination is essentially absent.
Spironolactone
An aldosterone antagonist with anti-androgen activity. Well supported as an oral treatment for acne in women; as a topical it has only small trials and pilot studies, which is a much weaker basis.
Form and route
Topical cream, applied nightly to affected areas.
The stated reason for a topical route with these three actives is to concentrate exposure at the pilosebaceous unit while reducing the systemic exposure that comes with oral dosing, which for oral spironolactone means potassium monitoring and other systemic considerations. That rationale is plausible and it is the premise of the published topical spironolactone trials, but it is a premise rather than a demonstrated equivalence: reducing systemic exposure also reduces the systemic mechanism that oral spironolactone's acne evidence depends on. Nightly application is a practical adherence choice, and the published topical spironolactone studies actually dosed twice daily.
What to expect, and when
The published topical spironolactone studies ran 8 weeks before their readouts, so this is not a fast category. In the placebo-controlled trial, total lesion count separated from placebo but the acne severity index did not, which is a realistic picture of the size of the effect that has been demonstrated for a topical. Local irritation, dryness or redness are the expected tolerability issues. Because three of the four actives have limited or absent topical outcome evidence, individual response is genuinely unpredictable here, and follow-up with your prescriber matters more than usual. Whether this formula suits you, and whether an oral option would be more appropriate, is your prescriber's decision.
Regulatory status
Flawless is a four-active compounded cream and is not FDA-approved. Three of its actives are systemic drugs being used topically and off-label: metformin, progesterone and spironolactone are approved as oral products for other indications, and none is approved as a topical acne treatment. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Pregnancy, or if you are trying to become pregnant or are breastfeeding. Spironolactone is an anti-androgen and both spironolactone and progesterone are hormonally active; the published topical spironolactone pilot excluded pregnancy and lactation.
Anyone using this as a substitute for a PCOS diagnosis or an endocrine work-up. PCOS is a diagnosis a physician makes after evaluation. This formula is not a diagnostic, is not a test, and does not replace hormonal assessment or the management of the underlying condition.
Anyone with a hormone-sensitive condition, kidney impairment, high potassium, or who takes potassium supplements or potassium-sparing medicines, without their physician's review. Systemic absorption from a compounded topical is not characterised, so this needs a prescriber's judgment rather than an assumption.
Anyone with known sensitivity to azelaic acid, metformin, progesterone, spironolactone or any component of the formula.
Broken, eczematous or acutely inflamed skin, where irritation from a multi-active compound is more likely and absorption is less predictable.
Source: No FDA label exists for any of these actives as a topical acne product; entries above are drawn from the exclusion criteria and safety discussion in the published topical spironolactone trials and from the systemic labels' hormonal and renal cautions, and should be reviewed by the prescribing clinician. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
The Drift Protocol Sleep
DRIFT is two prescription sleep offerings that take opposite approaches. SleepE contains a single active, ramelteon, a melatonin receptor agonist that the FDA-approved reference product's label indicates for insomnia characterised by difficulty with sleep onset, and which the label states is not a controlled substance. Knockout is a three-active compounded tablet that stacks an antihistamine sedative, an antidepressant used off-label for sleep, and a dietary supplement; compounded medications are not FDA-approved, and no trial has tested that combination.
Ramelteon is not a controlled substance. Does that apply to Knockout too? ▾
No, and the distinction is important. Ramelteon is a melatonin MT1 and MT2 receptor agonist, it has no appreciable affinity for the GABA receptor complex, and it is not a controlled substance, which is what SleepE is built around. Knockout is a different formulation with different pharmacology: it contains trazodone and doxylamine, and the non-controlled framing does not carry over to it. Stacking sedating agents also means additive central nervous system depression, which is its own consideration.
Is SleepE the same as Rozerem? ▾
The active is the same and it is an approved active, but SleepE is compounded, so it is not the FDA-approved product and the two are not interchangeable. It is worth knowing that the effect size on falling asleep reported in the ramelteon trials is modest, and the label notes the formal assessments of sleep latency were made at defined points across trials of up to six months.
What are the risks in Knockout specifically? ▾
Several, and they come from the actives. Trazodone is approved for major depressive disorder and its label carries a boxed warning for suicidal thoughts and behaviours in pediatric and young adult patients, plus warnings for priapism, serotonin syndrome, QT prolongation and orthostatic hypotension. Doxylamine is a sedating antihistamine with anticholinergic effects that are more pronounced in older adults, and tolerance to its sedative effect is commonly described. Melatonin is regulated as a dietary supplement in the United States, so content can vary from label claim. No trial has studied these three together.
How long should I be taking a sleep medication? ▾
That is a question for your prescriber, and the labels are direct about it. Both the ramelteon and the related hypnotic labels advise re-evaluating if insomnia has not resolved after seven to ten days, because persistent sleep disturbance can be the presenting sign of another physical or psychiatric problem that deserves assessment in its own right. Neither of these is a substitute for that assessment.
Knockout
A nightly compounded tablet combining doxylamine, trazodone and melatonin. It is the stronger of the two DRIFT options and is aimed at staying asleep rather than only falling asleep.
SleepE
A nightly compounded chewable containing a single active, ramelteon. It targets the body clock rather than sedating, and the reference label states that ramelteon is not a controlled substance.
How it is understood to work
The three actives sedate through three different routes. Doxylamine blocks histamine, the same signal that makes some allergy medicines drowsy. Trazodone acts on serotonin receptors and on the adrenaline receptors that keep you alert, which is why low doses make people sleepy even though the drug is approved as an antidepressant. Melatonin is the hormone that signals night to the body clock. The idea behind combining them is that three different routes give a deeper effect than one. The predictable trade-off is that three sedatives together add up, so next-day grogginess and impairment are the risk, and no study has measured what this specific combination does.
The pharmacology underneath
Trazodone selectively inhibits neuronal reuptake of serotonin and acts as an antagonist at 5-HT2A, with additional antagonism at 5-HT2B, 5-HT2C, alpha-1A and alpha-2C receptors and partial agonism at 5-HT1A; the label notes the alpha-1 adrenergic antagonism may be associated with postural hypotension. Peak plasma levels occur roughly one hour after dosing on an empty stomach or two hours with food, and trazodone is metabolised via CYP3A4 to the active metabolite mCPP. Doxylamine is an H1 antagonist with nonspecific anticholinergic activity, which is the source of both its sedation and its dry mouth, blurred vision and cognitive effects. Melatonin acts at MT1 and MT2 receptors on the circadian system. The pharmacological point that matters clinically is additive central nervous system depression: three agents with sedating mechanisms dosed together produce a combined effect that has not been characterised for this formulation.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
The trazodone label carries a boxed warning stating that antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. In pooled analyses of roughly 77,000 adult and over 4,400 pediatric patients, the drug-placebo difference was 14 additional patients per 1,000 with suicidal thoughts or behaviors under age 18 and 5 additional per 1,000 aged 18 to 24, with 1 fewer per 1,000 aged 25 to 64 and 6 fewer per 1,000 aged 65 and over.1Pooled placebo-controlled antidepressant trials across pediatric and adult patients.Different indication and different dose. These data come from antidepressant-dose trials in depression, not from low-dose sedative use for insomnia. The direction of the risk is age-dependent, and it is the reason this warning belongs on a sleep product prescribed to younger adults.
The trazodone label states that trazodone is indicated for the treatment of major depressive disorder in adults. It lists no insomnia indication. It further warns of serotonin syndrome, QT prolongation with instruction to avoid use with other QT-prolonging drugs and in patients with risk factors, orthostatic hypotension and syncope, increased risk of bleeding with aspirin, NSAIDs or anticoagulants, priapism, activation of mania or hypomania, potential for cognitive and motor impairment, and angle-closure glaucoma.1Label population for oral trazodone in major depressive disorder.Direct on safety, indirect on efficacy. Using trazodone for sleep is off-label, so the entire benefit side of this active rests on clinical practice and guideline discussion rather than on an approved indication, while the safety side of the label applies in full.
A meta-analysis of exogenous melatonin for primary sleep disorders found melatonin decreased sleep onset latency by a weighted mean difference of 11.7 minutes overall (95 percent CI -18.2 to -5.2), and in people with insomnia specifically by 7.2 minutes (95 percent CI -12.0 to -2.4) across 12 trials. The effect was substantially larger in delayed sleep phase syndrome at 38.8 minutes.2Adults and children across randomized trials in primary sleep disorders, with an insomnia subgroup of 12 trials.Route is the same but the product is not. Those trials used melatonin as a standalone supplement at defined doses, not as one of three actives in a compounded tablet. Because melatonin is a dietary supplement in the United States, actual content can differ from label, so trial doses and product doses are not reliably comparable. The measured effect is also modest and it is on falling asleep, not on staying asleep, which is what this offering is positioned for.
A Gerontological Society of America workgroup on OTC sleep aids in older adults reported that when doxylamine efficacy has been studied, doses of 25 and 50 mg were superior to placebo with no difference between the two dose levels for sleep induction and duration in subjects accustomed to taking a nighttime sleep medication, and that clinical studies supporting the efficacy and safety of oral doxylamine are limited. It also notes that the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults recommends avoiding OTC sleep medications containing first-generation antihistamines because of anticholinergic effects, and that rebound insomnia and tolerance appear to be more frequently reported.3Older adults, with reference to the general doxylamine efficacy literature.The efficacy data for doxylamine are thin and were generated as monotherapy at defined OTC doses. Nothing there measures doxylamine inside a three-active compounded tablet, and the Beers Criteria caution is a direct reason this offering needs age-specific prescriber judgment.
The American Academy of Sleep Medicine clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults grades agents by strength of evidence and by insomnia subtype, sleep onset versus sleep maintenance versus combined. The American College of Physicians guideline on chronic insomnia in adults reviews pharmacologic and behavioral approaches and positions cognitive behavioral therapy for insomnia as the first-line approach.4Adults with chronic insomnia across the guideline evidence base.Guidelines evaluate single agents at studied doses. Neither guideline evaluates a compounded three-active tablet, and neither supports combining sedatives in this way. Both also position behavioral treatment ahead of medication, which the page should not leave out.
Where the evidence stops
There is no trial of doxylamine plus trazodone plus melatonin in one tablet. Every number above belongs to one of the three actives studied alone, at doses that are not necessarily our doses, and the strongest single body of evidence in the formula, the trazodone label, is for a different indication entirely. Stacking three sedating agents has a predictable consequence that no trial here quantifies: additive central nervous system depression, meaning more sedation, more next-day impairment and more interaction risk with alcohol and other depressants than any one agent alone.
What is inside
Doxylamine
A first-generation H1 antihistamine with nonspecific anticholinergic and sedative effects, approved by FDA in 1978 as an over-the-counter sleep aid. It contributes the initial sedation.
Trazodone
A serotonin reuptake inhibitor and 5-HT2 receptor antagonist approved for major depressive disorder. It is prescribed off-label at low doses to support sleep; its alpha-1 adrenergic and histaminergic antagonism is the usual explanation for the sedation. This is the active that carries a boxed warning.
Melatonin
A dietary supplement in the United States, not an approved drug. Meta-analysis evidence describes a modest effect on sleep onset latency. Because it is a supplement, potency and content are not held to drug manufacturing standards, and its contribution inside this tablet is not established.
Form and route
Oral tablet, taken nightly about 30 minutes before bed.
A single combined tablet exists for adherence, not for pharmacokinetics: it makes one dose out of three, which matters at bedtime. The timing reflects trazodone's absorption, with peak plasma levels roughly one hour after dosing on an empty stomach and about two hours when taken with food, and doxylamine's onset. Note that combining three agents into one tablet also removes the ability to adjust one component without changing the others, which is a real trade-off against the convenience.
What to expect, and when
Sedation is usually noticeable the first night, which is the point of an antihistamine plus low-dose trazodone. Next-day grogginess, dry mouth, dizziness on standing and impaired concentration are the common trade-offs, and the label describes potential for cognitive and motor impairment and warns about operating machinery. The literature on first-generation antihistamines describes tolerance to the sedative effect and rebound insomnia as more frequently reported, so the sedation may not hold at the same intensity over time. Because no trial has tested this three-active combination, we cannot describe a typical timeline for it with any precision. Chronic insomnia guidelines place cognitive behavioral therapy first, and a medication is one part of a plan your prescriber sets.
Regulatory status
Knockout is a three-active compounded tablet and is not FDA-approved. Trazodone is approved only for major depressive disorder, so its use here is off-label; doxylamine is an over-the-counter antihistamine sedative; and melatonin is regulated in the United States as a dietary supplement rather than as a drug. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Anyone taking, or within 14 days of stopping, a monoamine oxidase inhibitor, including linezolid or intravenous methylene blue. This is an absolute contraindication on the trazodone label because of the risk of serotonin syndrome.
Children and adolescents. Trazodone is not approved for use in pediatric patients, and the boxed warning describes increased suicidal thoughts and behaviors in pediatric and young adult patients treated with antidepressants.
Anyone with a history of, or risk factors for, prolonged QT interval, or who takes another medicine that increases the QT interval. The trazodone label directs avoiding use in these situations.
Men who have had priapism or who have a condition predisposing to it. The label describes cases of painful and prolonged penile erections and priapism and directs seeking immediate medical attention if they occur.
Anyone taking another serotonergic medicine, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone or St John's Wort, without a prescriber's review, because of serotonin syndrome risk.
Anyone with untreated anatomically narrow angles, since the label directs avoiding antidepressants including trazodone in that setting, and because doxylamine's anticholinergic activity carries the same concern.
Anyone drinking alcohol or taking another sedative, opioid or central nervous system depressant. Three sedating actives together add up, and the combined effect has not been studied.
Older adults, without specific prescriber judgment. The Beers Criteria recommend avoiding OTC sleep medications containing first-generation antihistamines such as doxylamine in older adults because of anticholinergic effects including cognitive impairment, dizziness and falls.
Anyone who needs to drive or operate machinery before the drug has cleared. The label warns of potential for cognitive and motor impairment and of orthostatic hypotension and syncope.
Source: FDA label, TRAZODONE HYDROCHLORIDE (trazodone hydrochloride), SPL v12, effective 2026-08-10, with the doxylamine and older-adult entries drawn from the Gerontological Society of America workgroup recommendations on OTC sleep aids and the Beers Criteria they cite. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
How it is understood to work
Ramelteon acts on the same receptors your own melatonin uses to tell your body it is night. It is not a sedative in the usual sense: the label notes it has no appreciable affinity for the GABA receptor complex, which is the target of the older sleeping pills. That is the basis for the label statement that it is not a controlled substance and that it did not produce physical dependence in the studies described. The trade-off is that it is aimed at falling asleep rather than staying asleep, and the size of the effect on falling asleep is measured in minutes rather than hours.
The pharmacology underneath
Ramelteon is a melatonin receptor agonist with high affinity for MT1 and MT2 and relative selectivity over MT3; the label states these receptors are thought to be involved in maintaining the circadian rhythm underlying the normal sleep-wake cycle, and that ramelteon has no appreciable affinity for the GABA receptor complex or for receptors binding neuropeptides, cytokines, serotonin, dopamine, noradrenaline, acetylcholine or opiates. Absorption is rapid with median peak concentrations at about 0.75 hours after fasted dosing, but absolute oral bioavailability is only 1.8 percent because of extensive first-pass metabolism, and inter-subject variability in Cmax and AUC is high, with a coefficient of variation around 100 percent. CYP1A2 is the major metabolising isozyme. The parent half-life is roughly one to 2.6 hours, and the active metabolite M-II, which has lower receptor affinity but circulates at 20 to 100 times greater systemic exposure, has a half-life of two to five hours. A high-fat meal raises AUC 31 percent, lowers Cmax 22 percent and delays Tmax by about 45 minutes, which is why the label directs against taking it with or immediately after a high-fat meal.
What the research actually shows
FindingPopulation studiedHow it differs from what we dispense
The reference label states that ramelteon is indicated for the treatment of insomnia characterised by difficulty with sleep onset, supported by trials up to six months in duration. Three randomized double-blind polysomnography trials are described: a 35-day parallel study in adults aged 18 to 64 in which ramelteon reduced average latency to persistent sleep at each timepoint versus placebo, with the 16 mg dose conferring no additional benefit; a three-period crossover in subjects 65 and older in which both 4 and 8 mg reduced latency to persistent sleep; and a six-month study in adults in which ramelteon 8 mg reduced sleep latency at each timepoint.1Adults aged 18 to 64 and adults aged 65 and older with chronic insomnia, plus a transient insomnia first-night model in healthy adults.Same active and same oral route, but a different product. Those trials used the FDA-approved tablet at defined strengths; SleepE is a compounded chewable, so the formulation, and therefore its dissolution and absorption behaviour, were not the ones tested. That matters more than usual here because ramelteon's absolute bioavailability is only 1.8 percent and inter-subject variability is roughly 100 percent.
A critical appraisal of ramelteon in insomnia reports that compared with placebo, ramelteon's reduction in sleep latency varied from 7 to 19 minutes and averaged around 13 minutes, with the effect lasting up to six months after initiation and comparable with that of other hypnotics. In a first-night transient insomnia model, latency to persistent sleep was 12.2 minutes on ramelteon 8 mg versus 19.7 minutes on placebo; in chronic insomnia at week 1, latency to persistent sleep was 32.2 minutes on 8 mg and 28.9 minutes on 16 mg versus 47.9 minutes on placebo.2Pooled adult insomnia trial populations, including both transient and chronic insomnia.This is the honest size of the effect, and it is modest: an average of roughly 13 minutes off the time taken to fall asleep. It is also measured on the approved tablet, not on a compounded chewable, and it addresses sleep onset rather than sleep maintenance or total sleep time.
The label states that ramelteon is not a controlled substance, that discontinuation in animals or humans after chronic administration did not produce withdrawal signs, and that ramelteon does not appear to produce physical dependence. In a human laboratory abuse potential study in 14 subjects with a history of sedative, hypnotic or anxiolytic drug abuse, no differences in subjective responses indicative of abuse potential were found between ramelteon and placebo at doses up to 20 times the recommended therapeutic dose, while the positive control triazolam showed a consistent dose-response effect.1Fourteen subjects with a history of sedative, hypnotic or anxiolytic drug abuse, plus animal studies.Direct: same active, same oral route. The abuse liability study is small at 14 subjects, and it was conducted on the approved product. This is the claim on this offering with the strongest label support.
A systematic review and meta-analysis of melatonin and ramelteon for the acute and long-term management of insomnia disorder in adults assessed both agents across the randomized evidence base. Separately, the AASM clinical practice guideline for the pharmacologic treatment of chronic insomnia grades agents by insomnia subtype and strength of evidence, and the ACP guideline positions cognitive behavioral therapy for insomnia as the first-line treatment for chronic insomnia in adults.3Adults with insomnia disorder across the pooled and guideline evidence bases.Guideline and meta-analytic evidence evaluates the approved ramelteon product at studied doses, not a compounded chewable. Both guidelines also place behavioral treatment ahead of any medication, which is context this page should carry.
Where the evidence stops
The active is FDA-approved and the indication matches what this offering is for, which makes SleepE the best-evidenced item in DRIFT. The limitation is the product, not the pharmacology: every trial cited used the approved oral tablet, and a compounded chewable is a different dosage form whose absorption has not been tested against it. That gap matters more here than it would for most drugs, because ramelteon has only 1.8 percent absolute oral bioavailability with roughly 100 percent inter-subject variability, so formulation changes are not trivially interchangeable. The second limitation is the size of the effect: an average of about 13 minutes off sleep latency is a real but modest result, and it applies to falling asleep, not to staying asleep.
What is inside
Ramelteon
The sole active. A melatonin receptor agonist with high affinity for MT1 and MT2 receptors and relative selectivity over MT3, indicated on the reference label for insomnia characterised by difficulty with sleep onset.
Form and route
Oral chewable, taken nightly about 30 minutes before bed.
The 30-minute timing follows the reference label, which directs taking the dose within 30 minutes of going to bed and matches the median peak concentration at about 0.75 hours after fasted dosing. The label also directs against taking it with or immediately after a high-fat meal, because a high-fat meal raised AUC 31 percent, lowered Cmax 22 percent and delayed Tmax by around 45 minutes. The chewable form is a practical and adherence choice rather than a pharmacokinetic upgrade: no data show a chewable performs like the approved tablet, and ramelteon undergoes rapid, high first-pass metabolism regardless of how it is swallowed.
What to expect, and when
In the trials on the approved product, the average reduction in the time taken to fall asleep was roughly 13 minutes, with a range across studies of about 7 to 19 minutes. That is a real but modest change, and it is about falling asleep, not about staying asleep or total sleep time. The label directs re-evaluation if insomnia does not remit after 7 to 10 days of treatment. Because ramelteon acts on the circadian system rather than by sedating, it does not feel like a sleeping pill to most people. Reported effects include next-day somnolence, dizziness and fatigue, and the label directs avoiding driving or operating machinery after taking it and confining activities to preparing for bed. Individual response varies substantially, and treatment is your prescriber's decision.
Regulatory status
SleepE is compounded, so it is not the FDA-approved ramelteon product even though the active ingredient is FDA-approved. The approved reference product is an oral tablet; this is a chewable prepared by a 503A pharmacy, and compounded medications are not FDA-approved. Compounded medications are not FDA-approved. A licensed physician decides whether any protocol is appropriate for you; nothing here is a diagnosis or a substitute for one.
Who it is not for
Anyone taking fluvoxamine. This is a contraindication on the reference label: fluvoxamine increased ramelteon AUC approximately 190-fold and Cmax approximately 70-fold, and the two should not be used together.
Anyone who has developed angioedema while taking ramelteon. The label states these patients should not be rechallenged with the drug, and notes rare cases of angioedema involving the tongue, glottis or larynx where airway obstruction may occur and be fatal.
Anyone with severe hepatic impairment. The label states ramelteon is not recommended in this population, and directs caution in moderate hepatic impairment.
Anyone with severe sleep apnea, for whom the label states ramelteon is not recommended.
Anyone drinking alcohol. The label states alcohol and ramelteon may have additive effects and directs that they should not be used in combination.
Children and adolescents. Safety and effectiveness in pediatric patients have not been established, and the label notes further study is needed before use in prepubescent and pubescent patients.
Anyone whose insomnia has not been evaluated. The label directs that symptomatic treatment of insomnia should only be initiated after careful evaluation, and that failure to remit after 7 to 10 days may indicate a primary psychiatric or medical illness that should be evaluated.
Source: FDA label, RAMELTEON (ramelteon), SPL v1, effective 2026-07-27. This is a summary, not the complete list — read the full Important Safety Information and talk to your prescriber.
Prescription only, if appropriate — a licensed provider determines whether this is right for you. Compounded medications are not FDA-approved. Important Safety Information
What are compounded medications?
Compounded medications are prescription drugs custom-prepared for an individual patient by a licensed pharmacist. Unlike mass-produced medications that come in fixed doses and forms, a compounded medication can be tailored — adjusting the dose, changing the delivery form, or combining several active ingredients into one formulation.
This is not a new idea. Compounding is how all medications were made before mass manufacturing existed. Today, compounding pharmacies serve patients who need a dose or a combination that is not commercially available.
The key distinction: compounded medications are not FDA-approved drugs and are not interchangeable with brand-name medications. They are prepared for you specifically, by a licensed pharmacist, on a physician's prescription. Many of the actives in these protocols are also prescribed off-label, meaning for a use, dose, route or population the FDA has not reviewed. Both of those facts are repeated on every offering below, because they apply to every one of them.
How the prescribing process works
Every protocol begins with a licensed physician through our telehealth partner, MDI. There are no shortcuts and no rubber stamps.
Step 1
Health assessment
You complete a detailed wellness questionnaire covering your health history, current medications, goals and any contraindications. It takes about five minutes.
Step 2
Physician review
A licensed physician reviews your assessment in full, evaluates your eligibility, and decides whether a protocol is clinically appropriate and at what dose.
Step 3
Prescription issued
If clinically appropriate, your physician writes a prescription and sends it to the compounding pharmacy. If you are not a candidate, you are told immediately and not charged.
Step 4
Ongoing oversight
Your provider follows your progress through check-ins and adjusts as needed. You can message your provider through your patient portal.
How 503A pharmacies are regulated
Nuvari partners exclusively with 503A-licensed compounding pharmacies, which operate under Section 503A of the Federal Food, Drug, and Cosmetic Act.
State board of pharmacy licensing — every pharmacy holds a current license in the states where it operates, subject to routine inspection.
FDA registration and oversight — 503A pharmacies are registered with the FDA and subject to FDA inspection. The compounded medications themselves remain non-FDA-approved.
Pharmacist oversight — all compounding is performed by or under the direct supervision of a licensed pharmacist.
Valid prescription required — every compounded medication requires an individualized prescription for a specific patient. No bulk manufacturing.
USP standards — pharmacies follow USP chapters 795 (non-sterile) and 797 (sterile) for compounding procedures.
Why 503A matters: unlike 503B outsourcing facilities, which produce in bulk without individual prescriptions, a 503A pharmacy compounds each medication against a specific prescription for a specific patient.
Quality testing and verification
Raw ingredient testing — active pharmaceutical ingredients are sourced from FDA-registered suppliers and tested for identity, purity and potency before use.
Certificate of Analysis — each batch of raw material arrives with a COA verifying composition and purity.
Beyond-use dating — every compounded medication is assigned a beyond-use date based on stability data.
Sterility testing — injectable compounds are tested for microbial contamination.
Potency verification — finished products are tested to confirm the active concentration matches the prescription within defined tolerances.
Environmental monitoring — compounding areas are monitored for air quality, surface contamination and clean-room compliance.
Cold chain: protocols that require refrigeration ship in validated insulated packaging with cold packs, in tamper-evident and unmarked boxes.
Frequently asked questions
What is a compounded medication? ▾
A compounded medication is a prescription drug custom-prepared for an individual patient by a licensed pharmacist. Unlike mass-produced medications that come in fixed doses, compounded medications can be tailored to specific dosage needs. Compounded medications are not FDA-approved drugs and are not interchangeable with brand-name medications.
Are compounded GLP-1 medications FDA-approved? ▾
No. Compounded GLP-1 medications are not FDA-approved as finished products. They are legally prescribed and dispensed through 503A compounding pharmacies that are licensed by state boards of pharmacy and subject to FDA oversight, and the active pharmaceutical ingredients are sourced from FDA-registered suppliers.
What does off-label mean here? ▾
Off-label means a physician is prescribing a medication for a use, a dose, a route or a population the FDA has not reviewed for that product. It is legal and common in medical practice, and it is the prescriber's clinical judgement rather than an FDA finding. Many of the actives in these protocols are prescribed off-label, and each offering below says so specifically.
Why does each offering list how the research differs? ▾
Because it is the honest way to present the evidence. A trial of a subcutaneous injection does not automatically apply to a troche, a study in premenopausal women does not automatically apply to men, and a brand product is not the same as a compounded one. Every evidence table on this page names that distance so you can weigh the finding yourself and discuss it with your provider.
Is 503A or 503B better? ▾
They serve different purposes. 503A pharmacies compound medications for individual patients based on a specific prescription, which allows for personalized dosing. 503B facilities produce larger batches without individual prescriptions. Nuvari partners with 503A pharmacies so each medication is compounded specifically for the patient.
How do I know the pharmacy is legitimate? ▾
Every pharmacy Nuvari works with holds an active license from the state board of pharmacy in the states where it operates, is registered with the FDA, and follows USP chapters 795 and 797 for non-sterile and sterile compounding. License information is verifiable through state pharmacy board websites.
What quality testing is done? ▾
Raw active pharmaceutical ingredients are tested for identity, purity and potency and arrive with a Certificate of Analysis. Finished compounds undergo potency verification to confirm concentration matches the prescription. Injectable compounds are tested for sterility. Compounding environments are monitored for air quality and contamination.
Can I get a refund? ▾
If a physician determines a protocol is not medically appropriate for you during the review, you are not charged. Because compounded medications are prepared specifically for the individual patient once a prescription is issued, dispensed medication generally cannot be returned for a refund. Contact support for details on your specific situation.
Ready to get started?
Take the quiz to find your protocol. Physician-reviewed. Pharmacy-compounded. Delivered to your door.
